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 Small molecules are a powerful tool to illuminate biological mechanisms and assist in the 
identification and validation of therapeutic targets. KRAS is the single most frequently mutated oncogene 
in human cancer, with particularly high mutation frequencies observed in pancreas (95%), colon (45%), 
and lung (35%) cancer. However, despite three decades of effort, there is no clinical viable KRAS cancer 
therapy. The first part of this thesis focuses on exploring the potential of directly targeting the KRAS 
nucleotide binding site. Directly targeting oncogenic KRAS with small molecules in the nucleotide-
binding site has had limited success due to the high affinity of KRAS for nucleotide GTP and the high 
cellular concentration of GTP. The strategy of generating engineered KRAS allele based on shape and 
covalent complementarity was exploited herein to address this challenge. Using fragment-based small 
molecule design, a cell-membrane-permeable covalent inhibitor able to irreversibly modify the 
engineered nucleotide-binding site of KRAS was developed. The second part of this thesis describes the 
investigation of the therapeutic potential of imidazole ketone erastin (IKE), a small molecule inhibitor of 
the cystine/glutamate antiporter system xc–, in a subcutaneous xenograft model of Diffuse Large B Cell 
Lymphoma (DLBCL). A biodegradable polyethylene glycol-poly(lactic-co-glycolic acid) nanoparticle 
formulation was employed to aid in the delivery of IKE to cancer cells in vivo. This IKE nanoparticle 
system showed improved tumor accumulation and therapeutic index relative to free IKE, indicating its 
potential for treating DLBCL. The final part of this thesis describes the study of lipid metabolism features 
of ferroptotic cell death using quantitative reverse transcription PCR (RT-qPCR) and mass spectrometry-
based lipidomic analysis. In summary, this work illustrates how chemistry and chemical biology 
approaches can supplement existing efforts towards the design and discovery of new drugs for 
challenging targets, as well as aid in the study of therapeutic mechanisms.  
i 
 
Table of Contents 
List of Figures .............................................................................................................................................. v 
List of Tables .............................................................................................................................................. ix 
Chapter 1 Introduction ............................................................................................................................... 1 
1.1 Small molecule design as the tool to validate targets and probe biological mechanisms ........... 1 
1.1.1 Advancement in target identification and small molecule design ............................................... 1 
1.1.2 Fragment-based drug design ....................................................................................................... 2 
1.2 RAS superfamily of small GTPases ................................................................................................ 5 
1.2.1 RAS plays a key role in cell signaling ........................................................................................ 5 
1.2.2 RAS isoforms .............................................................................................................................. 7 
1.2.3 Strategies for drug discovery in RAS and current progress ........................................................ 9 
1.3 Ferroptosis ....................................................................................................................................... 11 
1.3.1 Classical view of cell death and new classification of cell death .............................................. 11 
1.3.2 Molecular and pharmaceutical modulators of ferroptosis ......................................................... 11 
1.3.4 Labile iron regulation in ferroptosis .......................................................................................... 15 
1.3.5 Application of ferroptosis in therapeutics ................................................................................. 17 
1.4 Lipid metabolism in ferroptosis .................................................................................................... 18 
1.4.1 Fatty acids structure, nomenclature, and effects on ferroptosis ................................................ 18 
1.4.2 Involvement of phospholipids biosynthesis in ferroptosis ........................................................ 19 
1.4.3 Participation of lipid peroxidation in ferroptosis ...................................................................... 21 
1.4.4 Mass spectrometry platform-based lipidomics analysis ............................................................ 22 
1.5 Application of nanoparticles in drug delivery .............................................................................. 24 
ii 
 
1.5.1 Abnormal tumor vasculature offers both challenges and opportunities in drug delivery ......... 24 
1.5.2 Perspectives on polymer-based nanoparticle design ................................................................. 25 
1.6 Overview of dissertation ................................................................................................................ 28 
Chapter 2: Design of Small Molecules that Compete with Nucleotide Binding to an Engineered 
Oncogenic KRAS Allele1 .......................................................................................................................... 29 
2.1 Introduction .................................................................................................................................... 29 
2.2 Results .............................................................................................................................................. 31 
2.2.1 Design of KRAS allele .............................................................................................................. 31 
2.2.2 Functional study of the engineered KRAS allele and biophysical assay design ....................... 34 
2.2.3 in silico design of inhibitors ...................................................................................................... 38 
2.2.4 Synthesis of ligand library ......................................................................................................... 44 
2.2.5 Evaluation of small molecule activities in biophysical assays .................................................. 44 
2.2.6 Evaluation of covalent binding of small molecules to KRAS* ................................................. 48 
2.2.7 Inhibition effect of the compound on signaling pathway .......................................................... 48 
2.3 Conclusion and Discussion ............................................................................................................. 52 
2.4 Methods ........................................................................................................................................... 54 
Chapter 3: Pharmacokinetic and Pharmacodynamic Study of IKE2 ................................................... 78 
3.1 Introduction .................................................................................................................................... 78 
3.2 Result ............................................................................................................................................... 80 
3.2.1 DLBCL have differential sensitivity to IKE ............................................................................. 80 
3.2.2 Pharmacodynamics study of IKE in vitro ................................................................................. 83 
3.3.3 Pharmacokinetics (PK) and pharmacodynamics (PD) study of IKE in vivo ............................. 87 
iii 
 
3.3 Conclusion and Discussion ............................................................................................................. 90 
3.4 Methods ........................................................................................................................................... 91 
Chapter 4: in vivo Study of IKE Nanoparticle Formulation in Xenograft Model3 ........................... 100 
4.1 Introduction .................................................................................................................................. 100 
4.2 Results ............................................................................................................................................ 101 
4.2.1 PLGA and PEG-PLGA nanoparticle system optimization ..................................................... 101 
4.2.2 IKE PEG-PLGA NPs have suitable properties to be applied in vivo ...................................... 106 
4.2.3 Investigation of ferroptosis biomarker expression in IKE and IKE PEG-PLGA efficacy study
 .......................................................................................................................................................... 109 
4.3 Discussion ...................................................................................................................................... 113 
4.4 Methods ......................................................................................................................................... 114 
Chapter 5 Untargeted Lipidomics Study of IKE Induced Ferroptosis4 ............................................. 119 
5.1 Introduction .................................................................................................................................. 119 
5.2 Results ............................................................................................................................................ 120 
5.2.1 Untargeted lipidomics study of IKE induced ferroptosis in cell culture ................................. 120 
5.2.2 Investigation of enzymes relating to IKE induced lipids change ............................................ 122 
5.2.3 Untargeted lipidomics study of IKE induced ferroptosis in vivo ............................................ 124 
5.3 Discussion ...................................................................................................................................... 128 
5. 4 Methods ........................................................................................................................................ 131 
Chapter 6 Conclusions and Future Directions ..................................................................................... 136 
6.1 Target validation using protein engineering strategy ............................................................... 136 
6.1.1 Summary ................................................................................................................................. 136 
iv 
 
6.1.2 Significance ............................................................................................................................. 137 
6.1.3 Future directions ...................................................................................................................... 139 
6.2 Application of IKE in vivo ............................................................................................................ 140 
6.2.1 Summary ................................................................................................................................. 140 
6.2.2 Significance ............................................................................................................................. 141 
6.2.3 Future directions ...................................................................................................................... 142 
6.3 Nanoparticles as drug carriers .................................................................................................... 144 
6.3.1 Summary ................................................................................................................................. 144 
6.3.2 Significance ............................................................................................................................. 144 
6.3.3 Future directions ...................................................................................................................... 145 
6.4 Identification of ferroptosis biomarkers ..................................................................................... 146 
6.4.1 Summary ................................................................................................................................. 146 
6.4.2 Significance ............................................................................................................................. 148 
6.4.3 Future directions ...................................................................................................................... 148 





List of Figures 
Figure 1. 1 Schematic overview of Venetoclax (ABT-199) discovery. ........................................................ 5 
Figure 1. 2 Schematic overview of RAS signaling pathways. ...................................................................... 7 
Figure 1. 3 Schematic illustration of pathways regulating ferroptosis. ....................................................... 14 
Figure 1. 4 The summary of structure-and-activity relationship study of erastin analogs .......................... 15 
Figure 1. 5 Schematic overview of iron metabolism in ferroptosis ............................................................ 16 
Figure 1. 6 Schematic of phospholipids structure in different classes and the hydrolysis sites of different 
phospholipases. ........................................................................................................................................... 21 
 
Figure 2. 1 Schematic overview of protein engineering strategies to validate KRAS. ............................... 30 
Figure 2. 2 Representation of KRAS G12V (PDB code: 4TQ9) and engineered KRAS* structures ......... 33 
Figure 2. 3 Sequence alignment of RAS and small GTPases superfamily ................................................. 33 
Figure 2. 4 A BRAF-RBD pull down assay proved that only GTP-bound but not GDP-bound KRAS* 
could bind with BRAF. ............................................................................................................................... 34 
Figure 2. 5 Nucleotide exchange of GTP in KRAS protein ........................................................................ 35 
Figure 2. 6 Schematic of establishing a stable transfected engineered cell line ......................................... 36 
Figure 2. 7 Western blot indicated the overexpression of RAS in KRASG12V MEFs and KRAS* MEFs. .... 37 
Figure 2. 8  RAS mRNA level measurement by RT-qPCR ......................................................................... 37 
Figure 2. 9 Schematic principle of fluorescence polarization assay. .......................................................... 38 
Figure 2. 10 Screen of fragments in biophysical assay. .............................................................................. 39 
Figure 2. 11 Fragment-based small molecule design targeting KRAS* nucleotide binding site ................ 40 
Figure 2. 12 Combinatorial library design .................................................................................................. 41 
Figure 2. 13 YZ0711 ligand interaction diagram. ....................................................................................... 42 
Figure 2. 14 Watermap performed on YZ0711 bound KRAS* .................................................................. 43 
Figure 2. 15 Synthesis route of compound YZ0711 ................................................................................... 44 
Figure 2. 16 The structure and activity relationship of selected covalent inhibitors................................... 45 
vi 
 
Figure 2. 17 Binding affinity test of covalent inhibitors in fluorescence polarization assay ...................... 46 
Figure 2. 18 Analysis of compounds’ cellular activities and cell membrane permeabilities ...................... 47 
Figure 2. 19 Exchange rate of BODIPY-GTP by small molecule YZ0711 in KRAS ................................ 47 
Figure 2. 20 YZ0711 covalently labels KRAS* but not KRAS G12V ....................................................... 49 
Figure 2. 21 Desthiobiotin-GTP pull down assay suggested YZ0711 occupied KRAS* nucleotide binding 
site covalently ............................................................................................................................................. 50 
Figure 2. 22 YZ0711 specifically inhibited KRAS* MEFs proliferation ................................................... 50 
Figure 2. 23 YZ0711 disrupted KRAS*-BRAF interaction ........................................................................ 51 
Figure 2. 24 YZ0711 inhibited RAS-MAPK pathway................................................................................ 52 
 
Figure 3. 1 Chemical structure of erastin and imidazole-ketone-erastin (IKE). ......................................... 79 
Figure 3. 2 Pathways regulating sensitivity of DLBCLs to IKE ................................................................. 80 
Figure 3. 3 Test of DLBCL sensitivity to IKE using cell viability assay ................................................... 81 
Figure 3. 4 CBS, SLC7A11, and FTL gene expression levels in different sensitivity groups of DLBCL ... 82 
Figure 3. 5 Measurement of GSH level in IKE treated SUDHL-6 cells ..................................................... 83 
Figure 3. 6 Measurement of lipid peroxidation level in IKE treated SUDHL-6 cells using flow cytometry
 .................................................................................................................................................................... 84 
Figure 3. 7 Measurement of MDA level in SUDHL-6 cells using immunofluorescence ........................... 85 
Figure 3. 8 IKE induced ferroptosis marker change in a time-dependent way. .......................................... 86 
Figure 3. 9 SLC7A11, CHAC1, and PTGS2 are specific for IKE-induced ferroptosis ............................... 86 
Figure 3. 10 Caspase-3 activity measurement using Apo-ONE assay and western blot ............................ 87 
Figure 3. 11 PK/PD study of IKE in NCG mice bearing SUDHL-6 xenograft .......................................... 89 
Figure 3. 12 Analysis of ferroptosis gene biomarkers in tumor tissues of IKE treated SUDHL-6 
xenografts .................................................................................................................................................... 89 
Figure 3. 13 Measurement of MDA level in tumor tissues of IKE treated SUDHL-6 xenografts using 
immunofluorescence ................................................................................................................................... 90 
vii 
 
Figure 3. 14 Measurement of 8-OHdG level in tumor tissues of IKE treated SUDHL-6 xenografts using 
immunofluorescence ................................................................................................................................... 91 
 
Figure 4. 1 Principles of nanoparticle formulation using microfluidic system ......................................... 102 
Figure 4. 2 Optimization of organic phase in PEG-PLGA nanoparticle formulation ............................... 103 
Figure 4. 3 Optimization of concentration step in PEG-PLGA and PLGA nanoparticle formulation ...... 104 
Figure 4. 4 Optimization of IKE loading in nanoparticles ........................................................................ 104 
Figure 4. 5 Nanoparticles’ size and surface potential parameters ............................................................. 105 
Figure 4. 6 IKE PEG-PLGA nanoparticles have enhanced cellular activity comparing with free IKE. .. 106 
Figure 4. 7 IKE and IKE NPs inhibited tumor growth in NCG mice bearing SUDHL6 xenografts ........ 107 
Figure 4. 8 Measurement of IKE accumulation in tumor tissues .............................................................. 108 
Figure 4. 9 Measurement of PTGS2 level in tumor tissues from efficacy study by immunofluorescence
 .................................................................................................................................................................. 109 
Figure 4. 10 Measurement of MDA level in tumor tissues from efficacy study by immunofluorescence 111 
Figure 4. 11 Measurement of MDA level in tumor tissues from efficacy study by TBARS assay .......... 111 
Figure 4. 12 Measurement of 8-OHdG in tumor tissues from efficacy study by immunofluorescence ... 112 
Figure 4. 13 Measurement of cleaved-caspase 3 abundance in tumor tissues from efficacy study .......... 112 
Figure 4. 14 Schematic overview of IKE-induced ferroptosis .................................................................. 114 
 
Figure 5. 1 Untargeted lipidomics study in SUDHL-6 cells ..................................................................... 121 
Figure 5. 2 Expression level of genes involving lipid metabolism ........................................................... 123 
Figure 5. 3 Schematic view of fatty acid biosynthesis, lipids remodeling, and arachidonic acid oxidation
 .................................................................................................................................................................. 123 
Figure 5. 4 Untargeted lipidomics study in vivo ....................................................................................... 125 
Figure 5. 5 Metscape network analysis of lipids identified in IKE treatment in vivo ............................... 126 
Figure 5. 6 Gene expression analysis in vivo ............................................................................................ 127 
viii 
 






List of Tables 
Table 1. 1 KRAS mutation frequencies in different cancers ........................................................................ 6 
 
Table 2. 1 Representation of different engineered alleles of KRAS and the evaluation of pocket sizes and 
stabilities ..................................................................................................................................................... 32 
 
Table 3. 1 IKE distribution in plasma through IP, IV and PO administration routes ................................. 88 
Table 3. 2 IKE distribution in plasma and tumor tissue through IP administration .................................... 88 
 







 There are many people who have provided me with mentorship, support, help and friendship over 
my graduate school career that I would like to acknowledge. First, I would like to thank my advisor, Brent 
Stockwell, for his consistent support and feedback through my entire graduate study. I have learned far 
more than what I could have ever imagined with his mentorship. Thank you for guiding my scientific 
development, encouraging my creativity, providing me with limitless opportunities to explore different 
scientific disciplines, and fostering an innovative and collaborative lab culture.  
 I am fortunate to come to an amazing lab and work with all wonderful people in Stockwell lab. 
Stockwell group is composed of scientists from a diverse scientific background. It is being a true pleasure 
to learn from each other and work on multidisciplinary projects together. Specifically, I would like to 
thank Dr. Marie-Hѐléne Larraufie for teaching me about computational-aided small molecule design 
techniques, getting me started in Stockwell lab, and provided a lot of help in the engineered KRAS 
project. I would like to thank Leila Musavi for teaching me protein purification, Nen Pagano for teaching 
me cell culture work, Huizhong Feng for teaching me protein crystallization, Anna Kaplan for teaching 
me everything I know about biophysical evaluation of small molecules in protein, Pieter Bos for helping 
me in synthetic aspects of ferrostatin analogs and computational chemistry techniques, Arie Zask  for 
constant help in synthetic organic chemistry and helping me edit part of my thesis, and Tal Hirschhorn 
and Niki von Krusenstiern for helping me edit my thesis. I would like to thank Hui Tan, Jacob Daniels, 
Fereshteh Zandkarimi, and Hengrui Liu for their contribution in the IKE project. Hui has been incredibly 
helpful in nanoparticle formulation, mouse efficacy study, and cell work. Jacob has put a lot of time 
helping me optimize the mouse xenograft study and mass spectrometry analysis, I would also like to 
thank him for critically reading and editing my thesis. Fereshteh has helped me understand untargeted 
lipidomics study, the field I have never worked before. Hengrui Liu has helped me finish 
immunofluorescence analysis of all efficacy samples.  
I would like to acknowledge the researchers I have collaborated with outside of the Stockwell lab. 
I am grateful to Dr. Lewis Brown and Dr. Hermanth Akkiraju for their help on mass spectrometry 
xi 
 
analysis in the engineered KRAS project. I am grateful to Dr. Owen O’Connor for providing diffuse large 
B cell lymphoma cancer cell lines, Dr. Koji Uchida for providing the monoclonal anti-MDA antibody, 
and Dr. Lewis Brown for supporting the untargeted lipidomics study in the IKE project. 
 I would like to thank my committee member, Dr. Richard Friesner and Dr. Ann McDermott, for 
serving on my committee for the last five years, as well as Dr. Wei Min, Dr. Neel Shah, and Dr. Simon 
Cheng for serving on my defense committee. I greatly appreciate their time and feedback on my projects, 
as well as their support on my career development.  
 I am also very grateful for all the administrative support I have received from our lab manager 
Elise Jiang, computer support- Anthony Gomez, and the administrators of the Department of Chemistry 
including Alix Lamia, Alison Doyle, Socky Lugo, and Dani Farrell.  
 I deeply appreciate the educators and the education I received prior to beginning my PhD. I 
would like to thank Dr. Wei He for the constant mentorship he extended to me during my time in his lab 
at Tsinghua University and beyond, and my mathematics and science teachers in elementary school, 
middle school, and high school for fostering my love to science.  
 Finally, I would like to express my gratitude to my friends, classmates, and family who have 
offered me friendship and support over the years. I am especially thankful to my patents for supporting all 

















Chapter 1 Introduction 
1.1 Small molecule design as the tool to validate targets and probe biological mechanisms 
1.1.1 Advancement in target identification and small molecule design  
Small molecules can be discovered by screening chemical libraries for changes of protein 
activities (target-based) or desired phenotypes in cell or organism-based assays (phenotypic). For the last 
30 years, the pharmaceutical industry has widely used target-based screens to identify medicines for 
specific diseases. There are many successes using this strategy, for example, the discovery of Gleevec 
(imatinib) which selectively inhibits BCR-ABL and revolutionized the treatment of chronic myeloid 
leukemia. However, this approach is limited in exploring new mechanisms of action and more disease-
relevant models. Phenotypic screening allows identifying biologically active small molecules in an 
unbiased way, which means the targets could be any protein or biologic and the small molecules could 
use different actions such as agonist/antagonist, protein-protein interaction inhibitor, and allosteric 
inhibitor. Analysis of FDA approved drugs between 1999 and 2008 revealed that there are 75 first-in-
class drugs among the 259 approved agents, 37% of them are from phenotypic screening, 23% are from 
target-based screening, 7% are modified natural products, the rest 33% are biologics1. Giving the high 
need for new medicines based on new mechanisms of action, there is a resurgence of phenotypic 
screening despite the complexity of identifying targets, discovering suitable biomarkers, and establishing 
dose-response relationships using this approach.  
  Although target-based and phenotypic screening have different methodologies and criteria 
during drug discovery, both approaches face the problems of target identification and validation, and 
small molecule design. Fortunately, there are many technologies aiding the above processes. First, target 
identification and validation is greatly facilitated by the advancement of genetic technologies including 
siRNA, zinc finger nucleases (ZFN), transcription activator-like effector nucleus (TALEN), 
meganucleases, and CRISPR-Cas9 system1.  Second, the improvement of phenotypic screening in stem-
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cell and primary-cell, and 3D and micro-physiological culture systems enables the application of more 
disease-relevant models in high-throughput screens. Third, ‘omics’ analysis including genomics, 
transcriptomics, proteomics, and metabolomics combined with bioinformatics provides multi-dimensional 
parameters on small molecule modulation. At the same time, high-throughput medicinal chemistry, beads 
chemistry, and new synthetic methods enable synthesizing small molecules more efficiently. Finally, 
computational chemistry and structural biology techniques, especially, cryo-electron microscopy (Cryo-
EM), greatly accelerate drug design processes and are now an indispensable tool in small molecule design.  
Small molecule design and drug discovery is an interdisciplinary research involving 
computational and medicinal chemistry, biophysics, genomics, proteomics, cell and molecular biology, 
and pharmacology. Chemical biology sits at the intersection of these disciplines and is an essential 
component of modern drug discovery. For example, chemical biology provides small molecule tools to 
identify and validate new targets, methodologies for disease-relevant phenotypic screens, approaches for 
designing therapeutic agents, and profiling targets and side effects through chemical proteomics. We 
anticipate seeing these efforts promote preclinical drug discovery and illuminate new paradigms for 
developing novel therapies.  
1.1.2 Fragment-based drug design 
There are different approaches to obtain chemical starting points in small molecule design, for 
example, from existing drugs or natural products/ligands with known biological clinical activities, high-
throughput screening (HTS), and fragment-based drug discovery (FBDD). Among these approaches, HTS 
is one of the dominant paradigms for discovering new molecules in the pharmaceutical industry. 
However, the chemical space is unimaginably large, an estimate of 1063 molecules can be formed with up 
to 30 C, N, O, S atoms2. The current global screening collection has around 108 molecules3, which 
represent only a very tiny fraction of possible chemical space. Besides, HTS libraries contain molecules 
that have inappropriate physical properties such as high lipophilicity, poor solubility, and tendency of 
aggregation, leading to production of false positives results. Thus, recent HTS has focused on screening 
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‘drug-like’ compounds with pharmacophores known to exhibit desirable biological activities to eliminate 
false positives. 
FBDD has emerged as a complementary approach to HTS. FBDD is based on screening a 
collection of low molecular weight molecules (fragments, MW< 300 Da) to increase “hit” identification 
rates, followed by either linking the two fragments bound to adjacent pockets of the protein target or 
elaborating the initial fragments by adding functional chemical groups to increase the complexity, 
selectivity, and potency of the small molecule. Compared with HTS which screens more complex 
moieties, FBDD has higher hit rates because of less possibilities of fragments to form mismatches with 
the receptor4. Besides, the chemical space is around 108 with up to 11 C, N, O and F atoms (MW<160)5, 
thus, a relativly small library of fragments is required to represent the chemical space. Furthermore, it is 
easier to control the physical parameters of lead compounds developed from small and efficiently binding 
fragments than from more complex molecules which might contain non-essential groups for binding6.   
Common strategies used in FBDD screening include fluorescence-based thermal shift, NMR 
spectrometry, X-ray crystallography, mass spectrometry, surface plasmon resonance (SPR), and virtual 
screening. The development of leads from FBDD requires the integration of structural biology, synthesis, 
computational chemistry, and biophysics. There are many cases of developing clinical candidates using 
this pipeline, for example, Vemurafenib (PLX4032) which targets BRAFV600E kinase, Venetoclax (ABT-
199) which targets BCL-2 (B cell CLL/lymphoma 2), and Onalespib (AT13387) which targets molecular 
chaperone HSP90. A brief overview of Venetoclax design will be described here to show how the FBDD 
approach facilitate drug discovery (Figure 1.1).  
Venetoclax is the first protein-protein interaction inhibitor, the first apoptosis-targeting 
therapeutic for cancer, and the second FBDD-derived drug approved by FDA7. It mimics BH3-only 
proteins and binds to the hydrophobic groove of BCL-2 proteins thus inhibiting BCL-2 activity and 
restoring apoptotic cell death in cancer cells. To discover initial fragments, NMR spectroscopy screening 
of a fragment library was performed on BCL-XL protein, which has high sequence similarity to BCL-2. 
As a result,  two fragments bound to the adjacent pockets of the BCL-XL (Figure 1.1A) were identified8. 
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The discovery of acylsulfonamide as a linker followed by parallel synthesis led to the development of 
Compound 1, which could occupy both of the adjacent pockets (Figure 1.1B). Further structure-based 
design produced ABT-737 and ABT-263, which have high affinity for both BCL-2 and BCL-XL and 
prevent cancer cell proliferation in a BAX- and BAK-dependent manner9. However, inhibiting BCL-XL 
resulted in a decrease of platelets, and BAX- and BAK-mediated thrombocytopenia, which limits the dose 
of ABT-263 in patients. Therefore, a small molecule with higher selectivity to BCL-2 over BCL-XL was 
required to eliminate the thrombocytopenia side effect. Researchers solved this challenge with the 
structural guidance of BCL-2 small molecule cocrystal structures and developed ABT-199 as a BCL-2 
selective inhibitor. ABT-199, which has an indazole group, is 100-fold more potent to BCL-2 than BCL-
XL (Ki for BCL-2 is 0.01 nM, Ki for BCL-XL is 46 nM). This drug is now used in treating chronic 
lymphocytic leukemia and small lymphocytic lymphoma. 
FBDD is not only used in pharmaceutical industry, but also widely exploited by academic groups 
for the development of chemical tools. Fragment libraries are commercially available. Both the library 
and the screening costs are within the budget of academic research groups. Particularly, virtual screening 
(in silico docking) has been widely used for enriching compounds pool and analyzing binding modes. In 
silico docking performs a recursive search and evaluation algorithm on a collection of ligand 
confirmations until the convergence to the minimum energy is reached10. A scoring function based on the 
electrostatic and van der Waals energies, as well as penalizing interactions, is then used to rank the 
ligands10. The top-scoring fragments can be refined in silico again to improve characterization of ligand-
receptor interactions and physical properties before selecting hits for pharmacological evaluation, which 
provides an effective and inexpensive way to enrich compounds. Collectively, virtual screening and 




1.2 RAS superfamily of small GTPases 
1.2.1 RAS plays a key role in cell signaling  
The RAS superfamily proteins are small membrane-associated guanosine triphosphatases 
(GTPases) consisting of more than 150 GTP-binding proteins that play key roles in the regulation of cell 
growth and survival11. There is speculation that several members of this family, including RAS, RAC1, 
RHOA and RHEB proteins, could serve as effective targets in multiple diseases. For example, around 
   A                                                   B                                                         C 
             
          
D                                                                E 
         
 
Figure 1. 1 Schematic overview of Venetoclax (ABT-199) discovery. 
(A) Structure of fragments and co-crystal of fragments bound to BCL-XL (PDB: 1YSG) (B) Structure 
of compound 1, which was designed based on the two fragments, and co-crystal of compound 1 
bound to BCL-XL (PDB: 1YSI) (C) Structure of ABT-263 and co-crystal of ABT-263 bound to BCL-




30% of human cancers are driven by RAS oncogenes, specifically, pancreatic (71%), colorectal (42%), 
and lung (20%) cancers (Table 1.1). KRAS is the most frequently mutated (86%) among the three RAS 
isoforms12. The RAS protein functions as a molecular switch, cycling between a GTP-bound active state 
and a GDP-bound inactive state (Figure 1.2). There are two classes of regulators catalyzing the exchange 
between these two states: i) Guanine nucleotide exchange factors (GEFs) including son of sevenless 
homologue (SOS) and RAS guanyl nucleotide-releasing protein (RASGRP), which catalyze GDP release 
from RAS ii) GTPase-activating proteins (GAPs), which catalyze the hydrolysis of GTP to GDP. Upon 
binding with GTP, the confirmation of RAS switch I region (residues 30-38) and switch II region 
(residues 60-76) change substantially to enable RAS binding with effectors. As a result, pathways 
including RAF-MEK-ERK, PI’3 kinase-AKT-mTOR, and RalGDS (RAL guanine nucleotide-dissociation 
stimulator) -RAL are activated to mediate cell survival, proliferation, vehicle trafficking and cytoskeletal 
organization. 
 
Table 1. 1 KRAS mutation frequencies in different cancers 
 %KRAS %HRAS %NRAS %All RAS 
Pancreas 71 0 <1 71 
Colon 35 1 6 42 




1.2.2 RAS isoforms 
RAS isoforms are encoded by three genes (HRAS, KRAS, and NRAS), while KRAS has two splice 
variants, resulting in a total of four proteins, HRAS, NRAS, KRAS4A and KRAS4B. These three RAS 
 
 
Figure 1. 2 Schematic overview of RAS signaling pathways. 
The exchange of GDP-bound RAS to GTP-bound RAS is mediated by GEF including SOS1, SOS2, 
and RASGRP1-4. The hydrolysis of GTP is catalyzed by GAP. GTP-bound RAS has two states and 
only the state 2 is able to  interact with PI3’ kinase, RalGDS, and RAF effectors to stimulate the 




isoforms are not identical in aspects of structure, post-translational modifications, distribution, function, 
and mutation rates in different cancers.  
First, the four RAS proteins are composed of a highly homologous catalytic domain (the G 
domain, 92-98% sequence identity) and a flexible C-terminal hypervariable region (HVR) which contains 
the membrane anchor sequence such as the CAAX box (“A” refers to an aliphatic residue)13. Because of 
the significant difference in HVR across the RAS isoforms, they possess different post-translational 
modifications and subcellular localizations. For example, HRAS, NRAS, and KRAS4A can undergo 
prenylation and palmitoylation at the first and second cysteine in the CAAX box, which facilitates their 
shuttle between the plasma membrane and the endomembrane. KRAS4B lacks the second cysteine in the 
CAAX box, thus, could not have such localization modification. In addition, the polybasic sequence in 
KRAS4A and poly-lysine sequence in KRAS4B enhance their membrane anchoring through electrostatic 
interactions, which are different from HRAS and NRAS. The multiple membrane-anchoring mechanisms 
possessed by RAS isoforms leads to the difficulty of developing a single drug to inhibit RAS localization.  
Second, KRAS, NRAS, and HRAS have different tissue distribution and physiological functions. 
While Hras or Nras-deficient mice are born and grow normally, Kras deficient embryos have abnormal 
ventricular walls, increased motoneurons death, fetal liver defects, and anemia, and eventually die during 
the embryonic period, which suggests Kras is essential for normal mouse embryogenesis14-15. A later 
study demonstrated that modification of Kras gene to express HRAS protein supports normal embryonic 
development despite inducing cardiovascular pathology in adult mice, indicating KRAS protein is not 
essential in embryogenesis but has a unique role in specific tissue homeostasis16. Because of the important 
localization role of different RAS isoforms, especially KRAS, target validation of RAS using genetic 
tools have many differences than those using pharmacological tools. 
 Finally, RAS isoforms have distinct roles in cancer as shown by cancer-type-specific mutational 
profiles. For example, there is near-exclusive mutation of KRAS in pancreas, lung, and colon cancer; 
while, HRAS mutations are predominant in neck and head squamous cell carcinoma; NRAS mutations are 
predominant in cutaneous melanoma and acute myelogenous leukemia (AML).  The most frequently 
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mutated sites in RAS are residues 12 and 13 in the phosphate-binding loop (P-loop, residues 10-17) and 
residue 61 in switch II, both regions are around the nucleotide-binding pocket.  Oncogenic mutations in 
RAS impair its intrinsic and GAP-mediated GTP hydrolysis, resulting in the accumulation of RAS-GTP 
that constitutively activates RAS downstream signaling. 
 
1.2.3 Strategies for drug discovery in RAS and current progress 
Despite the prevalence of RAS mutations in cancer, mutant RAS has remained an intractable 
target for decades. RAS function relies on membrane targeting, GTP binding, protein-protein interaction 
and the activation of downstream pathways. Thus, there are different strategies targeting RAS 
accordingly. First, RAS targeting could be achieved by direct inhibition including disrupting RAS 
localization on the membrane, decreasing GTP-bound RAS, and blocking RAS-effector interactions, 
which will be discussed in detail in the following section. Second, there are indirect inhibition approaches 
which include inhibiting RAS downstream signaling pathways, inhibition of RAS synthetic lethal 
interactors, and inhibition of metabolic targets relating to RAS. The indirect strategies could be 
challenging due to genetic context, complex feedback mechanisms, intrinsic resistance, and drug potency. 
To disrupt RAS membrane anchoring, at least six farnesyltransferase inhibitors (FTIs) have been 
tested in clinical trials, however, none of them have achieved the expected activity against tumors17. One 
reason is that FTIs are able to inhibit HRAS function but not other isoforms because HRAS prenylation is 
exclusively modified by farnesyltransferase, while the other three isoforms have alternative membrane-
anchoring mechanisms such as geranylgeranyltransferase I-mediated prenylation18.  Another reason is that 
more than 30 proteins including the RAS and RHO family proteins require post-translational 
farnesylation for localization. As a consequence, FTIs have a small therapeutic window and could not be 
used in treating HRAS-mutation driven cancers17.  
10 
 
Considering the high concentration of GTP in the cell (~0.5 mM) and the picomolar binding 
affinity of GTP to RAS, designing compounds competing with nucleotide binding is challenging. The 
esterified electrophilic GDP analog showed some specificity to KRAS G12C, but the compound was not 
potent enough, and inhibited ERK and AKT phosphorylation at 100 uM19. Based on the above facts, 
decreasing GTP-bound RAS through inhibition of GEF such as SOS1 and SOS2 is more feasible. A 
variety of methods including virtual, NMR-based, fragment-based, and peptidomimetic screens have been 
attempted to disrupt RAS-GEF binding and have discovered some hits including small molecules 
targeting the catalytic site of SOS120, and a α-helix that mimic α-helices on SOS protein surface21-22. At 
the same time, there are some previously unknown binding pockets on RAS that have been discovered, 
for example, a hydrophobic pocket in SOS CDC25 domain adjacent to RAS switch II region23.  
With the advancement of computational chemistry, designing small molecules targeting protein-
protein interactions (PPI) in RAS is viable. A PPI inhibitor could be designed to either directly target 
RAS and block the effector binding, or target the RAS-binding domain (RBD) on effectors. For instance, 
a pan-RAS inhibitor MEW3144, which was designed to interact with adjacent sites in switch I and switch 
II regions of KRAS, exhibited nanomolar activity in cancer cell lines. The molecule showed tumor-
suppression effects in the MDA-MB-231 (KRAS G12D) subcutaneous xenograft model24-25. Alternatively, 
a RAS-mimetic small molecule rigosertib inhibits RAF-RAS interaction by binding to the  RAS-binding 
domain (RBD) of RAF kinases26.  Rigosertib is currently in phase III clinical for the treatment of 
myelodysplastic syndromes (MDS), which is active either as a single agent or in combination with 
Azacytidine.  
Recently, a covalent allosteric binding strategy showed the feasibility of targeting a specific 
KRAS mutant, KRAS-G12C 13, 27-29. This type of electrophile aims to stabilize the inactive KRAS G12C 
and block GTP binding. KRAS-G12C-selective inhibitor ARS-1620 showed tumor suppression effect in 
six subcutaneous cell line-derived p.G12C tumor models and patient-derived tumor xenografts (PDX) 
harboring KRAS p.G12C  but not  p.G12V, p.G12D, and wild-type tumor models, indicating the potency 
and selectivity of this small molecule to KRAS-G12C mutant29. The design of KRAS-G12C-selective 
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inhibitors requires intensive structure-based drug design efforts. For example, an orally available KRAS-
G12C inhibitor MRTX849 was developed by analyzing >150 cocrystal structures and synthesizing >2000 
discrete small molecules30. MRTX849 will prove whether the covalent allosteric binding strategy could 
be translated to clinic.   
 
1.3 Ferroptosis 
1.3.1 Classical view of cell death and new classification of cell death 
Cell death is of fundamental importance in life and plays essential roles in regulating organism 
development, tissue homeostasis, immune system, stress and defense response. The balance between cell 
death and cell survival/proliferation controls physiological and pathological settings in life. Thus, the 
investigation of molecular mechanisms that regulate multiple cell death pathways is key to understanding 
disease development and to discover new therapeutics31-32. For a long time, morphotypes has been 
employed to classify cell death into three types: apoptosis, autophagy, and necrosis. With the increasing 
number of cell death mechanisms discovered, the Nomenclature Committee on Cell Death (NCDD) has 
updated cell death definitions based on molecular aspects33. Cell death is divided into the accidental cell 
death, which is caused by extreme physical, chemical, or mechanical insults, and regulated cell death 
(RCD), which is dependent on signal transduction and can be modulated pharmacologically or 
genetically. For example, apoptosis, the first well characterized RCD, is initiated by extracellular or 
intracellular microenvironmental perturbations and regulated by executioner caspases. Besides apoptosis, 
there are several other regulated cell death pathways discovered in last two decades. For instance, 
ferroptosis was named by Stockwell and colleagues in 2012 to describe a regulated cell death driven by 
iron-dependent lipid peroxidation that can be inhibited by iron chelators and lipophilic antioxidants33-37.   
 
1.3.2 Molecular and pharmaceutical modulators of ferroptosis 
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Ferroptosis can be induced by both reduced glutathione (GSH) depletion and glutathione 
peroxidase 4 (GPX4) inactivation (Figure 1.3). Ferroptosis has two key regulators, system xc– and GPX4. 
System xc– mediates the import of cystine which is intracellularly reduced to cysteine, a necessary 
component of reduced glutathione (GSH) biosynthesis in cells. GPX4 reduces lipid peroxides by 
consuming GSH.  Inhibition of system xc– or GPX4 could enhance lipid peroxidation thus leading to 
ferroptotic cell death, while iron chelators and antioxidants could inhibit lipid peroxidation and rescue 
ferroptotic cell death. In this section, the essential components of ferroptosis will be discussed to show 
how ferroptosis is distinct from other regulated cell death pathways.   
GSH is an important antioxidant that eliminates cellular damage caused by reactive oxygen 
species. GSH depletion has features of increased lipid peroxidation, 8-hydroxy-2-deoxyguanosine (8-
OHdG) formation, chromosomal giant DNA fragmentation, and membrane integrity loss38-44. GPX4 
reduces membrane phospholipid hydroperoxides by consuming GSH to suppress ferroptosis. The 
inactivation or depletion of GPX4 would cause lipid hydroperoxides accumulation. For example, the 
kidney of Gpx4-/- mice had increased levels of di-oxygenated species of PC (PC-OOH), PE (PE-OOH), 
and CL (CL-OOH) compared with control mice45. In addition to the above molecular modulators, several 
other pathways also contribute to modulate cell sensitivity to ferroptosis. NRF2 transcription factor 
controls the expression of specific types of iron-signaling genes and antioxidant genes, and promotes 
resistance to ferroptosis34. Ferroptosis sensitivity is also modulated by the stress-responsive transcription 
factor and canonical tumor suppressor protein p53. The role of p53 in ferroptosis is different depending 
on the context. For instance, acetylation-defective p53 sensitizes cells to ferroptosis, independently of 
cell-cycle arrest, apoptosis and senescence46.  However, stabilization of wild type p53 was proved to 
delay the onset of ferroptosis in response to cystine deprivation47. And, some results suggest that p53 
suppresses ferroptosis by blocking dipeptidyl-peptidase-4 activity48. Defining the context during the 
investigation of ferroptosis molecular modulators is thus important. 
In addition to the endogenous molecular modulators, there are many ferroptosis pharmaceutical 
modulators including both inducers and inhibitors. Ferroptosis inducers could be classified according to 
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the targets. Class 1 ferroptosis inducers include glutamate, sulfasalazine, sorafenib, as well as erastin and 
erastin analogs, which inhibit the cystine (Cys2)/glutamate (Glu) antiporter system xc– resulting in cystine 
deprivation and subsequent GSH depletion34-35, 49-52. Among these inducers, sorafenib is the only 
clinically-approved anticancer drug which was first discovered to be a multi-kinase inhibitor then 
identified to have system xc– inhibition activity in multiple cancer cell lines53. Moreover, canonical 
hallmarks of apoptosis, such as pro-caspase-3 cleavage and poly (ADP ribose) polymerase 1 (PARP 1) 
cleavage, did not occur in sorafenib induced cell death,  implying that the anticancer effect of sorafenib is 
not through apoptosis53. Class 2 ferroptosis inducers include RSL3, ML162, and DPI compounds, which 
inhibit GPX4 directly to induce ferroptosis. For example, RSL-3 is a nanomolar small molecule inhibitor 
which covalently modifies the selenocysteine residue in GPX4. Class 3 ferroptosis inducers, which 
include FIN56 and CIL56, induce ferroptosis by depleting GPX4 and at the same time, depleting 
coenzyme Q10 (CoQ10) through mevalonate pathway. Also, there are more compounds including FINO2, 
statins, silica-based nanoparticles, and ferric ammonium citrate, which induce lipid peroxidation and 
ferroptosis through various mechanisms.  
There are three principle events in free radical-mediated peroxidation. The first step is the 
initiation through hydrogen atom transfer. Second is the propagation cycle including reaction of the lipid 
radical with molecular oxygen to produce a lipid peroxyl radical, followed by fragmentation, 
rearrangement, and cyclization of the lipid peroxyl radical. The third step is the termination reaction of 
forming nonradical products54. Inhibition of either step one or step two would inhibit ferroptosis34. Class 1 
ferroptosis inhibitors are iron-chelators such as deferoxamine and deferiprone, which eliminate cellular 
free irons and prevent Fenton chemistry mediated-lipid peroxidation. Class 2 ferroptosis inhibitors are 
deuterated-polyunsaturated fatty acids (D-PUFAs). PUFA peroxidation is initiated by hydrogen atom 
abstraction at the bis-allylic site. PUFAs deuterated at the bis-allylic sites prevent the hydrogen atom 
transfer because of the isotope effect. Class 3 ferroptosis inhibitors are antioxidants, including the 
naturally occurring ones, Vitamin E (α-tocopherol) and CoQ10, and the synthetic small molecules, 
Ferrostatin-1 (Fer-1) and lipostatin-1 (Lip-1), which inhibit ferroptosis by reducing the reactive oxygen 
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species. Fer-1 and Lip-1 function as radical-trapping antioxidants, and are more reactive in inhibiting 
oxidations in phosphatidylcholine (PC) lipid bilayers comparing to Vitamin E, which is consistent with 
the potency of these three inhibitors in ferroptosis55. 
 
1.3.3 Structure and activity relationship study of erastin analogs 
Erastin (Eradicate RAS-and Small T transformed cells) was discovered by phenotypic screening 
of cell lines expressing mutant HRAS56. Structure-and-activity relationship study of erastin analogs have 
demonstrated that the quinazolinone and imidazole group (highlighted as red) are amenable to a wide 
range of substitutions or bioisosteric replacements to tune the binding affinity and water solubility 
(Figure 1.4) 52, 57. While, the piperazine and chloro-benzyne methoxy groups (highlighted as black) are 
essential for the binding. For example, even the substitution of chlorine with fluorine on the benzyne 
methoxy group would decrease the binding affinity for more than twenty fold52. Besides, the introduction 
 
 
Figure 1. 3 Schematic illustration of pathways regulating ferroptosis.  




of carbonyl group largely increases erastin analogs’ binding affinity which probably results from the 
reversible covalent reaction of carbonyl group and lysine residues to form the Schiff base. In addition, the 
substitution of isopropyl group on methoxy benzyne ring (highlighted as blue) enhances metabolic 
stability. Overall, imidazole-ketone-erastin (IKE) is the most potent and metabolically stable analog of 
erastin synthesized thus far52, 57.  
 
1.3.4 Labile iron regulation in ferroptosis 
Labile iron pool is capable of catalyzing lipid peroxidation through Fenton reactions and has been 
proved to be required during ferroptosis.  There is a speculation that regulating labile iron pool through 
iron import, export, metabolism, and storage would affect the cellular sensitivity to ferroptosis.  
Iron metabolism is very fine tuned. Iron is imported to cells by transferrin receptor (TFR) upon 
loading on transferrin (TF) (Figure 1.5). Cellular labile iron pool is kept at the lowest enough level to 
protect cells from oxidative stress. The excess iron is either stored in ferritin or effluxed by ferroportin. 
Investigation to the links between ferroptosis and autophagy revealed that autophagy promotes ferroptosis 
 
 
Figure 1. 4 The summary of structure-and-activity relationship study of erastin analogs  





through ferritin degradation and labile iron release58. Inhibition of nuclear receptor coactivator 4 
(NCOA4) or knockdown of autophagy-related 5 (ATG5) and ATG7, which mediate iron release from 
ferritin, suppressed erastin-induced ferroptosis. A RNA interference experiment proved that knock down 
of iron-sulfur cluster biosynthetic enzyme NFS1 in low oxygen condition (3% O2) limits iron-sulfur 
cluster availability and activates the iron-starvation response, which further leads to glutathione 
biosynthesis inhibition and triggers ferroptosis59. At the same time, the author found that lung 
adenocarcinoma cell lines are dependent on high levels of NFS1 to prevent oxidative damage and 
ferroptosis. More work is needed toward understanding the relationship of labile iron, oxygenation, and 
ferroptosis so that key regulators controlling cell sensitivity to ferroptosis could be revealed. 
 
A                                                                        B 
                
 
Figure 1. 5 Schematic overview of iron metabolism in ferroptosis 
(A) Overview of iron absorption and metabolism. Fe3+ is carried by circulating apo-Transferrin (TF) 
in plasma to form diferric TF. The Transferrin-(Fe3+)2 is imported by cell surface transferrin receptor 
(TFR). Fe3+ is released by endocytosing followed by reduction to Fe2+ to enter cellular labile iron 
pool. Excess iron is stored in ferritin or effluxed by ferroportin.  Authophagy promotes ferroptosis 
through degradation of ferritin mediated by nuclear receptor coactivator 4 (NCOA4) and authophagy-
related proteins (ATGs). (B) The relationship between iron regulation and ferroptosis. GPX4 
inactivation and glutathione (GSH) depletion, induced by system xc- inhibition, produce oxidative 
stress to cells, which results in free iron-mediated- or enzyme-mediated-lipid peroxidation. Iron 
chelators and antioxidants prevent ferroptosis by decreasing free iron and lipid peroxides in cells 
individually. Increasing labile iron pool through activating transferrin (TF) and decreasing ferritin will 
increase cells sensitivity to ferroptosis. 
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1.3.5 Application of ferroptosis in therapeutics 
Ferroptosis is a regulated cell death nexus linking metabolism and disease. The diverse 
ferroptosis pharmacology modulators provide important tools to investigate different types of diseases. 
Increasing evidence suggests that ferroptosis is involved in brain injury and neurodegenerative 
diseases, which includes Huntington’s disease, Alzheimer’s disease, and Parkinson’s disease. Analysis of 
brain tissues identified increased iron levels, oxidative stress, GSH levels, and lipid peroxidation in 
neurodegenerative diseases60-65. Besides, ferroptosis inhibitors such as antioxidants, including CoQ10 and 
Vitamin E, entered in clinical studies and have been proved to slow or reduce neurodegenerative 
diseases65. For example, a 2 years study of CoQ10 in 300 patients with mild to moderate stage Alzheimer’s 
disease has proved dose-related benefits on patients’ cognition66. Moreover, the ferroptosis inhibitor Fer-1 
has shown the inhibition of cell death in cellular models of Huntington’s disease and periventricular 
leukomalacia, indicating the potential application of ferrostatin analogs in brain injury and 
neurodegenerative diseases67.  
Small molecules-induced ferroptosis has shown tumor inhibition effect in cell culture. Specific 
types of cancer cell lines are especially sensitive to ferroptosis due to their dependence on ferroptosis 
regulators, such as the dependence on system xc– for B cell-derived lymphomas51, GPX4 for renal cell 
carcinomas (RCC)51, 68,  and ACSL4 for subtypes of breast cancer cell lines69 70-72. Targeting ferroptosis 
might be hold potential benefit for treating these types of cancers. The obvious strategy is to inhibit tumor 
cell growth using single ferroptosis inducer. For example, cells of clear-cell renal cell carcinoma 
(ccRCC), which is intrinsically resistant to chemotherapy and radiation therapy, possess a lineage-specific 
vulnerability to ferroptosis inducer RSL373. Other strategies could be the combination of therapies 
including chemotherapy, radiation therapy and oxygenation therapy. For example, the ferroptosis inducer 
erastin synergizes with several chemotherapies, including cisplatin, temozolomide, adriamycin and 
doxorubicin in cell culture studies74-78. Moreover, oxygenation therapy, which could enhance free radical 
generation, might further elevate oxidative stress in tumor cells by combining with ferroptosis inducers. 
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Furthermore, ferroptosis regulator system xc– is not only a critical regulator in cysteine 
metabolism but also essential in glutamate signaling. System xc– is widely distributed in macrophages, 
liver, kidney, and brain. Exploring potential application of IKE in glutamate signaling and neuroscience is 
also of therapeutic interest. For example, the excess glutamate secreted by system xc– is associated with 
cancer-induced bone pain in distal breast cancer metastases. A system xc– inhibitor capsazepine showed 
the potential of preventing cancer-induced bone pain in a murine model mimicking human metastatic 
breast cancer to the bone79. 
Collectively, targeting ferroptosis could be an alternative option to treat neurodegenerative 
diseases and cancers including cancers that are intrinsically resistant to conventional chemotherapy or 
radiotherapy.  
 
1.4 Lipid metabolism in ferroptosis 
Ferroptosis is an iron-dependent and lipid peroxidation-induced cell death which can be rescued 
by antioxidants. Lipid metabolism is heavily involved in ferroptosis execution80. Given by the complexity 
of lipid metabolism, I will introduce fatty acids structure and the effects of specific fatty acids on 
ferroptosis, followed by discussion of phospholipids biosynthesis and lipid peroxidation in ferroptosis. 
Finally, I will describe the application of mass spectrometry in untargeted lipidomics and the progress of 
mass spectrometry based lipidomics study in ferroptosis.  
 
1.4.1 Fatty acids structure, nomenclature, and effects on ferroptosis 
Fatty acids (FA) exit in mammalian cells both as free fatty acids (FFA) and esters, the latter ones 
include phospholipids, glycolipids, and triacylglycerols. Most of the naturally occurring fatty acids (FAs) 
are unbranched and have diverse carbon (C)-chain length and number of double bonds. FAs with chain-
lengths of 11-20 carbons are classified as long chain fatty acids. FAs with >20 carbons are called very-
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long chain fatty acids, which are less abundant than long chain fatty acids. Depending on the number of 
double bonds in the FAs, they can be classified into saturated FAs (SFAs), monounsaturated FAs 
(MUFAs), or polyunsaturated FAs (PUFAs). Because of the complexity of FAs structures, they are often 
named using the form of C:D, n-x (or ω-x), where C is the number of carbon atoms in the FA, D is the 
number of double bonds in the fatty acid, n (or ω)  represents counting the double bond from the terminal 
methyl carbon toward the carbonyl carbon, and x is the position of the first double bond. For example, 
arachidonic acid is termed as 20:4, n-6 or 20:4, ω -6. FA from the same n-x series are likely to share a 
biosynthetic pathway.  
Free FA and FA esters not only function as energy sources, but also serve as components of cell 
membranes, protein post-translational modifications, and messengers in signaling transduction81. 
Emerging evidence has indicated lipids and lipid metabolism heavily involved in ferroptosis and 
regulated cell death80. It has been reported that fatty acids could trigger or potentialize ferroptosis. For 
example, PUFAs such as arachidonic acid, γ-linolenic acid, linoleic acid, cardiolipin, cholesterol, and 
ceramide enhanced ferroptosis and cell membrane integrity loss39, 82. Particularly, the addition of 
arachidonic acid reduced caspase-3 activity, decreased cellular ATP level, mitochondrial membrane 
potential, and activated 12-lipoxygenase protein expression in C6 rat glioma cells43. However, the MUFA 
oleic acid interestingly protects against lipid peroxidation in ferroptosis, which might because oleic acid 
does not have bisallylic sites, which are the sites vulnerable for lipid peroxidation initiation39, 82-83.  
 
1.4.2 Involvement of phospholipids biosynthesis in ferroptosis 
Phospholipids are a major component of cell membranes, and are responsible for maintaining the 
structural integrity of cells. An in silico model of membrane dynamics suggests that ferroptosis induces 
changes in various membrane properties including thickness, fluidity, permeability, and curvature, which 
is in alignment with experimental results84. 
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Biosynthesis of phospholipids is divided to two different pathways, the de novo pathway 
(Kennedy pathway) by using acyl-CoA and diacylglycerol, and the remodeling pathway (Lands’ cycle) by 
using acyl-CoA and lysophospholipids85. In the de novo pathway, acetyl-CoA carboxylases (ACC) 
catalyze the conversion of acetyl-CoA to malonyl-CoA followed by FA synthase (FASN) and FA 
elongase (ELOVLs)-mediated elongation to synthesize long chain FA-CoA. Then, long chain FA-CoA 
are converted to lysophospholipids (LPA) by glycerol-3-phosphate acyltransferase (GPAT) with the 
expense of glycerol-3-phosphate (G3P). Fatty acids are esterified to form phospholipids in an asymmetric 
manner. Saturated (SFA) and monounsaturated FAs (MUFA) are usually esterified at the sn-1 position, 
while, polyunsaturated FAs (PUFA) including arachidonic acid and eicosapentaenoic acid are mainly 
located at the sn-2 position.  
Lysophospholipid acyltransferases (LPTs), such as lysophosphatidylcholine acyltransferase 
(LPCAT), lysophosphatidylethanolamine acyltransferase (LPEAT) and lysophosphatidylserine 
acyltransferase (LPSAT), are involved in catalyzing phospholipids synthesis from lysophospholipids. 
There are different classes of phospholipases including phospholipase A1 (PLA1), phospholipase A2 
PLA2, phospholipase C (PLC), phospholipase D (PLD), which catalyze the hydrolysis of phospholipids to 
lysophosphalipids at sn-1, sn-2, sn-3, and phosphate sites respectively (Figure 1.6). Under oxidative 
stress, phospholipase activation protects cells by cleaving the oxidized PUFAs to maintain cell membrane 
integrity. LPCAT2, LPCAT3, and Group IVA phospholipase A2 (LPA2G4A) specifically participate in 
arachidonic acid acylation or hydrolyzation reactions. Therefore, these three isoforms represent the 
essential enzymes in arachidonic acid-mediated oxidative stress and inflammation generation.  
Genes encoding lipid biosynthesis enzymes have been proved to regulate cell sensitivity to 
ferroptosis.  First, the depletion of acyl-CoA synthetase long-chain family member 4 (ACSL4), which 
catalyzes the conversion of free long-chain FA to FA-CoA esters, or LPCAT3, which mediates the 
conversion of LPC to PC, results in resistance to GPX4 inhibition86. A genome-wide CRISPR-based 
genetic screen on Pfa1 cells and RSL3-resistant clones also discovered that ACSL4 expression was 
dramatically decreased in the resistant clones69. Second, untargeted lipidomics studies performed in 
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ferroptosis occurring cells have identified that there was accumulation of LysoPC and depletion of PUFA, 
indicating that lysophospholipid acyltransferases (LPTs) might be activated during ferroptosis to cleave 




1.4.3 Participation of lipid peroxidation in ferroptosis 
With the induction of oxidative stress, lipids can be oxidized via both enzymatic and non-
enzymatic pathways. The enzymatic pathway relies on the catalysis by three main enzymes including 
cyclooxygenase (COX), lipoxygenase (LOX), and cytochrome P450 (CYP) isoforms. The non-enzymatic 
pathways include free radical-mediated oxidation and free radical independent non-enzymatic oxidation.  
There are many classes of lipid peroxidation products. PUFA can form the intermediate 
oxygenated lipid derivatives including octadecanoids which are derived from 18-carbon PUFA, 
eicosanoids which are derived from 20-carbon PUFA, and docosanoids which are derived from 22-carbon 
 
 
Figure 1. 6 Schematic of phospholipids structure in different classes and the hydrolysis sites of 
different phospholipases.  
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PUFA. The free radical-mediated oxidation products  F2-isoprostanes and neuroprostanes, which are 
derived from arachidonates and docosahexanoates respectively, are well-characterized and often used as 
oxidative stress biomarkers in vivo87. These intermediate derivatives can be degraded to secondary 
products including reactive carbonyl compounds such as aldehydes and dicarbonyls, and stable products 
such as ketones and alkanes. The reactive carbonyl compounds can further modify the proteins to form 
adducts that induce protein dysfunctions and other cellular responses. For example, 4-hydroxynoneal (4-
HNE), 4-hydroxyhexenal (4-HHE), and malondialdehyde (MDA) can react with histidine (His), cysteine 
(Cys) or Lysine (Lys) residues to form stable Michael adducts88. The reactive carbonyl compounds can be 
determined using TBA reactive substances (TBARS) assay, mass spectrometry, enzyme-linked 
immunosorbent assay (ELISA), as well as polyclonal or monoclonal antibodies against reactive carbonyl 
compounds-protein adducts to evaluate oxidative stress in cells and tissues.  
Increasing evidence has shown the accumulation of specific lipid peroxides and participation of 
the associated enzymes during ferroptosis. A quantitative redox global phospholipidomics revealed that 
doubly and triply oxygenated species of PE are significantly increased in ferroptosis89. PEs containing 
arachidonoyl (AA) and adrenoyl moieties (AdA) were identified as the preferred substrates for oxidation 
in ferroptosis90. Inhibition of lipoxygenases (ALOXs) but not cyclooxygenases (COXs) and cytochrome 
P450 prevented RSL-3 induced ferroptosis90. An independent research confirmed that both genetically 
silencing of ALOX (arachidonate lipoxygenase) genes and pharmaceutically inhibition of ALOX could 
lead to cells’ resistance to ferroptosis82.  
 
1.4.4 Mass spectrometry platform-based lipidomics analysis 
Comprehensive analysis of lipids is full of challenges because of the structural complexity and 
low abundance of lipids and lipid oxidation products. First, lipids are composed of eight families 
containing around 1.68 million species91. Lipids formation is regio-, stereo-, and enantio-specific 
depending on the substrates, enzymes, and reaction conditions. The large variety of species, as well as 
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their omplex structures, and biosynthesis/degradation pathways render complete lipid analysis incredibly 
difficult. Second, many types of lipids, especially lipids oxidation products, are not abundant in vivo, 
leading to the difficulties of detecting these types of lipids. Additionally  some lipids are sensitive to 
oxidation which might result in artificial oxidation during sample preparation. 
The mass spectrometry (MS) platform provides a high-throughput analytical tool to analyze 
complex lipids simultaneously in a single sample with high sensitivity and specificity89, 92. MS is 
composed of 3 parts, an ion source, a mass analyzer, and a detector. The commonly used ionization 
methods include electrospray ionization (ESI), ESI tandem MS (MS/MS), atmosphere pressure chemical 
ionization (APCI), atmosphere pressure photoionization (APPI), desorption electrospray ionization 
(DESI), and matrix-assisted laser desorption ionization (MALDI)91. Each has its own advantages: (i) ESI 
could be used either in shotgun analysis to detect lipids at different modes by tuning pH value and adding 
specific ionization reagents or by coupling with separation techniques such as liquid chromatography 
(LC) and ultra-performance liquid chromatography (UPLC); (ii) ESI tandem MS (MS/MS) is able to 
analyze fragments of lipids thus providing double bond location information; (iii) APCI and APPI are 
more suitable for analyzing nonpolar lipids and are less susceptible to ionization suppression; (iv) DESI 
provides an ambient ionization method with minimal sample preparation which extracts sample locally 
and is widely used in direct tissue analysis; (v) MALDI is not generally suitable for lipid detection due to 
the lack of proper matrix, but the recent development of MALDI imaging mass spectrometry (MALDI-
IMS) could possibly provide high resolution and accuracy of lipids distribution93. The commonly used 
analyzers in lipidomics are quadrupole (Q), ion trap (IT), (quadruple) time of flight (Q)(TOF), TOF-TOF, 
Fourier-transform ion cyclotron resonance (FTICR), and orbitrap analyzer. The last four analyzers greatly 
accelerated the lipidomics research by allowing simultaneously analyzing multiple metabolites at high 
resolution without separation94.  
Mass spectrometry-based lipidomics studies have identified some trends of lipids change in 
ferroptosis. For example, metabolomic profiling of erastin-treated HT1080 cells has identified depletion 
of PUFAs including eicosapentaenoate (20:5 n-3), linoleate (18:2 n-6), linolenate (18:3 n-3/6), and 
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docosahexaenoate (22:6 n-3)67. A quantitative redox lipidomics study proved PE oxidation in the 
endoplasmic-reticulum as an essential process in ferroptosis90. In the future, the advancement of mass 
spectrometry-based imaging platform may yield even more information on lipids distribution in 
ferroptosis.  
 
1.5 Application of nanoparticles in drug delivery 
1.5.1 Abnormal tumor vasculature offers both challenges and opportunities in drug delivery 
A primary goal in designing cancer therapies is to accumulate therapeutic levels of a drug at the 
tumor site but not distribute in healthy tissues and organs. Tumors have abnormal vasculature, which 
offers both challenges and provides opportunities for new approaches in drug delivery. In this section, I 
will first illustrate the general features of tumor vasculature and then discuss challenges of delivering 
conventional cancer therapies and how nanoparticles can offer new approaches to deliver 
chemotherapeutics. 
Normal vasculature is arranged in a hierarchy of evenly spaced, well-differentiated vessels, with 
most of the cells in human body within a few cell diameters of a blood vessel, which allows for the 
efficient delivery of oxygen and nutrients to the cells. The rapid proliferation of tumor cells, however, 
results in abnormal blood vessels that are irregular and leaky in tumors, preventing efficient oxygen and 
nutrient delivery to tumors95-96. As a result, tumors have a characteristic hypoxic and low-nutrient 
microenvironment. In addition, solid tumors have defective lymphatic systems, leading to high interstitial 
pressure in tumors which limits the extravasation of macromolecules and the accumulation of metabolites, 
including lactic and carbonic acids, that leads to an acidic microenvironment. The dysfunctional vessel 
also hinders the delivery of small-molecule and macromolecular therapies to tumor cells that are distant 
from functional blood vessels97.  
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The effectiveness of anticancer drugs relies on efficient penetration in tumor tissue to reach a 
therapeutic concentration. Conventional drugs are often hindered by problems such as water solubility, 
metabolic stability, cell membrane permeability, and the ability to penetrate solid tumors. Nanoparticle 
carriers are often able to overcome these limitations. For instance, free drugs may diffuse across tumor 
tissue nonspecifically, while nanoparticles have increased tumor accumulation due to the enhanced 
permeability and retention (EPR) effect, whereby the large pore openings in defective angiogenesis and 
dysfunctional lymphatic drainage in tumor microenvironment leads to the specific accumulation of 
nanoparticles in tumors98.  Currently, FDA-approved nanoparticle formulations, including Abraxane®, an 
albumin-based formulation of paclitaxel, Nanoxel®, a nanoliposome containing paclitaxel, and Doxil®, a 
nanoliposome containing doxorubicin, are being used in the clinic. All these nanoparticle formulations 
have decreased systemic toxicity compared to the parent drug.  
1.5.2 Perspectives on polymer-based nanoparticle design 
The design of nanoparticles for drug delivery requires precise control of the composition, size, 
shape, and surface properties. Both natural materials and synthetic materials can be used in the synthesis 
of nanoparticles; although natural materials have the advantages of abundance, high biocompatibility and 
biodegradability, nanoparticle materials are dominated by synthetic materials due to the precise control of 
the physicochemical properties offered by synthetic materials. In particular, the FDA-approved, 
biodegradable polyester poly(lactic acid) (PLA) and poly(lactide-co-glycolide) (PLGA) grafted with 
poly(ethylene glycol) (PEG) have been widely used. As such polymers are less likely to induce toxicity, 
immune responses, and chronic inflammation. PEG offers the additional benefit of having a hydrophilic 
surface, which prevents the aggregation and phagocytosis of nanoparticles, prolonging the nanoparticle 
circulation time in plasma. Moreover, biodegradability ensures complete degradation of the material and 
release of drug by multiple mechanisms, including surface and bulk erosion and diffusion (Figure 1.7). 
Nanoparticles used in drug delivery typically have diameters ranging from 20 nm to 200 nm99. 
This represents an ideal size for nanoparticles as the cutoff size of extravasation into tumors is around 400 
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nm and particles larger than 200 nm or smaller than 20 nm are rapidly cleared by liver, kidney, or spleen 
(Figure 1.8). Finally, diffusion-mediated penetration is inversely correlated with the particle size, thus 
smaller nanoparticles have greater tumor penetration ability. For these reasons, it is important that 
nanoparticles are designed with a diameter no smaller than 20 nm to ensure enhanced tumor 
accumulation.  
The shape of nanoparticles influences their cellular uptake, circulation lifetime, and in vivo 
fates99. For example, discoidal nanoparticles are more prone to tumbling and oscillatory effects in 
vasculature, thus increasing nanoparticle-cell wall contact and possibility of extravasation99.  Polymer-
based nanoparticles are mostly spherical nanoparticles, which have smaller surface area comparing with 
discoidal and other non-spherical nanoparticles at the same size, which might be advantageous in tumor 
penetration100.   
The surface of nanoparticles offers additional means to achieve specific targeting to tumors. 
Nanoparticles with a slightly positive or negative charge will not readily aggregate due to repulsion 
forces. A high positive surface charge, however, will lead to cellular toxicity and quick clearance by 
macrophages. In addition, modifying the surface with antibodies, peptides, and aptamers allows for 
specific targeting towards cells and tissues. For example, antibody-conjugated nanoparticles offer 
increased tumor accumulation by combining the advantages conferred by nanoparticles with their 
increased ability to penetrate tumors and with the ability to recognize specific cells.    
Of course, there are more factors to consider during nanoparticle design, such as deformability 
and ease of production. Further understanding of biological processes governing the uptake, 
transportation, distribution, and excretion of nanoparticles will enable the innovations on developing new 







Figure 1. 6 Nanoparticles formed by biodegradable polymers have three drug releasing mechanisms 
(1) bulk erosion by breaking down the whole matrix, (2) surface erosion by degrading or dissociation 
of polymers, (3) diffusion from swollen matrix 
 
 
Figure 1. 7 Schematic overview of nanoparticle design used in drug delivery. 
Nanoparticles used in drug delivery need to have size smaller than 200 nm but larger than 20 nm to 
enable extravasation and avoid quick clearance by kidney, spleen, and liver. The surface charge of 
nanoparticles need to be slightly positive or negative to avoid aggregation and cytotoxicity. The 
surface of nanoparticles should be hydrophilic to prevent mononuclear phagocytic system (MPS) 
recognition and clearance. Besides, the material used in nanoparticle formulation should be 
biocompatible and biodegradable to decrease the toxicity and possible immune responses and have 




1.6 Overview of dissertation 
 The work described in this thesis employed computer based small molecule design in the target 
validation of KRAS, nanoparticle technology in the investigation of ferroptosis therapeutic potential in 
vivo, and untargeted lipidomics study in the characterization of lipid metabolism in ferroptosis. In the 
second chapter, I describe my work in design of small molecule that compete with nucleotide binding to 
an engineered oncogenic KRAS allele101. Using fragment based small molecule design, I successfully 
designed and synthesized a covalent inhibitor which can permanently modify the engineered KRAS and 
inhibit its downstream signaling in cells. In the third chapter, I investigated in vitro and in vivo 
pharmacodynamics of IKE, a metabolically stable, highly potent and selective system xc– inhibitor, using 
quantitative-RT-PCR, immunofluorescence, and metabolites measurement. Besides, I identified the 
differential sensitivities of a set of DLBCL cell lines to IKE and established a xenograft tumor model 
using a sensitive cell line, SUDHL-6. In the fourth chapter, I applied the principles of nanoparticle carrier 
design in the formulation of a biocompatible and biodegradable nanoparticle to deliver IKE in vivo and 
demonstrated the reduced toxicity with nanoparticle IKE formulation in vivo. In the fifth chapter, I 
analyzed the distinct lipids change of IKE-induced ferroptosis in vitro and in vivo with the help of my 
colleague on mass-spectrometry based lipidomics study. In addition, I identified the key enzymes 
participating in IKE-induced lipid metabolism change. In the final chapter, I consider the perspectives and 





Chapter 2: Design of Small Molecules that Compete with Nucleotide Binding to an 
Engineered Oncogenic KRAS Allele1 
2.1 Introduction 
RAS mutations are found in 30% of all human cancers, with KRAS the most frequently mutated 
among the three RAS isoforms (KRAS, NRAS, HRAS). However, directly targeting oncogenic KRAS with 
small molecules in the nucleotide-binding site has been difficult due to the high affinity of KRAS for 
GDP and GTP. We designed an engineered allele of KRAS, and a covalent inhibitor that competes for 
GTP and GDP. This ligand-receptor combination demonstrates that the high affinity of GTP/GDP for 
RAS protein can be overcome with a covalent inhibitor and a suitably engineered binding site. The 
covalent inhibitor irreversibly modifies the protein at the engineered nucleotide binding site and is able to 
compete with GDP and GTP. This provides a new tool for studying KRAS function and suggests 
strategies for targeting the nucleotide-binding site of oncogenic RAS proteins. 
Generating engineered, inhibitable alleles of proteins to validate targets has proved successful for 
kinases and other proteins102-111 The essence of this strategy resides in the design of engineered alleles of 
the protein of interest that are sensitized to small-molecule inhibition, while being functionally 
indistinguishable from wild-type counterparts (Fig. 1A). Treatment with a complementary small-molecule 
probe can then provide selective, rapid, and dose-dependent inactivation of the protein of interest. More 
recently, Shah and co-workers reported a strategy for the selective inhibition and activation of an 
engineered H-Ras mutant by unnatural GDP and GTP analogues112. However, future applications of that 
study were limited by using GDP analogues as molecular probes, which are inherently non-cell-
permeable and not selective. Moreover, that study did not address the feasibility of designing drug-like 
small molecule that target engineered small GTPases. 
                        
1 This chapter is adapted from the manuscript:  Zhang, Y.; Larraufie, M.-H.; Musavi, L.; Akkiraju, H.; 
Brown, L. M.; Stockwell, B. R., Design of small molecules that compete with nucleotide binding to 
an engineered oncogenic KRAS allele. Biochemistry 2018, 57 (8), 1380-1389. 
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We aimed to address this issue by testing whether we could design a cell-permeable small 
molecule probe that would allow us to test the effects of pharmacological inhibition of suitably 
engineered small GTPases (Figure 2.1). We focused on the design of small molecules capable of 
inhibiting an engineered mutant allele of oncogenic KRAS (termed KRAS*). We were concerned that 
mutation of key conserved residues in KRAS might alter its natural nucleotide selectivity and important 
protein-protein interactions, making the mutant activated in a GEF-independent way and lose the switch 
function112-114, as first suggested for RAS (N116I)115. Shah and co-workers have reported, however, that 
H-RAS (L19A, N116A) mutations remain fully functional as the wild-type enzyme112. We also 
demonstrated that the engineered inhibitable KRAS* allele we designed could bind to BRAF effector 
only after loading with GTP but not GDP. We report herein the computational design of a mutant 
engineered oncogenic allele of KRAS bearing an enlarged nucleotide binding site and a cysteine residue 
that can serve as a site for covalent targeting. We found that this mutant KRAS* was functionally 





Figure 2. 1 Schematic overview of protein engineering strategies to validate KRAS.  
The engineered KRAS* harbors an enlarged pocket and a cysteine residue, which enables selective 
targeting by a covalent small molecule. The KRAS* should be capable of binding with nucleotides 
and functional in cells to stimulate RAS downstream pathways. The covalent small molecule is 
expected to covalently lock the KRAS* in inactive state to disable KRAS* function but not interact 






2.2.1 Design of KRAS allele 
Small GTPases in the RAS family have a conserved binding site and share similar nucleotide-
binding pockets116. Shah and co-workers demonstrated that mutation of L19 and N116, located on the 
backside of the HRAS GTP-binding site, to smaller alanine residues allowed access to a buried 
hydrophobic cavity. The crystal structure of KRASG12V in the GDP-bound conformation (4TQ9) 117was 
used as a template to model the influence of point mutations in the nucleotide-binding site. Prime and 
BioLuminate (Schrödinger) were used to calculate the change in structure and stability of the protein after 
introducing mutations (Table 2.1). N116 is necessary to be mutated to alanine to create a hydrophobic 
pocket around the nucleotide binding site. Besides, we would like to engineer a cysteine in the binding 
pocket to enable the covalent small molecule interaction. However, the single mutation of N116A 
combining with L19C is only able to generate a 4Å*3Å*4Å pocket, which is not big enough to facilitate 
the small molecule design. Thus, mutation of L19AN116AV114C or L19AN116AT144C would achieve 
the aim. Since V114 is in the middle of the cavity, which might be more versatile for binding with 
covalent inhibitors.  
Residues 19 and 116 were mutated in silico and all residues within 10 Å of either mutation were 
minimized. A new hydrophobic cavity 3 Å wide and 10 Å long appeared in the nucleotide-binding site 
(Figure 2.2). We next wished to introduce a cysteine residue in the hydrophobic pocket that could then be 
used as a handle for covalent inhibition25. Indeed, we envisioned that the use of covalent inhibitors might 
be key to be able to cope efficiently with the high cellular concentration of GTP (~1 mM)13. For that 
purpose, a cysteine residue (C114) that could be targeted by electrophilic moieties was installed in the 
backside of the engineered hydrophobic pocket. The stability of the engineered protein 
(KRAS*G12VL19AN116AV114C, termed KRAS*) was predicted to have decreased energy of 52.96 kcal/mol.   
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Table 2. 1 Representation of different engineered alleles of KRAS and the evaluation of pocket sizes and 
stabilities 
 
mutation Pocket size (from MOE) D stability 
(solvated) 
(kcal/mol) 
1 L19AN116A 10Å*3Å*4Å  37.92 
2 L19AN116C No hydrophobic pocket around guanine 
nucleotide-binding site 
33.35 
3 L19AV114C No hydrophobic pocket around guanine 
nucleotide-binding site 
38.94 
4 N116AL19C 4Å*3Å*4Å 36.39 
5 N116AV114C Cys114 is not near to the pocket 31.55 
6 N116AL23C Cys23 is not near to the pocket 29.14 
7 N116AL79C Cys79 is not near to the pocket 37.94 
8 N116AF156C Cys156 is not near to the pocket 38.27 
9 N116AV152C Cys152 is not near to the pocket 27.43 
10 N116AT144C 4Å*3Å*3Å 25.41 
11 L19AN16AV114C 10Å*3Å*4Å  52.96 
12 L19AN16AT144C 10Å*3Å*4Å  44.60 
13 L19AN16AL23C Cys23 is not near to the pocket 51.65 
14 L19AN16AL79C 14Å*3Å*4Å 59.89 
15 L19AN16AF156C 11Å*3Å*4Å 59.52 
16 L19AN116AV152C 10Å*3Å*4Å 48.04 
 
D stability (solvated): Change in the stability of the protein due to the mutation, calculated using the 
Prime energy function with an implicit solvent term. The stability is defined as the difference in free 
energy between the folded state and the unfolded state. A positive value of the change means that the 




The predicted structure of the engineered protein showed that C114 was orientated to perform a 
nucleophilic attack on electrophilic moieties in the pocket (Figure 2.2). Importantly, the three mutated 
residues in KRAS* are in a conserved site among the GTPases, so they could potentially be translated to 







Figure 2. 2 Representation of KRAS G12V (PDB code: 4TQ9) and engineered KRAS* structures 
 (structure was minimized using Schrödinger Prime). Mutagenesis of L19AN116AV114C in KRAS 
G12V (KRAS G12VL19AN116AV114C, termed KRAS*) created a hydrophobic pocket in the GDP/GTP 
binding site.  
 
 
Figure 2. 3 Sequence alignment of RAS and small GTPases superfamily  
(conserved residues are in BOLD). Mutated residues in KRAS* are conserved in small GTPases. 
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2.2.2 Functional study of the engineered KRAS allele and biophysical assay design 
To verify that the engineered mutant allele functions well as a “switch”, KRAS* was loaded with 
GDP or GTP and incubated with RAF1 RBD (RAS binding domain) protein attached to glutathione 
Sepharose beads. The unbound KRAS* was removed during the washing step, while the bound KRAS* 
was quantified by immunobloting with anti-RAS antibody. As expected, RAF 1 RBD specifically bound 
to GTP-loaded KRAS* but not GDP-loaded KRAS* (Figure 2.4).  
 
 
To prove that the KRAS* is not nucleotide-free analog of RAS as suggested for HRAS(N116I), 
we tested the binding of GDP and GTP by KRAS* and KRASG12V protein (Figure 2.5). Both KRAS* and 
KRASG12V were nucleotide exchanged to BODIPY-GTP, a fluorescent analog of GTP which have high 
polarization value when binds with protein and low polarization value in unbound form. BODIPY-GTP 
was displaced by GDP or GTP in both KRAS* and KRASG12V, indicating KRAS* retains nucleotide 
selectivity. Compared with KRASG12V, the faster nucleotide exchange rate of BODIPY-GTP to GTP or 
GDP might come from the low binding affinity between KRAS* and BODIPY-GTP.   
 
 
Figure 2. 4 A BRAF-RBD pull down assay proved that only GTP-bound but not GDP-bound KRAS* 
could bind with BRAF.  
Purified GST-tag KRAS* was nuclear exchanged to GDP or GTP-bound form then incubate with 
BRAF-RBD followed by washing of non-specific binding and western blot for visualization of 





To further verify KRAS* function in cells, we used RAS-less MEFs.  K-Raslox(H-Ras-/-;N-Ras-/-
;K-Raslox/lox;RERTnert/ert) mouse embryonic fibroblasts (MEFs) were stably transfected with KRAS* or 
KRASG12V alleles118. The MEFs were generated to carry null HRAS and NRAS alleles along with a floxed 
KRAS locus and a knocked-in inducible Cre recombinase. After transfection with KRASG12V, KRAS*,  or 
BRAFV600E-CAAX individually, 4-hydroxytamoxifen was used to induce of Cre recombinase, resulting in 
the complete elimination of endogenous KRAS gene after two weeks (termed KRAS* MEFs, KRASG12V 





Figure 2. 5 Nucleotide exchange of GTP in KRAS protein 
Nucleotide exchange of GTP in KRAS* is catalyzed by SOS1 and EDTA, same as what in KRAS 




The ability of KRAS* to activate RAF/MEK/ERK signaling was examined by measuring the 
abundance of phosphorylated ERK (pERK) and phosphorylated AKT (pAKT) in the transfected cell lines. 
Following EGF treatment, pERK and pAKT levels were increased in the transfected cell lines (Figure 
2.7), demonstrating that the engineered mutations did not prevent KRAS* from activating effector 
proteins. The EGF-dependent signal in KRAS* MEFs also revealed that its binding to GTP was not GEF-
independent as suggested for RAS (D119N)114.  
KRAS mRNA levels were measured in the transfected cell lines by qPCR. We found that the 
KRAS* mRNA was more abundant than the KRASG12V mRNA (Figure 2.8). Compared with the similar 
protein level of KRAS in KRAS* MEFs and KRASG12V MEFs (Figure 2.7), that indicates KRAS* may be 




Figure 2. 6 Schematic of establishing a stable transfected engineered cell line 
 K-Raslox(H-Ras-/-;N-Ras-/-;K-Raslox/lox;RERTnert/ert) mouse embryonic fibroblasts (MEFs) are 
transfected with K-RAS*, K-RASG12V, BRAFV600E-CAAX individually followed by activation of Cre 





To test the binding affinity of fragments and lead compounds, we developed an in vitro 
fluorescence polarization assay to test the ability of small molecules to displace BODIPY-GTP, a 
 
 
Figure 2. 7 Western blot indicated the overexpression of RAS in KRASG12V MEFs and KRAS* MEFs.  
“empty pBabe K-Raslox MEFs” represents the K-Raslox(H-Ras-/-;N-Ras-/-;K-Raslox/lox;RERTnert/ert) MEFs 
transferred with empty pBabe vector as a control. The RAS downstream signaling was activated upon 
EGF treatment in K-Raslox MEFs, KRAS* MEFs, and KRASG12V MEFs. 
 
 
Figure 2. 8  RAS mRNA level measurement by RT-qPCR 
RT-qPCR showed KRAS expression is 1.7-fold in KRASG12V MEFs, and 10-fold in KRAS* MEFs 




fluorescent analog of GTP. In this assay, test compounds that were able to competitively replace 
BODIPY-GTP bound to KRAS* resulted in a decrease in the polarization of BODIPY-GTP (Figure 2.9).  
 
 
2.2.3 in silico design of inhibitors 
A GDP-bound KRASG12V crystal structure (PDB: 4TQ9) was used to design compounds that 
covalently lock KRAS* in the GDP-bound state, inactivating its signaling function. KRASG12V was 
mutated in silico to KRAS*, and the engineered structure was refined by Schrödinger Protein Preparation 
Wizard for docking studies. A fragment-based design strategy was applied in the search for a covalent 
inhibitor119 and two series of covalent inhibitors were designed and synthesized.  177,911 fragments were 
screened using the Schrödinger Glide program and the top-ranked fragments were used as scaffolds for 
further design. The first series of inhibitors harbor a carboxylic acid group, which is predicted to interact 
with the magnesium ion and multiple residues in the GTP-binding pocket, thus giving a high predicted 
 
 
Figure 2. 9 Schematic principle of fluorescence polarization assay.  
The binding of Fluo-GTP (BODIPY-GTP is used in this assay) to GTP-binding site yields a high 
fluorescence polarization (FP) value. With the displacement of small molecule inhibitors, Fluo-GTP 
is free in solution, thus having a fast tumbling and yielding a low FP value. 
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binding affinity (as good as -12 for Glidescore). These inhibitors had high predicted binding affinity to 
the KRAS* protein, but low cellular activity, making it difficult to study the KRAS therapeutic index in 
cells. Esterification one carboxylic acid groups improved the compounds’ cell-membrane-permeable but 
didn’t increase the cellular activity. The low cellular activity might thus derive from their inability to 
block KRAS-effector interactions in cells. 
We then found that the conserved aspartate residue D119 is a key residue determining the 
specificity for GTP over other nucleotides through hydrogen bonding. We reasoned that the discovery of 
a compound that can form hydrogen bonds with D119 is thus important for a successful design. H-bond 
constraints to D119 were applied in fragment screens for a second inhibitor design series. Top-ranked 
fragments without carboxylic acid groups were tested in a fluorescence polarization assay to measure 
binding affinity to KRAS*. We found that an indazole fragment G, with a docking score of -7.1, could 
compete with GTP binding for KRAS in vitro in the 100 micromolar range (Figure 2.10), and was chosen 





Figure 2. 10 Screen of fragments in biophysical assay. 
8 fragments which have high predicted binding affinity for the GTP-binding site were tested in 
fluorescence-polarization (FP) assay. Fragment G showed highest binding affinity to GTP-binding 




As a next step, the hydrophobic pocket of the engineered allele was targeted by attaching a 
lipophilic group (Figure 2.11) to the appropriate site on fragment G. This produced compound G*, which 
had a more favorable docking score of -9.1, compared to -7.1 for compound G (note that the Glide 
docking score is a log scale, so this predicted a 100-fold improvement in affinity). Based on the structure 
of compound G, a number of covalent inhibitors with electrophile warheads at different positions were 
designed and evaluated using Schrödinger’s Covalent Docking program120. This showed that having a 2-
chloroacetamide electrophile at the meta-position (compound YZ0468) had the best-predicted affinity 
score in silico (docking structure showed in Figure 2.11).  
 
A 





Figure 2. 11 Fragment-based small molecule design targeting KRAS* nucleotide binding site 
Design of a second series of small molecule and representation of the proposed binding mode of 
compound YZ0468 in KRAS*. Covalent docking of compound YZ0468 in KRAS* showed favorable 
formation of covalent bond between C114 and the chloroacetyl moiety. The ligand interaction 
diagram showed possible non-covalent interactions between ligand and KRAS* (Purple: H-bond 




On the basis of this indazole scaffold, a customized compound library employing amide coupling, 
reductive aminations, and cross coupling reactions was created (Figure. 2.12) and evaluated using 
Schrödinger’s Glide docking and Covalent Docking program. The top-scoring compounds were 
synthesized and tested in the fluorescence polarization assay to further assess inhibition activity.  
 
 
The combinatorial library (Figure 2.12) was screened using Glide Docking by removing the 
covalent warheads first followed by Covalent Docking of the top scoring compounds in the Glide 
Docking. To discover cell membrane permeable probes, the predicted Caco-2 cell permeability of top 
scoring compounds were calculated by Qikprop (Schrödinger Release 2018-3: QikProp, Schrödinger, 
LLC, New York, NY, 2018). The compounds with predicted-Caco-2 cells permeability larger than 25 
nm/sec were synthesized (Caco-2 cells are a model for the gut-blood barrier. Predicted cell permeability 
value smaller than 25 nm/sec is considered as poor. Predicted cell permeability value larger than 500 
nm/sec is considered as great). A compound with 3,4-(methylenedioxy)phenyl group (later named 
YZ0711) has the highest predicted Caco-2 permeability, 294 nm/sec, among all screened compounds. The 
predicted binding showed a favorable binding of Serine 17 residue with 3,4-(methylenedioxy)phenyl 
group (Figure 2.13). 
              
 
Figure 2. 12 Combinatorial library design 





WaterMap (Schrödinger Release 2018-3: WaterMap, Schrödinger, LLC, New York, NY, 
2018), which calculates thermodynamics associated with water hydration sites in protein active sites121-
122, was used here to check whether there is room to further optimize the compound. WaterMap showed 
that compound YZ0711 displaced nearly all high-energy hydration sites in the nucleotide binding site of 
KRAS* (Figure 2.14). This result indicated possible favorable binding between compound YZ0711 and 
KRAS* protein.  
 
 
Figure 2. 13 YZ0711 ligand interaction diagram. 
The ligand interaction diagram showed possible non-covalent interactions between ligand YZ0711 
and KRAS* (Purple: H-bond interaction, Red: Pi-Cation interaction, Green: Pi-Pi interaction). N-1 on 











Site Occupancy dH -TdS dG        Site Occupancy dH -TdS dG 
34 0.74 6.45 2.36 8.81 30 0.78 1.33 2.44 3.77 
66 0.48 5.62 1.46 7.08 4 1 -1.06 4.82 3.76 
3 1 1.42 5.33 6.75 18 0.86 -0.08 3.51 3.43 
10 0.96 2.09 3.72 5.81 32 0.74 0.96 2.47 3.43 
42 0.64 3.24 2.05 5.29 76 0.44 1.93 1.22 3.15 
41 0.66 2.41 2.29 4.7 50 0.6 1.23 1.86 3.09 
43 0.64 2.48 2.15 4.63 40 0.67 1.05 2.01 3.06 
6 0.99 0.36 4.08 4.44 99 0.34 1.97 1.02 2.99 
22 0.82 1.44 2.7 4.14 19 0.85 0.17 2.71 2.88 
 
Figure 2. 14 Watermap performed on YZ0711 bound KRAS* 
WaterMap shows the thermodynamic-properties properties including enthalpy, entropy, and free 
energy of water occupying hydration sites of protein active site. (A) The interaction of compound 
YZ0711 with KRAS* protein and the overlay of compound YZ0711 with hydration sites showed 
favorable binding between the ligand and the protein. Hydrogen bond interaction is shown in purple. 
A cation-pi interaction is shown in red. Stable hydration sites (ΔG < 3 kcal/mol) are shown in green, 
significantly unstable hydration sites (ΔG > 5 kcal/mol) are shown in red, and moderately unstable 
sites (3 kcal/mol < ΔG < 5 kcal/mol) are shown in brown. (B) The thermodynamics of high-energy 




2.2.4 Synthesis of ligand library 
A set of promising covalent small molecule inhibitors was thus synthesized (Methods). As an 
example, the synthetic route developed for compound YZ0711 is illustrated in Figure 2.15. The indazole 
scaffold was synthesized by heating 2-fluoro-5-nitrobenzonitrile and hydrazine monohydrate in refluxing 
ethanol followed by the selective BOC-protection of the N-1 position of the indazole and subsequent 
palladium-catalyzed hydrogenation123. The resulting diaminoindazole could be acylated selectively at the 
C-5 amine using an acid chloride. In the next step, the C-3 amine was acylated in pyridine to yield 
compound 4. Catalytic hydrogenation of the nitro group in compound 4 followed by acylation of the 




2.2.5 Evaluation of small molecule activities in biophysical assays  
 
 
Figure 2. 15 Synthesis route of compound YZ0711 
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The designed covalent inhibitors and non-covalent inhibitors were able to compete with 
fluorescent GTP binding for the engineered mutant, but not for KRASG12V (Figure 2.16, 2.17), thus 
satisfying the selectivity criterionCompared with compounds bearing acrylamide and vinyl sulfonate 
warheads, compounds bearing a chloroacetamide warhead had a better ability to bind to KRAS* (Figure 
2.16). This might result from the relatively small pocket in KRAS*. Indeed, an extra chloro group on the 
benzyl moiety of YZ0571-1 decreased potency, consistent with a small available space in the binding site. 
In addition, a non-covalent analog (YZ0571-4) was not able to displace BODIPY-GTP. Based on this 
result, a series of covalent inhibitors incorporating chloroacetyl warheads were synthesized.  
 
A                                                                                 B 





Figure 2. 16 The structure and activity relationship of selected covalent inhibitors.  
Covalent inhibitor s selectively occupies GTP binding pocket of KRAS*, but not KRASG12V protein. 
Compound YZ0571-1, bearing a 2-chloroacetyl chloride moiety, has optimal activity in the 




Compound YZ0714 and YZ0719 had comparable binding affinity to YZ0571-1 (Figure 2.18). 
Compound YZ0719 has low activity in a cell viability assay, which might result from its low cell 
membrane permeability. Compound YZ0711 had the best selectivity at inhibiting KRAS signaling among 
these electrophiles (data not shown) and was selected for further analysis.  
In addition, inhibitor binding was catalyzed by ethylenediaminetetraacetic acid (EDTA) but not 
SOS1, a guanine nucleotide exchange factor that promotes guanine nucleotide exchange (Figure 2.19). 
EDTA can chelate the magnesium iron to facilitate nucleotide exchange in RAS. 
 




Figure 2. 17 Binding affinity test of covalent inhibitors in fluorescence polarization assay 
Comparison of binding affinities of selected compounds for KRASG12V (left) and KRAS* (right) by 
fluorescence polarization assay. Covalent inhibitors selectively displace GDP from KRAS* protein, 










YZ0711 YZ0712 YZ0719 YZ0756 
Cellular accumulation fold1: 1.4 0.4 0.1 1.2 
Predicted Caco-2 cell 
Permeability (nm/sec)2 294 53 87 192 
 
Figure 2. 18 Analysis of compounds’ cellular activities and cell membrane permeabilities 
(A) Summary of binding affinity and cellular activity of selected covalent inhibitors. 
1 Relative IC50 is measured by fluorescence polarization assay through incubating the compounds 
with KRAS* protein overnight at 4 °C. 2 EC50 is measured by in KRAS* MEFs. 
(B) Summary of cellular accumulation and predicted Caco-2 cell.  1 Accumulation fold was measured 
by treating KRAS* MEFs with 20uM compound for 4hs followed by LC-MS measurement. 2 
Predicted by Schrödinger Qikprop. Caco-2 cells are a model for the gut-blood barrier. Predicted 
permeability < 25 is considered as poor; > 500 is considered as great 
     
Figure 2. 19 Exchange rate of BODIPY-GTP by small molecule YZ0711 in KRAS 
Comparison of replacement of BODIPY-GTP by YZ0711 in KRAS* (left) and KRASG12V (right) as a 
function of time. EDTA catalyzed the replacement of BODIPY-GTP by YZ0711 in KRAS* but not in 
KRASG12V.  
 
























































2.2.6 Evaluation of covalent binding of small molecules to KRAS* 
To determine whether compound YZ0711 could covalently bind to KRAS*, purified KRAS (20 
µM) was incubated with 200 µM YZ0711 and 1 mM EDTA overnight at 4°C. The protein was then 
labeled with iodoacetamide and digested with trypsin. The resulting peptides were analyzed by nano 
LC/MS. LC/MS analysis revealed a modification of peptide (103-117) with YZ0711 at cysteine (C114) or 
lysine (K117) residues (Figure 2.20). A peptide (103-117) lacking cysteine but containing lysine in 
KRASG12V was not modified with YZ0711, indicating that YZ0711 modification was exclusive to C114 in 
KRAS*. 
Besides, a pull-down assay was performed to prove whether the small molecule YZ0711 could 
covalently modify KRAS* in cells. Desthiobiotin-GTP, which can covalently modify conserved lysine 
residues in the nucleotide-binding site, was used to pull down KRAS in cell lysates. KRAS* MEFs 
treated with 50 μM YZ0711 have a decreased level of KRAS enrichment (Figure 2.21), suggesting that 
YZ0711 is able to penetrate the cell membrane and target the GTP/GDP-binding site. 
2.2.7 Inhibition effect of the compound on signaling pathway 
 In a cell growth inhibition assay, KRAS* MEFs and KRASG12V MEFs were treated with DMSO, 
25 µM YZ0711, or 25 µM YZ0756 (a structurally similar compound as YZ0711) for 4 days and cell 
numbers were counted on a Vi-Cell XR Cell Viability Analyzer. Compound YZ0711 showed 80% 
inhibition of KRAS* MEF number and 50% inhibition to KRASG12V MEFs, indicating that YZ0711 
exhibits some selectivity for KRAS* (Figure 2.22). Analog YZ0756 exhibited 25% inhibition in KRAS* 












Figure 2. 20 YZ0711 covalently labels KRAS* but not KRAS G12V  
(A) Liquid chromatography/mass spectrometry (LC/MS) analysis of cleaved peptides in KRAS* 
incubated with YZ0711. Peptide 103-117 in KRAS* was detected to be labeled by YZ0711 at either 
Lysine or Cysteine residue. (B) LC/MS analysis of cleaved peptides in KRASG12V incubated with 
YZ0711. No labeling was detected in peptide 103-117 in KRASG12V. (C) Sequence alignment between 







To test whether compound YZ0711 can disrupt KRAS*-effector binding, RAF RBD protein, 
which can selectively pull down GTP loaded KRAS*, was used. The GTP-loaded KRAS* protein was 
incubated with DMSO or YZ0711 (40uM) for 15 min and the reaction was stopped by adding MgCl2 
(65mM), then incubated with RAF RBD protein. Minimal KRAS* was observed for YZ0711-bound 
KRAS* compared with GTP-loaded KRAS* (DMSO control group) (Figure 2.23 A).  Treatment of 
 
 
Figure 2. 21 Desthiobiotin-GTP pull down assay suggested YZ0711 occupied KRAS* nucleotide 
binding site covalently 
The pull down assay was performed by treatment of KRAS* MEFs with 100 µM YZ0711 or DMSO 
for 6hs prior to probing with desthiobiotin-GTP. 
                
 
                
 
Figure 2. 22 YZ0711 specifically inhibited KRAS* MEFs proliferation 
MEFs were treated with 25 µM  YZ0711, 25 µM YZ0756, or DMSO for 4 days.  
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KRAS* MEFs with YZ0711 also resulted in decreased RAS-bound BRAF, suggesting YZ0711 can 
disrupt RAS signaling (Figure 2.23 B). 
To further investigate whether compound YZ0711 can inhibit the RAS-RAF-MEK-ERK and 
RAS-PI3K-AKT signaling pathways in cells, the phosphorylation levels of ERK and AKT were analyzed 
by western blot (Figure 2.24). Treatment of KRAS* MEFs with YZ0711 resulted in decreased pERK and 









Figure 2. 23 YZ0711 disrupted KRAS*-BRAF interaction 
(A) YZ0711 loaded KRAS* was not able to bind with RAF-RBD. (B) KRAS* MEFs cells treated with 
compound YZ0711 (100 µM) or DMSO was lysed and immunoprecipitated by RAS-antibody 





2.3 Conclusion and Discussion  
Before embarking on a small molecule drug discovery project directed against a specific target 
protein, it is critical to first validate the therapeutic effectiveness of the target in a specific disease, as well 
as the therapeutic index associated with target inhibition124. “Chemical” and “genetic” methods are two 
main approaches used in this target validation where small molecules or genetic tools are used to 
modulate the target function125. Genetic methods including gene knockout and RNAi may have problems 
of generating null mutants for essential genes and lacking alignment between RNAi and inhibitor 
studies125. Small molecule approaches can overcome above difficulties and provide additional information 
about druggability, toxicity, and safety of inhibiting a target.  
KRAS is an essential gene and its gene product interacts with multiple upstream and downstream 
effectors. However, there is a lack of suitable chemical tools that can directly target KRAS. We 
developed a scalable system for testing the in vitro consequences of pharmacological inhibition of KRAS. 
 
 
Figure 2. 24 YZ0711 inhibited RAS-MAPK pathway  
MEFs were treated with DMSO, 1 µM, 5 µM, and 25 µM YZ0711 for 24hs. The pERK and pAKT 
levels were decreased in KRAS* MEFs but not KRASG12V MEFs with the treatment of YZ0711. 
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An enlarged binding pocket was engineered into GTP binding site of KRAS through mutation of two 
conserved residues to alanine. The engineered KRAS is functionally distinguishable from KRASG12V in 
cell. We have designed and synthesized a small-molecule probe that covalently binds to an engineered 
KRAS mutant with high affinity and displaces GTP from the binding pocket. The probe allows selective 
binding to the engineered protein, but not the wild-type protein. The probe is also cell membrane 
permeable and can selectively inhibit RAS signaling in cells.  
There are two challenges facing in fragment-based small molecule design: identification of 
suitable fragment to develop and elaborating the initial fragment to a lead compound. In this chapter, by 
setting critical hydrogen bond interaction during docking, and carefully choosing fragments with suitable 
cell membrane permeability, structural modification possibility and binding affinity, an indazole 
piperidine was selected to be the initial fragment. By employing combinatorial library, a 124 k 
compounds library was generated which largely increased the screening space.  Then, we synthesized top 
scoring compounds shown in Caco-2 cell permeability prediction, glide docking, and covalent docking 
programs, which saved a lot of time and resources. The covalent small molecule developed using this 
approach has improved selectivity to the target and exclusively modifies the engineered cysteine residue, 
which proved the success of this fragment based small molecule design approach.  
While this covalent inhibitor showed specific on-target effect in cells, the cellular activity is not 
as high as expected. There could be many reasons. Firstly, GTP, the endogenous ligand of KRAS, has 
picomolar binding affinity with KRAS and around 0.5 mM concentration in cells. The potency and 
selectivity of small molecule could be dramatic decreased with such high concentration of endogenous 
ligands126. Secondly, KRAS* has a quick turn over in cells comparing with KRASG12V, this quick turn 
over results in higher dosing of inhibitors. Thirdly, SOS1 could not effectively catalyze the exchange of 
GTP to the covalent inhibitor YZ0711, which might result in a low binding rate of YZ0711 to KRAS*. 
Small GTPases contribute to multiple cellular processes and different stages of cancer 
development and progression24, 127-131. They have conserved GTP/GDP binding pockets and share similar 
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activation/deactivation mechanisms. Guanine nucleotide exchange factors (GEFs) catalyze the exchange 
of GDP by GTP, while GTPase-activating proteins (GAPs) accelerate the intrinsic GTPase activity of 
small GTPases. In the active state (GTP-bound state), small GTPases associate with a variety of effectors 
and promote downstream signaling. The system we designed here can be expanded for the design of allele 
selective small molecule inhibitors of other proteins in small GTPase family, thus providing tools to 




Molecular docking and modeling was performed using Glide (versions 2012-2016, Schrödinger) and 
Molecular Operating Environment [MOE] (Chemical Computing Group). All chemical structures were 
drawn using ChemDraw Ultra version 10.0 (Perkin Elmer). All statistical analyses, potency 
determinations, and viability curves were produced using Prism 6.0 (GraphPad Software).  
In-silico libraries  
Libraries of commercially available molecules for general screening purposes were compiled from the 
inventories of Asinex, Enamine, Chembridge, ChemDiv, IBS, Life, Maybridge and TimTec. A fragment 
subset of ~200,000 compounds from the unfiltered library was selected using the following filter criteria: 
Log(P)<3, hydrogen bond acceptors </= 3, hydrogen bond donors </= 3, molecular weight <300, aqueous 
solubility > 0.5 mM. Chemical descriptors were calculated using MOE (Chemical computing group). 
Designed libraries of synthetically accessible molecules were compiled using selected commercially 
available reagents from the inventory of Sigma-Aldrich and Chem-Impex using the Combigen application 





For cell transfection, mutagenesis was performed on human K-RasG12V pBabe puro vector (a gift from Dr. 
Nicole Fehrenbacher, NYU Cancer Institute) using a QuikChange XL site-directed mutagenesis kit from 
Agilent technologies according to the manufacturer’s protocol. Primers were designed using the Agilent 
QuikChange Primer Design application and purchased from Integrated DNA Technologies. For protein 
expression and purification, the K-Ras constructs were cloned into in the pGEX-4T3 vector to obtain 
proteins with a Glutathione S-transferase (GST) tag and pET15b vector to obtain proteins with a His tag.. 
Expression and purification of KRAS*G12VL19AN116AV114C and KRASG12V 
For protein purification, an isolated colony was transferred to 5 mL LB media with 100 μg/mL ampicillin 
and the inoculated culture was incubated with shaking (225 rpm) at 37 °C for 3 h.  The starter culture was 
added to 1 L fresh LB with 100 μg/mL ampicillin.  The culture was incubated with shaking at 37 °C until 
the OD600 reached 0.6.  The temperature was then reduced to 30 °C or 15°C and shaking continued for 30 
min.  GST-tagged KRASG12V protein synthesis was induced by the addition of isopropyl -D-
thiogalactoside (500 μM) and the cells were incubated with shaking (225 rpm) at 15°C overnight. GST-
tagged KRAS*G12VL19AN116AV114C protein synthesis was induced by the addition of isopropyl -D-
thiogalactoside (100uM) and the cells were incubated with shaking (225 rpm) at 30°C overnight. His-
tagged KRASG12V and His-tagged KRAS*G12VL19AN116AV114C protein synthesis was induced by the addition 
of isopropyl -D-thiogalactoside (500uM) and the cells were incubated with shaking (175 rpm) at 15°C 
overnight. The bacteria were harvested by centrifugation at 4,000 × g for 20 min at 4 °C and the obtained 
pellet was stored at -20°C. 
Purification of GST-tagged KRAS*G12VL19AN116AV114C and KRASG12V 
The pellet was resuspended in 25 mL chilled lysis buffer (20 mM HEPES [pH 7.5], 75 mM KCl, 25 mM 
MgCl2, 1 mM TCEP, 0.1 mM EDTA, 0.05% Triton X-100, and Roche protease inhibitor cocktail).  The 
bacteria were lysed by sonication on ice for 3 min and the lysate was centrifuged at 15,000 × g for 45 min 
at 4 °C to remove cell debris.  The clarified lysate was incubated with glutathione Sepharose beads on a 
rotator at 4°C for 2 hours.  The beads were washed with lysis buffer once, and then with wash buffer (50 
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mM Tris-HCl [pH 7.5], 50 mM NaCl, 1 mM TCEP) three times.  The protein was eluted with 10 mM 
glutathione in wash buffer (pH 7.5) and concentrated.  Protein concentration was determined using 
absorbance at 280 nm with extinction coefficient of 55280 M-1 cm-1, and protein purity was assessed by 
gel electrophoresis. 
 
Purification of His-tagged KRAS*G12VL19AN116AV114C and KRASG12V 
The pellet was resuspended in 25mL chilled lysis buffer (100mM NaPhosph Monobasic, 300mM NaCl, 
20% Glycerol, 0.5% chaps (W/V), 15mM 2-mercaptoethanol, 5mM imidazole, pH 7.0, Roche protease 
inhibitor cocktail).  The bacteria were lysed by sonication on ice for 3 min and the lysate was centrifuged 
at 15,000 × g for 45 min at 4 °C to remove cell debris.  The clarified lysate was incubated with Ni 
Sepharose 6 Fast Flow beads (GE Life Sciences) on a rotator at 4°C for 1 hour.  The beads were washed 
with wash buffer (100mM NaPhosph Monobasic, 300mM NaCl, 20% Glycerol, 15mM 2-
mercaptoethanol, 5mM imidazole, pH 7.0) and non-specific binding buffer (20mM imidazole in wash 
buffer). The protein was eluted with 250 mM imidazole in wash buffer. The eluded protein was desalted 
using 10DG-biorad-desalting column immediately. The protein was further purified using gel filtration 
Superdex 100 column in FPLC buffer containing 25 mM Tris-HCl pH 8, 100 mM NaCl, 5 mM MgCl2, 
and 1 mM TCEP.  The fractions containing KRASG12D were pooled together and verified by SDS-PAGE.  
Protein concentration was determined using absorbance at 280 nm with extinction coefficient of 11920 M-
1 cm-1.   
 
Fluorescence polarization assay 
Small-molecule inhibitors (as 50 mM stocks in DMSO) were arrayed in an 10-points dilution series in 
384-well polypropylene plates (reaction buffer: 50 mM Tris pH 7.5, 50 mM NaCl, 5 mM MgCl2, 1 mM 
EDTA, 5 % glycerol, 1 mM TCEP). Compound solutions were transferred at a 1:2 dilution into the assay 
plates (Corning 384, #3821), followed by purified protein (GST-tagged KRAS, final concentration = 5 
μM). The plates were incubated at room temperature for 30 minutes. Then BODIPY-GTP (final 
57 
 
concentration = 125 nM) was added to the plate. Trials were also run with GDP as a reference, no protein 
as a positive control and DMSO as a negative control. The plates were incubated at 4 °C overnight to 
allow for equilibration of the solution.  The fluorescence intensity was measured on a Victor2 TMV plate 
reader (PerkinElmer, 485 nm excitation, 535 nm emission).  
 
Nucleotide exchange assay 
GST tagged KRAS*G12VL19AN116AV114C (20uM) or KRASG12V (20uM) was incubated with BODIPY-GTP 
(200 µM) at room temperature for 1hour in Tris buffer (100 mM Tris, pH 7.5, 1 mM EDTA, 1 mM 
TCEP). The reaction was stopped by adding MgCl2 (65 mM). NAP-5 column was equilibrated with 
reaction buffer (50 mM Tris, pH 7.5, 50 mM NaCl, 5 mM MgCl2, 1mM TCEP). The protein was then run 
through a NAP-5 column to remove free nucleotide. The concentration of the obtained protein was 
determined by Nano-drop and diluted to desired concentration in reaction buffer. For the assay, 5 µL of 
the prepared protein (final concentration 1 µM) in reaction buffer was added to a well of a low volume 
black bottom plate (Corning, 3676). 5 µL of GDP (final concentration 4 µM), GTP (final concentration 4 
µM), or compound YZ0711 (final concentration 4 µM) mixed with SOS1 (final concentration 1 µM), 
EDTA (final concentration 10 mM) in reaction buffer was added. The fluorescence polarization intensity 
was measured on a Victor2 TMV plate reader (PerkinElmer, 485 nm excitation, 535 nm emission). 
 
Retroviral Transfection of Mouse Embryonic Fibroblasts 
Phoenix Ampho packaging cells (ATCC: CRL-3213) were grown to 80% confluence in normal growth 
media (DMEM, 10% FBS, 1% Penicillin/Streptomycin, 2mM L-glutamine) (Invitrogen). 600,000 
cells/well were seeded in 6-well dishes (Corning).  After 20 hours, the media was aspirated and replaced 
with 800 μL Optimem (Life Technologies), and the cells were incubated for 20 minutes at 37°C.  
Meanwhile, 2.5 μg of pBabe puro vector was added to an eppendorf tube with 100 uL Optimem.  6μL of 
lipofectamine 2000 (Invitrogen) was added to 94μL of Optimem in a separate tube.  The two solutions 
were mixed together, and the mixture was then incubated for 20 min at 25°C.  The DNA/lipofectamine 
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emulsion was added dropwise to the Phoenix Ampho well, and the cells were incubated for 4 hours at 
37°C.  After 4 hours, 1mL of Optimem media with 20% FBS was added and the cells were incubated 
overnight at 37°C.  After 24 hours, the transfection media was aspirated and replaced with normal growth 
media.  The next day, 1.5 mL of virus supernatant was collected and kept at 4°C.  The media was 
replaced, and the procedure was repeated after 4, 8, and 24 hours.  The virus supernatants were combined 
and filtered through 0.45μm filter, and then polybrene was added. Meanwhile, Mouse Embryo Fibroblasts 
cells (Kraslox/lox, Hras-/-, Nras-/- RERTnert/ert cells carrying an inducible Cre recombinase, Cre-ERT2) 
(DU315-6, gift from Mariano Barbacid) were seeded at 160,000 cells/well in 6-well dishes. After 14 
hours, the media was removed and 2mL of filtered virus supernatant was added, and 2mL of virus 
supernatant was successively added at two-hour intervals until the total well volume was 6 mL.  After 24 
hours, the media was removed and replaced with selective media (DMEM, 10% HI-FBS, 1% 
Penicillin/Streptomycin, 1X Glutamax, and 1ug/ml puromycin). After 2 weeks of selection with 
puromycin, the cells were cultured in the presence of (Z)-4-hydroxytaoxifen (4OHT) (Sigma, 600nM) for 
another 2 weeks to ablate the endogenous Kras. Then the cells were analyzed for expression using 
western blot. KRAS expression was analyzed by western blot. 
 
Viability assay in Mouse Embryonic Fibroblasts 
KRAS*G12VL19AN116AV114C MEFs and KRAS*G12V MEFs were trypsinized, counted, and seeded into 384-well 
plates at 1,000 cells/well in DMEM/10% HI-FBS/1% p-s/1X Glutamax medium. After 16 h, compounds 
(from 50 mM stocks in DMSO) were arrayed in a 10-point 2-fold dilution series in 384-well 
polypropylene plates. Compound solutions were transferred at a 1:5 dilution into assay plates. After 48 h, 
a 50% Presto blue solution was added to a final concentration of 10% Presto blue. After 6 h of incubation, 
fluorescence intensity was determined using a Victor3 plate reader (Perkin Elmer) with a 535 nm 
excitation filter and a 590 nm emission filter. All compound measurements were performed in duplicate.  
 
Western blots for Analysis of Cell Line Transfection 
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0.25 million cells/well were seeded in DMEM with 1X Glutamax, 10% heat-inactivated FBS, and 1% 
P/S. After the cells grew to 80% confluence, the medium was changed to serum-free medium, and the 
cells incubated for 24 hr. The cells were stimulated with human EGF (10 ng/ml) for 15 min to stimulate 
RAS-dependent pERK and pAKT signaling. Then the cells were washed with cold PBS and lysed with 
RIPA lysis buffer (Thermo Fisher, catalog number: 89900) containing 1X protease inhibitor cocktail 
(Thermo Fisher, catalog number: 78430). Unlysed cells and debris were pelleted for 15 min at 13,000 rpm 
at 4°C. Samples were separated using SDS-PAGE and transferred to a natural cellulose membrane. 
Transfer was performed using the iBlot system (Invitrogen). Membranes were treated with Li-COR 
Odyssey blocking buffer for 20min at 25°C, then incubated with primary antibody (1:1000) in a 1:1 
solution of PBS-T and Li-COR odyssey blocking buffer overnight at 4°C. Following three 5 min washes 
in PBS-T, the membrane was incubated with secondary antibodies (1:2000) in a 1:1 solution of PBS-T 
and Li-COR Odyssey blocking buffer for 1 hour at 25°C. Following three 5 min washes in PBS-T, the 
membrane was scanned using the Li-COR Odyssey Imaging System. Antibodies for pERK1/2, ERK1/2, 
pAKT ser473, AKT, pan-RAS, PI3Kgamma, c-RAF, b-RAF (Cell Signaling), and alpha-Tubulin (Santa 
Cruz) were detected using a goat anti-rabbit or goat anti-mouse IgG antibody conjugated to an IRdye at 
800CW and 680CW conjugated, respectively (Li-COR Biosciences). 
 
RAF-RBD pull down assay to test KRAS* switch function 
His tagged KRAS*G12VL19AN116AV114C (0.0042 µg/µL) was incubated with GDP (40 µM) or GTP (40 µM) 
at room temperature for 15 min in Tris buffer (100 mM Tris, pH 7.5, 1 mM EDTA, 1 mM TCEP). The 
reaction was stopped by adding MgCl2 (65 mM). 0.42ug GDP loaded KRAS* or GTP loaded KRAS* was 
incubated with 7ug RAF RBD beads in 400 µL HEPES buffer (25 mM HEPES, pH 7.5, 150 mM NaCl, 5 
mM MgCl2, 10% glycerol, 1 mM TCEP, 0.1% Tween20, 0.5% Prionex) at 4°C for 1 hour. The beads 
were collected by centrifuging at 800 rpm for 2min and washed for 3 times with HEPES buffer. Then the 
beads was boiled with SDS sample buffer and analyzed by western blot.   
RAF-RBD pull down assay to test whether compound YZ0711 can disrupt KRAS* effector binding 
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His tagged KRAS*G12VL19AN116AV114C (1 µg/µL) was incubated with GTP (400 µM) at room temperature 
for 1hour in Tris buffer (100 mM Tris, pH 7.5, 1 mM EDTA, 1 mM TCEP). The reaction was stopped by 
adding MgCl2 (65 mM). The protein was then run through a NAP-5 column to remove free nucleotide. 
The concentration of the obtained protein was determined by Nano-drop. GTP loaded KRAS* (0.0042 
µg/µL) was incubated with DMSO or YZ0711 (40 µM) at room temperature for 15 min in Tris buffer. 
The reaction was stopped by adding MgCl2 to a final concentration of 65 mM. 0.42ug GTP loaded 
KRAS* (DMSO control) or YZ0711 loaded KRAS* was incubated with 7ug RAF RBD beads in 400 µL 
HEPES buffer (25 mM HEPES, pH 7.5, 150 mM NaCl, 5 mM MgCl2, 10% glycerol, 1 mM TCEP, 0.1% 
Tween20, 0.5% Prionex) at 4°C for 1 hour. The beads were collected by centrifuging at 800 rpm for 2min 
and washed for 3 times with HEPES buffer. Then the beads was boiled with SDS sample buffer and 
analyzed by western blot.   
 
Gene expression analysis using RT-qPCR experiment 
Cells from six-well plates were trypsinized and centrifuged at 3,000 rpm for 3 min. The cell pellet was 
then lysed and the RNA was extracted using the QIAshredder and RNAeasy extraction kits (QIAGEN) 
according to the manufacturer’s protocol. 2 mg of RNA from each sample was then converted to cDNA 
using the TaqMan RT Kit (Applied Biosystems). Primers for Quantitative PCR (qPCR) were designed 
with Primer Express. qPCR was performed using Power SYBR Green Master Mix (Applied Biosystems) 
in a 96-well format, in triplicate, using an Applied Biosystems 7300 Cycler set to absolute quantification. 
Expression changes were computed using the ΔΔCt method with Actin as an internal reference gene. 
 
Western Blotting with Treatment of YZ0711  
0.25 million cells/well were seeded in DMEM with 1X Glutamax, 10% heat-inactivated FBS, and 1% 
P/S. After the cells grew to 80% confluence, the medium was changed to serum-free medium containing 
DMSO or compound YZ0711 at indicated concentration, and the cells incubated for 24 hr. Then the cells 





KRAS*G12V L19A N116A V114C MEFs were seeded 16 h prior to use in DMEM/10% HI-FBS/1% p-s/1X 
Glutamax medium. The medium was then aspirated and replaced with medium containing the inhibitors 
(from 50mM DMSO stocks) and cells were incubated for 6 hr. The medium was removed, washed with 
cold PBS, lysed and spun down at 13,000 rpm at 4°C to remove unlysed cells and debris. The lysate was 
buffer exchanged using DG10 columns to PBS. The lysate was added with protease inhibitor cocktail and 
diluted with PBS to 2mg/ml. 500uL (1mg) was transferred to a microcentrifuge tube. 1uL of 0.5M EDTA 
was added and incubated for 5 minutes at room temperature. 5uM ActiveX GTP-desthiobiiotin (Thermo 
Scientific) and 20uM MgCl2 were added, mixed and incubated for 10 minute at room temperature. 500uL 
of 8M Urea/IP Lysis Buffer and 50uL of 50% High Capacity Streptavidin Agarose resin slurry were 
added. After 2 hour incubation on rotator, the sample was centrifuged at 800 x g for 2 minute and washed 
2X with 4M Urea/IP Lysis Buffe. The sample was then analyzed by western blotting procedure. 
 
Immunoprecipitations 
MEFs were seeded 16 h prior to use in 10% HI-FBS/1% p-s/1X Glutamax in DMEM. Media was 
aspirated and replaced with media containing YZ0711 (from a 50 mM DMSO stock). After 10h cells 
were washed 2X with ice cold buffer (25 mM tris, 100 mM NaCl, 1 mM TCEP, 5 mM MgCl2, 0.1% 
tween-20 and 1 protease inhibitor/25 mL). Cells were scrapped, pelleted at 13,000 rpm for 10 min at 4 oC, 
then passed through a 26 gauge needle several times. The solution was spun down a second time at 
13,000 rpm for 15 min at 4 oC, to remove unlysed cells and debris. Anti-RAS antibody (Abcam, 
EPR3255) was then added to the lysate (1:100) and the solution was rocked at 4 oC for 16 h. Protein A 
agrose beads were then added and the solution was rotated at 4 oC for an additional 6 h. The solutions 
were spun down at 1500xg for 2 min and the supernatant was removed by syringe. The beads were 




Determining cellular concentrations of compounds 
KRAS*G12VL19AN116AV114C MEFs were grown in DMEM/10% HI-FBS/1% p-s/1X Glutamax medium and 
seeded in 6-well plates at a density of 0.4x106 cells/well, followed by overnight incubation. On the 
following day, the growth medium was removed and the cells were rinsed twice with PBS, then DMEM 
growth medium (without FBS) containing 20uM compounds was added. Cells were treated for 4 hours. 
After treatment, the growth media was removed and the cells were rinsed with PBS, trypsinized and 
suspended in DMEM/10% HI-FBS/1% p-s/1X Glutamax media. The cells were counted on a Vi-Cell XR 
Cell Viability Analyzer (Beckman Coulter), and the average diameter was recorded. An aliquot of the 
appropriate volume of cell suspension (1 x 10^6 cells per sample) was transferred to a 15 mL Falcon tube 
(3 samples each). The cells were pelleted at 1000 g for 5 minutes. The cells were washed twice with PBS 
and transferred to a 1.5 mL Eppendorf tube. The cells were pelleted at 3000 rpm for 3 minutes, after 
which the PBS was removed and the pellet was lysed by adding 150 µL of methanol/acetonitrile (1:1). 
The suspension was mixed well by pipetting and the compound was extracted overnight at 4 oC. The 
samples were spun at 1400 g for 75 minutes at 4 oC, and the supernatant (75 µL) was withdrawn and 
transferred to a sample vial with insert. The samples were analyzed by LC-MS. LC-MS analysis was 
performed on a platform comprising a Thermo Scientific Dionex Ultimate 3000 and a Bruker amaZon SL 
equipped with an electrospray ionization source controlled by Bruker Hystar 3.2. Chromatographic 
separation was performed by injecting the sample on an Agilent Eclipse Plus C18 column (2.1 x 50 mm, 
3.5 µm) at 20 oC. The flow rate was maintained at 400 µL/min. The initial flow conditions were 60% 
solvent A (water containing 0.1% acetic acid) and 40% solvent B (methanol containing 0.1% acetic acid). 
Solvent B was raised to 60% over 0.25 minutes and to 70% by 6.75 minutes. Solvent B was raised to 95% 
by 7.00 minutes and lowered back to initial conditions (40%) by 8.00 minutes with a total run time of 
9.00 minutes. The peak area was converted to a concentration using a standard curve and the intracellular 
concentration was determined using the following formula:1 
𝐶𝑒𝑙𝑙𝑢𝑙𝑎𝑟 𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 = 𝑆𝑎𝑚𝑝𝑙𝑒 𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 ×  
𝑆𝑎𝑚𝑝𝑙𝑒 𝑉𝑜𝑙𝑢𝑚𝑒




(1)  Colletti, L. M.; Liu, Y.; Koev, G.; Richardson, P. L.; Chen, C. M.; Kati, W. Anal. Biochem. 2008, 
383 (2), 186. 
Liquid chromatography/mass spectrometry sample preparation 
20uM His-KRAS*G12VL19AN116AV114C and His-KRASG12V were incubated with 200uM YZ0711 overnight at 
4 oC in buffer (20mM Hepes, pH 7.5, 150mM NaCl, 1mM TCEP, 20% glycerol, 1mM EDTA). The 
reaction was stopped by adding MgCl2 to a final concentration of 65mM. The sample was then purified 
by NAP-5 column and concentrated using Millipore spin column with 10kDa cut off filter. For each 70ul 
of protein sample, 0.4uL of dithiothreitol (75ug/uL) was added and the sample was heated at 60 oC for 30 
minutes. Then the sample was cooled to room temperature and centrifuged briefly to bring down 
condensed droplets. 1.0uL iodoacetamide (110ug/uL) was added to the sample and the sample was placed 
in dark at room temperature for 30 minutes. Then the sample was separated by SDS PAGE gel for mass 
spectrometry analysis.  
 
Synthesis of chemical materials 
General information. All reactions were carried out under a nitrogen atmosphere under anhydrous 
conditions unless indicated otherwise. Anhydrous methylene chloride (DCM), tetrahydrofuran (THF), 
N,N-dimethylformamide (DMF) and pyridine were purchased from Sigma-Aldrich. Reactions were 
magnetically stirred and monitored by thin layer chromatography carried out by Merck pre-coated 0.25 
mm silica plates containing a 254 nm fluorescence indicator. Flash chromatography was performed on a 
Teledyne combiflash companion automatic flash chromatography system. Preparative thin layer 
chromatography was performed on 1 mm. Proton nuclear magnetic resonance spectra (1H NMR, 300 
MHz, 400 MHz, 500 MHz) and proton decoupled carbon nuclear magnetic resonance spectra (13C NMR, 
100 MHz, 125 MHz) were obtained on a Bruker DPX 300, 400, or 500 MHz instruments in 
deuterochloroform (CDCl3) with residual chloroform as internal standard. Other deuterated solvents that 
were used include d4-MeOD and d6-DMSO. 
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Abbreviations: TEA = triethyl amine, EtOAc = ethyl acetate, HCl = hydrochloric acid, MeOH = 
methanol, EtOH= ethanol, NaHCO3 = sodium bicarbonate, Na2SO4 = sodium sulfate, NH4Cl = 
ammonium chloride, rt = room temperature, TFA = trifluoroacetic acid, THF = tetrahydrofuran. BOC = 
tert-butyloxycarbonyl, SOCl2 = thionyl chloride, DMAP = 4-dimethylaminopyridine, NH2NH2  H2O = 
hydrazine monohydrate.  
 
Compound A synthesis 
1,750mg 2-fluoro-5-nitrobenzonitrile (1.0 equiv.) were dissolved in 29mL EtOH (0.36 M), the reaction as 
protected with N2 and heated to 50 °C, then 661uL Hydrazine monohydrate (2.0 equiv.) was added. The 
reaction was refluxed for 1.5 hours, and then cooled to room temperature. The precipitate was filtered and 
the filtrate was collected and concentrated. The resulting residue was dissolved in EtOAc and washed 
with saturated ammonium chloride. The organic phase was separated, dried with anhydrous Na2SO4, and 
concentrated to yield indazole. The crude product of indazole was used directly in the next step without 
purification.  
602mg indazole (1.0 equiv.), 729mg tertbutyldicarbonate (1.0 equiv.), 103mg DMAP (0.25 equiv.), and 
470uL triethylamine (1.0 equiv.) were dissolved in 16mL THF (0.2M) at room temperature under 
nitrogen. After stirring for 30min, the reaction was concentrated and the residue was dissolved in EtOAc, 
then washed with saturated ammonium chloride. The organic phase was separated, dried with anhydrous 
Na2SO4, and concentrated to yield indazole. The crude product of BOC-indazole was used directly in the 
next step without purification. 
1.0g BOC-indazole (1.0 equiv.) and 90mg 10% Pd/C (0.2 equiv.) were dissolved in 30mL MeOH 
(0.12M). The mixture was gas exchanged with H2 then stirred under H2 overnight. The reaction was 




























10% MeOH/DCM to afford compound A (86% yield over three steps). 1H NMR (400 MHz, Chloroform-
d) δ 7.61 (s, 1H), 6.76 (d, J = 8.9 Hz, 1H), 6.66 (s, 1H), 5.06 (s, 2H), 3.84 (s, 2H), 1.54 (s, 9H). 
 
Compound B synthesis 
720.8mg 3,4-(Methylenedioxy)phenylacetic acid (1.0 equiv.) and 435uL thionyl chloride (1.5 equiv.) 
were dissolved in 12mL dichloromethane (0.33M) at room temperature. Then 3 drops of 
dimethylformamide was added to the solution. After 2 hours, the reaction mixture was concentrated to 
provide 3,4-(Methylenedioxy)phenylacetyl chloride. 790 mg compound A (0.8 equiv.) and 557uL triethyl 
amine (1.0 equiv.) were dissolved in 60mL anhydrous dichloromethane and cooled to -15°C. 3,4-
(Methylenedioxy)phenylacetyl chloride in 1mL anhydrous dichoromethane was slowly added to the 
reaction. After 1 hour, the reaction was washed with brine. The organic phase was separated, dried with 
anhydrous Na2SO4, and concentrated. The product was purified by combiflash 0-5% MeOH/DCM to 
afford compound B (86% yield). 1H NMR (400 MHz, DMSO-d6) δ 10.20 (s, 1H), 8.20 – 8.14 (m, 1H), 
7.88 (d, J = 8.9 Hz, 1H), 7.51 (dd, J = 8.9, 2.0 Hz, 1H), 6.94 (d, J = 1.6 Hz, 1H), 6.90 – 6.78 (m, 2H), 
6.24 (s, 2H), 5.99 (s, 2H), 3.57 (s, 2H), 1.58 (s, 9H). 
 
Compound C synthesis 
641mg compound B (1.0 equiv.) was dissolved in 7mL anhydrous pyridine and cooled to 0°C. 581mg 3-
nitrobenzoyl chloride  (2.0 equiv.) was dissolved in 4mL anhydrous pyridine and was added to the 







































































After completion, 20mL EtOAc was added to the reaction, the reaction was washed with saturated 
ammonium chloride for several times. The organic phase was separated, dried with anhydrous Na2SO4, 
and concentrated. The product was purified by combiflash 0-5% MeOH/DCM to afford compound C 
(70% yield). 1H NMR (400 MHz, Chloroform-d) δ 9.31 (s, 1H), 8.85 (t, J = 2.0 Hz, 1H), 8.42 (ddd, J = 
8.3, 2.3, 1.0 Hz, 1H), 8.30 (ddd, J = 7.7, 1.8, 1.0 Hz, 1H), 8.11 (d, J = 2.0 Hz, 1H), 8.03 (d, J = 9.1 Hz, 
1H), 7.68 (ddd, J = 9.8, 7.7, 5.0 Hz, 2H), 7.38 (s, 1H), 6.81 (td, J = 8.1, 7.4, 4.1 Hz, 3H), 5.98 (s, 2H), 
3.67 (s, 2H), 1.68 (s, 9H). 
 
Compound D synthesis 
813mg compound C (1.0 equiv.) and 36mg 10% Pd/C (0.2 equiv.) was dissolved in 30mL 1:1 ratio of 
MeOH and EtOAc (0.05M). The mixture was gas exchanged with H2 then stirred under H2 overnight. The 
reaction was filtered through celite and concentrated under vacuo. The resulting mixture was purified by 
combiflash 0-10% MeOH/DCM to afford compound D (80% yield).  
 
Compound YZ0711 synthesis 
81.3mg compound D (1.0 equiv.) and 27uL dimethyl-isopropyl amine (1.1 equiv.) were dissolved in 
20mL anhydrous dichloromethane (0.008M), and cooled to -15°C. 13.5uL chloroacetyl chloride (1.1 
equiv.) dissolved in 1mL dichloromethane was added dropwise to the reaction. After 2 hours, the reaction 
was washed with brine. The organic phase was separated, dried with anhydrous Na2SO4, and 
concentrated. The crude product was dissolved in 1.6ml anhydrous dichloromethane and 0.8ml 
trifluoroacetic acid at 0°C. then the reaction was slowly warmed to room temperature and stirred under N2 

















10% MeOH/DCM to provide compound YZ0711 (40% yield). 1H NMR (400 MHz, DMSO-d6) δ 12.71 
(s, 1H), 10.70 (s, 1H), 10.48 (s, 1H), 10.07 (s, 1H), 8.20 (t, J = 1.9 Hz, 1H), 7.93 (d, J = 1.8 Hz, 1H), 7.88 
– 7.77 (m, 2H), 7.59 – 7.46 (m, 2H), 7.43 (d, J = 8.9 Hz, 1H), 6.93 – 6.75 (m, 3H), 5.97 (s, 2H), 4.29 (s, 
2H), 3.52 (s, 2H). MS (APCI) m/z: [M + H]+ Calcd for C25H20ClN5O5 506.12, found 506.4 
 
1H NMR (400 MHz, DMSO-d6) δ 12.70 (s, 1H), 10.67 (s, 1H), 10.32 (s, 1H), 10.07 (s, 1H), 8.26 (d, J = 
2.1 Hz, 1H), 7.99 – 7.90 (m, 1H), 7.93 (s, 1H), 7.78 (d, J = 7.8 Hz, 1H), 7.59 – 7.39 (m, 3H), 6.93 – 6.75 
(m, 3H), 6.46 (dd, J = 17.0, 10.1 Hz, 1H), 6.30 (dd, J = 17.0, 2.0 Hz, 1H), 5.96 (s, 2H), 5.79 (dd, J = 10.1, 
2.0 Hz, 1H), 3.52 (s, 2H). 
 
1H NMR (400 MHz, DMSO-d6) δ 12.71 (s, 1H), 10.69 (s, 1H), 10.48 (s, 1H), 10.12 (s, 1H), 8.20 (t, J = 
1.9 Hz, 1H), 7.95 (d, J = 2.0 Hz, 1H), 7.88 – 7.77 (m, 2H), 7.60 – 7.45 (m, 2H), 7.43 (d, J = 8.9 Hz, 1H), 
7.24 – 7.09 (m, 3H), 7.04 (d, J = 7.4 Hz, 1H), 4.29 (s, 2H), 3.57 (s, 2H), 2.28 (s, 3H). MS (APCI) m/z: [M 






























1H NMR (400 MHz, DMSO-d6) δ 12.71 (s, 1H), 10.67 (s, 1H), 10.33 (s, 1H), 10.12 (s, 1H), 8.26 (t, J = 
2.0 Hz, 1H), 7.95 (dd, J = 5.3, 2.1 Hz, 2H), 7.82 – 7.75 (m, 1H), 7.60 – 7.39 (m, 3H), 7.24 – 7.09 (m, 3H), 
7.04 (d, J = 7.5 Hz, 1H), 6.46 (dd, J = 17.0, 10.1 Hz, 1H), 6.30 (dd, J = 17.0, 2.1 Hz, 1H), 5.79 (dd, J = 
10.0, 2.1 Hz, 1H), 3.58 (s, 2H), 2.28 (s, 3H). MS (APCI) m/z: [M + H]+ Calcd for C26H23N5O3 454.18, 
found 454.4 
 
1H NMR (400 MHz, DMSO-d6) δ 12.71 (s, 1H), 10.70 (s, 1H), 10.50 (s, 1H), 9.90 (s, 1H), 8.23 (t, J = 2.0 
Hz, 1H), 7.95 (d, J = 1.8 Hz, 1H), 7.88 – 7.78 (m, 2H), 7.57 – 7.39 (m, 3H), 4.29 (s, 2H), 4.27 – 4.18 (m, 














































1H NMR (400 MHz, DMSO-d6) δ 12.76 (s, 1H), 10.74 (s, 1H), 10.53 (s, 1H), 10.21 (s, 1H), 8.20 (s, 1H), 
7.94 (s, 1H), 7.88 – 7.77 (m, 2H), 7.63 – 7.40 (m, 6H), 7.30 (d, J = 8.4 Hz, 1H), 4.29 (s, 2H), 3.72 (s, 2H), 
2.59 (s, 3H). MS (APCI) m/z: [M + H]+ Calcd for C26H21ClN6O4 517.13, found 517.4 
 
1H NMR (400 MHz, DMSO-d6) δ 12.75 (s, 1H), 10.72 (s, 1H), 10.36 (s, 1H), 10.21 (s, 1H), 8.25 (s, 1H), 
7.95 (dd, J = 7.4, 2.0 Hz, 2H), 7.78 (d, J = 7.7 Hz, 1H), 7.63 – 7.40 (m, 5H), 7.30 (dd, J = 8.4, 1.7 Hz, 
1H), 6.46 (dd, J = 16.9, 10.0 Hz, 1H), 6.29 (dd, J = 17.0, 2.0 Hz, 1H), 5.79 (dd, J = 10.0, 2.1 Hz, 1H), 
3.72 (s, 2H), 2.59 (s, 3H). 
 
1H NMR (400 MHz, DMSO-d6) δ 12.71 (s, 1H), 10.70 (s, 1H), 10.50 (s, 1H), 9.86 (s, 1H), 8.23 (d, J = 1.9 
Hz, 1H), 7.92 (s, 1H), 7.88 – 7.79 (m, 2H), 7.58 – 7.47 (m, 2H), 7.43 (dd, J = 8.9, 0.8 Hz, 1H), 6.85 – 































= 7.7 Hz, 2H). MS (APCI) m/z: [M + H]+ Calcd for C26H22ClN5O5 520.13, found 520.5
 
1H NMR (400 MHz, DMSO-d6) δ 12.70 (s, 1H), 10.65 (s, 1H), 10.12 (s, 1H), 9.86 (s, 1H), 8.20 (s, 1H), 
7.91 (s, 1H), 7.84 (d, J = 8.2 Hz, 1H), 7.76 (d, J = 7.8 Hz, 1H), 7.58 – 7.39 (m, 3H), 6.85 – 6.77 (m, 2H), 
6.74 – 6.67 (m, 1H), 5.95 (s, 2H), 2.83 (t, J = 7.6 Hz, 2H), 2.57 (t, J = 7.7 Hz, 2H), 2.08 (s, 3H). MS 
(APCI) m/z: [M + H]+ Calcd for C26H23N5O5 486.17, found 486.3 
 
1H NMR (400 MHz, DMSO-d6) δ 12.70 (s, 1H), 10.70 (s, 1H), 10.50 (s, 1H), 9.80 (s, 1H), 8.23 (t, J = 1.9 
Hz, 1H), 7.94 – 7.79 (m, 3H), 7.57 – 7.47 (m, 2H), 7.42 (d, J = 9.0 Hz, 1H), 6.82 – 6.75 (m, 2H), 6.66 
(dd, J = 7.9, 1.7 Hz, 1H), 5.93 (s, 2H), 4.30 (s, 2H), 2.88 (dd, J = 13.3, 7.6 Hz, 1H), 2.73 (p, J = 6.9 Hz, 
1H), 2.57 – 2.52 (m, 1H), 1.08 (d, J = 6.7 Hz, 3H). MS (APCI) m/z: [M + H]+ Calcd for C27H24ClN5O5 













































1H NMR (400 MHz, DMSO-d6) δ 12.69 (s, 1H), 10.62 (s, 1H), 9.80 (s, 1H), 7.94 (d, J = 1.8 Hz, 1H), 7.66 
– 7.54 (m, 2H), 7.52 – 7.35 (m, 3H), 7.14 (dd, J = 7.8, 2.3 Hz, 1H), 6.82 – 6.75 (m, 2H), 6.66 (dd, J = 7.9, 
1.7 Hz, 1H), 5.93 (s, 2H), 2.88 (dd, J = 13.3, 7.7 Hz, 1H), 2.73 (p, J = 6.8 Hz, 1H), 2.55 (s, 1H), 1.08 (d, J 
= 6.7 Hz, 3H). [M + H]+ Calcd for C25H23N5O4 458.18, found 458.4 
 
1H NMR (400 MHz, DMSO-d6) δ 12.68 (s, 1H), 10.65 (s, 1H), 10.13 (s, 1H), 9.80 (s, 1H), 8.20 (s, 1H), 
7.93 – 7.80 (m, 2H), 7.76 (d, J = 7.8 Hz, 1H), 7.56 – 7.38 (m, 3H), 6.78 (d, J = 7.9 Hz, 2H), 6.66 (d, J = 
7.9 Hz, 1H), 5.93 (s, 2H), 2.88 (dd, J = 13.3, 7.6 Hz, 1H), 2.73 (p, J = 7.0 Hz, 1H), 2.52 (d, J = 19.4 Hz, 
1H), 2.09 (s, 3H), 1.08 (d, J = 6.7 Hz, 3H). [M + H]+ Calcd for C27H25N5O5 500.19, found 500.4 
 
1H NMR (400 MHz, DMSO-d6) δ 12.71 (s, 1H), 10.70 (s, 1H), 10.50 (s, 1H), 9.87 (s, 1H), 8.23 (s, 1H), 
7.92 (s, 1H), 7.83 (t, J = 8.0 Hz, 2H), 7.57 – 7.47 (m, 2H), 7.42 (d, J = 8.9 Hz, 1H), 7.16 (d, J = 8.5 Hz, 
2H), 6.84 (d, J = 8.6 Hz, 1H), 6.49 (s, 1H), 4.29 (s, 2H), 3.70 (s, 3H), 2.85 (t, J = 7.7 Hz, 2H), 2.71 – 2.64 
































1H NMR (400 MHz, DMSO-d6) δ 12.71 (s, 1H), 10.68 (s, 1H), 10.35 (s, 1H), 9.87 (s, 1H), 8.28 (t, J = 1.9 
Hz, 1H), 7.99 – 7.90 (m, 2H), 7.80 (d, J = 7.8 Hz, 1H), 7.59 – 7.47 (m, 2H), 7.43 (dd, J = 8.9, 0.8 Hz, 
1H), 7.19 – 7.12 (m, 2H), 6.90 – 6.77 (m, 2H), 6.47 (dd, J = 17.0, 10.1 Hz, 1H), 6.31 (dd, J = 17.0, 2.0 
Hz, 1H), 5.80 (dd, J = 10.1, 2.0 Hz, 1H), 3.70 (s, 3H), 2.85 (t, J = 7.6 Hz, 2H), 2.64 – 2.52 (m, 2H). [M + 
H]+ Calcd for C27H25N5O4 484.19, found 484.4 
 
1H NMR (400 MHz, DMSO-d6) δ 12.72 (s, 1H), 10.70 (s, 1H), 10.49 (s, 1H), 10.07 (s, 1H), 8.20 (s, 1H), 
7.93 (s, 1H), 7.83 (dd, J = 15.1, 7.9 Hz, 2H), 7.58 – 7.40 (m, 3H), 6.83 (d, J = 1.4 Hz, 1H), 6.78 (d, J = 
1.2 Hz, 2H), 4.29 (s, 2H), 4.20 (s, 4H), 3.48 (s, 2H). [M - H]- Calcd for C26H22ClN5O5 518.13, found 
518.3 
 
1H NMR (400 MHz, DMSO-d6) δ 12.72 (s, 1H), 10.68 (s, 1H), 10.34 (s, 1H), 10.07 (s, 1H), 8.25 (t, J = 













































1H), 6.78 (d, J = 1.2 Hz, 2H), 6.47 (dd, J = 17.0, 10.1 Hz, 1H), 6.30 (dd, J = 17.0, 2.0 Hz, 1H), 5.80 (dd, J 
= 10.1, 2.0 Hz, 1H), 4.20 (s, 4H), 3.48 (s, 2H). [M + H]+ Calcd for C27H23N5O5 498.17, found 498.4 
 
1H NMR (400 MHz, DMSO-d6) δ 12.75 (s, 1H), 10.68 (s, 1H), 10.10 (s, 1H), 8.16 (d, J = 2.0 Hz, 1H), 
7.92 (s, 0H), 7.82 (dd, J = 8.1, 2.1 Hz, 1H), 7.71 (dd, J = 19.8, 8.2 Hz, 2H), 7.51 – 7.39 (m, 2H), 7.34 
(ddd, J = 8.3, 6.8, 1.1 Hz, 1H), 7.06 (dd, J = 8.0, 6.9 Hz, 1H), 2.06 (s, 3H). [M + H]+ Calcd for 
C16H14N4O2 295.11, found 295.3 
 
1H NMR (400 MHz, DMSO-d6) δ 12.77 (s, 1H), 10.75 (s, 1H), 10.48 (s, 1H), 8.21 (t, J = 1.9 Hz, 1H), 
7.83 (td, J = 7.6, 7.1, 1.9 Hz, 2H), 7.71 (d, J = 8.2 Hz, 1H), 7.50 (dd, J = 9.6, 8.2 Hz, 2H), 7.36 (ddd, J = 
8.3, 6.7, 1.1 Hz, 1H), 7.08 (dd, J = 8.1, 6.9 Hz, 1H), 4.29 (s, 2H). [M + H]+ Calcd for C16H13ClN4O2 
































1H NMR (400 MHz, DMSO-d6) δ 12.78 (s, 1H), 10.73 (s, 1H), 10.34 (s, 1H), 8.27 (t, J = 2.0 Hz, 1H), 
7.98 – 7.91 (m, 1H), 7.84 – 7.76 (m, 1H), 7.71 (dd, J = 8.2, 1.1 Hz, 1H), 7.54 – 7.45 (m, 2H), 7.36 (ddd, J 
= 8.3, 6.7, 1.1 Hz, 1H), 7.09 (ddd, J = 8.0, 6.8, 0.9 Hz, 1H), 6.47 (dd, J = 17.0, 10.1 Hz, 1H), 6.30 (dd, J = 
17.0, 2.0 Hz, 1H), 5.79 (dd, J = 10.0, 2.1 Hz, 1H). [M + H]+ Calcd for C17H14N4O2 307.11, found 307.3 
 
1H NMR (400 MHz, DMSO-d6) δ 12.76 (s, 1H), 10.74 (s, 1H), 10.17 (s, 1H), 7.83 – 7.75 (m, 2H), 7.69 
(d, J = 8.2 Hz, 1H), 7.53 – 7.41 (m, 2H), 7.41 – 7.30 (m, 2H), 7.11 – 7.02 (m, 1H), 6.83 (dd, J = 16.4, 
10.0 Hz, 1H), 6.13 (d, J = 16.4 Hz, 1H), 6.05 (d, J = 10.0 Hz, 1H). [M + H]+ Calcd for C16H14N4O3S 
343.37, found 343.3 
 
1H NMR (400 MHz, DMSO-d6) δ 12.80 (s, 1H), 10.89 (s, 1H), 10.05 (s, 1H), 8.40 (d, J = 2.1 Hz, 1H), 
7.95 (dd, J = 8.4, 2.1 Hz, 1H), 7.71 (dd, J = 8.3, 2.7 Hz, 2H), 7.52 – 7.37 (m, 1H), 7.40 – 7.30 (m, 1H), 




































1H NMR (400 MHz, DMSO-d6) δ 12.42 (s, 1H), 10.91 (s, 1H), 8.87 (s, 1H), 8.52 – 8.41 (m, 2H), 7.85 (t, 
J = 8.0 Hz, 1H), 7.26 (d, J = 8.9 Hz, 1H), 6.89 (dd, J = 8.9, 2.1 Hz, 1H), 6.66 (d, J = 2.0 Hz, 1H), 5.22 (d, 
J = 8.3 Hz, 1H), 4.15 (d, J = 13.3 Hz, 1H), 3.75 (d, J = 13.5 Hz, 1H), 3.45 (dd, J = 8.4, 3.5 Hz, 1H), 3.17 
(d, J = 5.1 Hz, 2H), 2.88 – 2.77 (m, 1H), 1.99 (s, 3H), 1.95 – 1.83 (m, 1H), 1.38 – 1.11 (m, 2H). 
 
1H NMR (400 MHz, DMSO-d6) δ 12.33 (d, J = 18.6 Hz, 1H), 10.46 (s, 1H), 10.12 (s, 1H), 8.16 (d, J = 1.9 
Hz, 1H), 7.82 (dd, J = 8.1, 2.1 Hz, 1H), 7.73 (d, J = 7.7 Hz, 1H), 7.44 (t, J = 7.9 Hz, 1H), 7.25 (dd, J = 
8.9, 3.7 Hz, 1H), 6.87 (dt, J = 9.0, 2.6 Hz, 1H), 6.66 – 6.59 (m, 1H), 5.24 (d, J = 25.1 Hz, 1H), 4.14 (dd, J 
= 11.4, 6.7 Hz, 1H), 3.76 (dd, J = 13.7, 4.5 Hz, 1H), 3.43 (tt, J = 11.8, 5.1 Hz, 1H), 3.17 (ddd, J = 13.6, 
10.7, 2.9 Hz, 1H), 2.54 (s, 1H), 2.07 (s, 2H), 2.05 – 1.84 (m, 5H), 1.42 – 1.15 (m, 2H). 
 
1H NMR (400 MHz, DMSO-d6) δ 13.02 (s, 1H), 10.88 (d, J = 6.1 Hz, 1H), 10.49 (s, 1H), 8.19 (d, J = 21.4 
Hz, 1H), 7.92 – 7.78 (m, 2H), 7.68 (d, J = 8.1 Hz, 1H), 7.59 – 7.46 (m, 2H), 7.23 (dt, J = 9.6, 1.9 Hz, 1H), 
4.65 (s, 1H), 4.42 (d, J = 13.3 Hz, 1H), 4.28 (s, 2H), 3.83 (dd, J = 15.3, 13.1 Hz, 2H), 3.10 (t, J = 12.9 Hz, 
1H), 2.56 (t, J = 12.7 Hz, 1H), 1.99 (s, 1H), 1.88 (s, 3H), 1.81 (d, J = 15.1 Hz, 1H), 1.26 – 1.09 (m, 1H). 































1H NMR (400 MHz, DMSO-d6) δ 12.42 (s, 1H), 10.86 (s, 1H), 8.37 (d, J = 8.4 Hz, 2H), 8.27 (d, J = 8.4 
Hz, 2H), 7.26 (d, J = 8.9 Hz, 1H), 6.88 (dd, J = 9.0, 2.1 Hz, 1H), 6.65 (d, J = 2.1 Hz, 1H), 5.22 (d, J = 8.3 
Hz, 1H), 4.15 (d, J = 13.3 Hz, 1H), 3.75 (d, J = 13.8 Hz, 1H), 3.50 – 3.38 (m, 0H), 3.22 – 3.11 (m, 2H), 
2.83 (s, 1H), 1.99 (s, 3H), 1.91 (d, J = 26.8 Hz, 1H), 1.31 (q, J = 13.6 Hz, 1H), 1.25 – 1.11 (m, 1H). MS 
(APCI) m/z: [M + H]+ Calcd for C21H22N6O4 423.17, found 423.4 
 
1H NMR (400 MHz, DMSO-d6) δ 13.01 (s, 1H), 10.78 (d, J = 9.9 Hz, 1H), 10.60 (s, 1H), 8.06 (d, J = 8.8 
Hz, 2H), 7.71 (dd, J = 25.1, 8.3 Hz, 3H), 7.55 (d, J = 8.8 Hz, 1H), 7.23 (d, J = 8.0 Hz, 1H), 4.64 (s, 1H), 
4.42 (d, J = 13.4 Hz, 1H), 4.31 (s, 2H), 3.85 (dt, J = 17.0, 13.9 Hz, 2H), 3.05 (s, 2H), 2.57 (d, J = 13.2 Hz, 
1H), 1.88 (s, 3H), 1.83 (s, 2H). 
 
1H NMR (400 MHz, DMSO-d6) δ 12.72 (s, 1H), 10.70 (s, 1H), 10.51 (s, 1H), 9.90 (s, 1H), 8.22 (t, J = 1.9 










































Hz, 1H), 4.44 – 4.34 (m, 1H), 4.29 (s, 2H), 3.86 (d, J = 13.6 Hz, 1H), 3.61 (pd, J = 6.6, 3.9 Hz, 1H), 3.06 
(td, J = 13.5, 3.1 Hz, 1H), 2.58 (ddd, J = 15.5, 9.5, 3.8 Hz, 2H), 2.00 (s, 3H), 1.79 (dt, J = 13.6, 7.8 Hz, 







Chapter 3: Pharmacokinetic and Pharmacodynamic Study of IKE2 
3.1 Introduction 
Ferroptosis is a type of regulated cell death driven by iron-dependent lipid peroxidation that can 
be inhibited by iron chelators and lipophilic antioxidants33-34. Ferroptosis has a role in regulating survival 
of some tumor cell types, such as lymphomas, renal cell carcinomas, and hepatocellular carcinomas70-72. 
Ferroptosis inducers synergize with several chemotherapies, including cisplatin, temozolomide, and 
doxorubicin in cell culture studies74-77. The ferroptosis-suppressing cystine (Cys2)/glutamate (Glu) 
antiporter system xc– is required in some cell contexts for providing cysteine34-35, 49; inhibition of system 
xc– can induce ferroptosis through cysteine deprivation, subsequent glutathione (GSH) depletion, and 
ultimately inactivation of glutathione peroxidase 4 (GPX4) 51-52. However, existing system xc– inhibitors, 
including sulfasalazine, glutamate, sorafenib, and erastin, are not suitable for in vivo evaluation due to the 
lack of potency, selectivity, and/or metabolic stability. IKE is an erastin analog with nanomolar potency, 
high metabolic stability and intermediate water solubility, thus potentially representing a suitable 
candidate for in vivo evaluation of the impact of ferroptosis driven through system xc– inhibition in mouse 
models of cancer57.   
Diffuse large B cell lymphoma (DLBCL) is an aggressive malignancy of B-lineage lymphocytes, 
accounting for 30-40% of non-Hodgkin’s lymphoma. DLBCL cell lines are particularly sensitive to 
ferroptosis induced by system xc– inhibition5, 51, 67, due to their inability to use the transsulfuration 
pathway to synthesize cysteine from methionine, making these cell lines dependent on uptake of 
cyst(e)ine from the micro-environment71. DLBCL is clinically heterogeneous, with 60% of patients 
curable with combination therapy, and the remainder succumbing to the disease132-133. Thus, therapies 
with distinct mechanisms of action may be beneficial for refractory patients, preventing disease relapse,  
 
2 This chapter is adapted from the manuscript submited:  Zhang, Y.; Tan, H.; Daniels J. D.; 
Zandkarimi, F.; Liu, H.; Brown, L. M.; Uchida, K.; O’Connor, O. A.; Stockwell, B. R., Imidazole 
ketone erastin nanoparticles induce ferroptosis and slow tumor growth in a mouse lymphoma model 
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and improving therapeutic outcomes. Here, we identified ferroptosis-sensitive and resistant DLBCL cell 
lines and established a subcutaneous DLBCL xenograft model to study the role of ferroptosis in treating 
DLBCL. We found that IKE exhibits antitumor activity in this DLBCL xenograft model and an 
associated increase in lipid peroxidation in tumors. These findings suggest that IKE can be effective as a 
novel potential therapeutic regimen for DLBCL. 
Erastin is a useful small molecule for in vitro studies but is metabolically labile and has low water 
solubility and potency, which precludes its use in vivo. The small molecule IKE is an erastin analog 
incorporating a metabolically stable carbonyl (Figure 3.1), which can potentially form a reversible 
covalent interaction with proteins, resulting in >100x potency improvement comparing to erastin in some 
cell lines51, 57. Substitution of an ethoxy moiety with isopropoxy resulted in improved metabolic stability, 
and the imidazole moiety in IKE helps increase water solubility, makes IKE soluble under acidic 
conditions.  




Figure 3. 1 Chemical structure of erastin and imidazole-ketone-erastin (IKE).  





3.2.1 DLBCL have differential sensitivity to IKE 
Yang and colleagues have proved high sensitivity of  DLBCL to ferroptosis inducer erastin by 
analyzing 127 cancer cell lines against diverse lethal compounds51, 67. The extreme sensitivity of DLBCL 
to ferroptosis might come from the dysfunctional transsulfuration pathways in DLBCL making these cell 
lines rely on the uptake of cysteine from the microenvironment or culture medium (Figure 3.2). 
 
 
We collected a panel of 18 DLBCL cell lines representing distinct DLBCL subtypes, including 
germinal center B cell-like (GCB), activated B cell like (ABC), and unclassified subgroups, to evaluate 
IKE sensitivity. The 18 DLBCL cell lines showed differential sensitivity to IKE inhibition, with cell lines 
exhibiting IC50 < 20 nM classified as sensitive cell lines, those with IC50 > 10 M classified as resistant 
cell lines, and those with IC50 values between 20 nM to 10 M classified as cell lines with intermediate 
 
 
Figure 3. 2 Pathways regulating sensitivity of DLBCLs to IKE 
DLBCLs have defective transsulfuration pathways resulting in disability to synthesis cysteine (Cys) 
thus heavily rely on the uptake of cysteine from the microenvironment.  
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resistance (Figure 3.3 A).  We further tested the degree of IKE-induced lethality upon co-treatment with 
the ferroptosis inhibitor ferrostatin-1 (fer-1)55, 67, a radical-trapping antioxidant that inhibits lethal lipid 
peroxidation during ferroptosis. Co-treatment with fer-1 rescued cell death induced by IKE in DLBCL 
cell lines, indicating that IKE-induced lethality in these cell lines resulted from lipid peroxidation and 
ferroptosis (Figure 3.3 B). Among the most sensitive DLBCL cell lines, we selected SUDHL-6 for 
generating a subcutaneous xenograft model in 6-week-old male NCG mice, which will be discussed in the 
next chapter.  
 
 
A                                                                                  B 
         
 
Figure 3. 3 Test of DLBCL sensitivity to IKE using cell viability assay 
(A) DLBCL lines have differential sensitivity to IKE. The cell viability was measured by incubating 
cells with a two-fold series dilution of IKE (starting from 100 μM) for 24 hours followed by a Cell 
Titor-Glo luminescent cell viability test. LY 8, DOHH 2, SUDHL 5, SUDHL 2, SUDHL 6, SUDHL 
10, and SUDHL 16 were classified as sensitive classified lines (red color). HBL 1, SUDHL 9, WSU-
NHL, SUDHL 8, RIVA, and KARPAS 422 were grouped as moderate resistant cell lines (black 
color). SUDHL 7, U937, A3/KAW, LY 7, and U2932 were classified as resistant cell lines (blue 
color). (B) Co-treatment with a two-fold series dilution of Fer-1 (starting from 200 μM) rescued cell 




 Since DLBCL cell lines have differential sensitivity to IKE, there must be some intrinsic factors 
affecting DLBCL’s sensitivity. We tried to explore the intrinsic biomarkers predicting DLBCL’s 
sensitivity to ferroptosis by analyzing expression levels of ferroptosis-related genes by RT-qPCR. ACSL4 
and LPCAT3, which were identified to be overexpressed in ferroptosis resistant cell lines86 didn’t shown 
differential expression across sensitive, medium resistant, and resistant DLBCL groups. Cystathionine-
beta-synthase (CBS), system xc– light chain xCT (SLC7A11), and ferritin light chain (FTL) have higher 
average expression in resistant DLBCL groups comparing with sensitive and medium resistant DLBCL 
groups (Figure 3.4). CBS catalyzes cysteine biosynthesis from cystathionine, the high expression level of 
this protein would increase cysteine synthesis making cells less dependent on system xc– mediated cystine 
(Cys-Cys) import. Ferritin is an iron storage protein; the high expression level of this protein might 
decrease the free iron concentration in cells making cells less likely to have ferroptotic cell death. 
However, it is hard to predict the sensitivity or resistance of a specific DLBCL cell line using CBS, 
SLC7A11, and FTL because there were extensive expression variabilities within each DLBCL group. 
 
A                                                          B                                                     C 
                                       
 
Figure 3. 4 CBS, SLC7A11, and FTL gene expression levels in different sensitivity groups of DLBCL 
Cystathionine-beta-synthase (CBS) (A), system xc– light chain xCT (SLC7A11) (B), and ferritin light 
chain (FTL) (C) have higher average expression in resistant DLBCL groups comparing with sensitive 




3.2.2 Pharmacodynamics study of IKE in vitro 
We aimed to investigate whether IKE specifically inhibited system xc– and induced ferroptosis in 
DLBCL cells. Inhibition of system xc– prevents cystine import and glutathione biosynthesis. A 
fluorometric method measuring reduced glutathione (GSH) concentration was used to evaluate IKE’s 
inhibitory effect on system xc–. Dose-dependent GSH depletion by IKE was observed (Figure 3.5A); this 
effect was reversed by co-treatment with 10 M β-mercaptoethanol (β-Me), which reduces cystine to 
cysteine, allowing its import into cells through system L, thus circumventing inhibiting of system xc– ( 
Figure 3.5B) .We observed that 250 nM IKE was able to deplete 94% of GSH in SUDHL-6 cells. The 
IC50 for GSH depletion by sulfasalazine was previously reported to be 1 mM134, while, the IC50 of GSH 
depletion by IKE that we measured was 34 nM (Figure 3.5A), indicating that IKE is a potent inhibitor of 
system xc–. 
 
We next sought to evaluate whether IKE treatment caused lipid peroxidation in DLBCL cells, as 
a marker of ferroptosis. Analysis of lipid ROS by flow cytometry using the C11-BODIPY probe, a lipid 
A                                                                                B 
        
 
Figure 3. 5 Measurement of GSH level in IKE treated SUDHL-6 cells  
GSH level was measured with a fluorometric-green probe in SUDHL6 cells treated with different 
concentration of IKE with or without 10 μM β-Me for 24 hours. (A) IKE induced glutathione 
depletion in a concentration-dependent way. The IC50 of glutathione depletion by IKE is 34 nM 
measured by three independent experiments. (B) Co-treatment of 10 M β-ME inhibited IKE induced 
glutathione depletion by promoting cysteine uptake through L systems. 
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peroxidation sensor, revealed increased lipid ROS upon IKE treatment in SUDHL-6 cells in a dose-
dependent manner (Figure 3.6A). Co-treatment with 10 M fer-1 inhibited this signal, as expected 
(Figure 3.6B).  
 
 
We reasoned that lipo-oxidative stress markers, including lipid-peroxide-derived protein 
modifications and aldehyde-derived protein modifications might also be used as ferroptosis biomarkers. 
Malondialdehyde (MDA) is a naturally occurring reactive carbonyl compound that is derived from lipid 
peroxidation of polyunsaturated fatty acyl moieties. Immunofluorescence staining with an anti-MDA-
lysine-adduct antibody (mAb 1F83), which specifically recognizes 4-methyl-1,4-dihydropyridine-3,5-
dicarbaldehyde (MDHDC)135-136, revealed that MDA adduct abundance was increased upon IKE 
treatment (Figure 3.7). 
A                                                                                B 
         
 
Figure 3. 6 Measurement of lipid peroxidation level in IKE treated SUDHL-6 cells using flow 
cytometry  
Lipid-peroxidation level shown as C11-BODIPY fluorescence increase was measured in SUDHL6 
cells treated with different concentration of IKE with or without 10 μM Fer-1. (A) With increasing 
IKE concentration, there was increased lipid peroxidation. (B) Co-treatment of 10 μM Fer-1 




To facilitate molecular characterization of ferroptosis induction in DLBCL cells, we analyzed 
gene expression biomarkers of ferroptosis in these cell lines by RT-qPCR. Expression of genes involved 
in ferroptosis34, such as glutathione peroxidase 4 (GPX4), cystathionine beta-synthase (CBS), and acyl-
CoA synthetase long-chain family member 4 (ACSL4) were analyzed upon IKE treatment. We determined 
that expression of the system xc– component SLC7A11, prostaglandin-endoperoxide synthase 2 (PTGS2, 
which encodes cyclooxygenase-2), and ChaC glutathione-specific gamma-glutamylcyclotransferase 1 
(CHAC1) were significantly increased following IKE treatment in cultured SUDHL-6 cells (Figure 3.8). 
SLC7A11, the substrate-specific subunit system xc–, exhibited increased expression following 500 nM 
IKE treatment for more than 1 h. PTGS2 was reported to be upregulated by the lipid peroxidation product 
4-hydroxy-2-nonenal (4-HNE)137 and by GPX4 depletion138. PTGS2 expression was increased following 
500 nM IKE treatment, and co-treatment with fer-1 inhibited this upregulation, suggesting that PTGS2 is 
a functional biomarker of ferroptosis (Figure 3.9). The mRNA level of CHAC1 was increased following 
500 nM IKE treatment, and fer-1 co-treatment did not inhibit its upregulation, as expected, indicating that 
CHAC1 is a parallel downstream marker of system xc– inhibition not affected by lipid peroxidation 
(Figure 3.9). In addition, co-treatment with 10 M β-Me prevented IKE-induced upregulation of 
 
 
Figure 3. 7 Measurement of MDA level in SUDHL-6 cells using immunofluorescence  
Immunofluorescence intensity of MDA in SUDHL6 cells with DMSO or 10 μM IKE treatment for 6 
hours indicated 3.4-fold increased MDA upon IKE treatment. **** P<0.0001 by t test. 
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SLC7A11, PTGS2, and CHAC1, suggesting that the upregulation of these genes was downstream of 
cysteine starvation. The upregulation of these three mRNAs was time-dependent (Figure 3.8), with 
increasing time of treatment, we observed increased gene expression, making these genes suitable for 
monitoring IKE pharmacodynamics. 
 
 
A                                                         B                                                       C                                             
     
 
Figure 3. 8 IKE induced ferroptosis marker change in a time-dependent way.  
RT-qPCR was performed in SUDHL-6 cells treated with 500 nM IKE for different time. (A) IKE 
induced PTGS2 upregulation very quickly, starting from 5 minutes, there was over 10-fold increased 
PTGS2 expression. (B) SLC7A11 expression was induced by IKE starting from 3 hours incubation. 
(C) CHAC1 expression was induced by IKE immediately, starting from 5 minutes, there was over 5-












































































































































Figure 3. 9 SLC7A11, CHAC1, and PTGS2 are specific for IKE-induced ferroptosis 
RT-qPCR was performed in SUDHL-6 cells treated with indicated compounds for 6 hours. (A) 500 
nM IKE treatment induced SLC7A11, CHAC1, and PTGS2 upregulation. Co-treatment of 10 μM fer-1 
inhibited PTGS2 upregulation but not SLC7A11 and CHAC1. Co-treatment of 10 μM β-Me inhibited 
all three genes upregulation.  
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 While, IKE induced cell death through inhibiting system xc– resulting in GSH depletion and lipid 
peroxidation, a distinct cell death mechanism different from apoptosis, we are curious about whether there 
is increased caspase-3 activity in this process. An Apo-ONE homogeneous caspase-3/7 (Promega) assay 
was performed to measure the caspase-3/7 cleavage activity through detecting the fluorescent Rhodamine 
which is cleaved from a pro-fluorescent caspase-3/7 consensus substrate (Figure 3.10A). Caspase 3/7 
activity was increased upon IKE treatment, which might result from the oxidative stress generated by 
system xc– inhibition because Fer-1 or β-Me cotreatment reduced caspase 3/7 activity resulted from IKE. 
A western blot measuring the abundance of cleaved-caspase 3 confirmed that IKE-induced oxidative 
stress would increase caspase-3 activity (Figure 3.10B).   
 
3.3.3 Pharmacokinetics (PK) and pharmacodynamics (PD) study of IKE in vivo 
To determine the suitability of IKE for in vivo studies, we first evaluated multiple dosage routes 
by administrating a single dose of IKE (50 mg/kg, 5% DMSO in HBSS) using IP, IV, and PO routes to 
A                                                                                   B 
 
 
Figure 3. 10 Caspase-3 activity measurement using Apo-ONE assay and western blot 
 (A) Caspase 3/7 activity was measured by Apo-ONE homogenous caspase-3/7 assay in SUDHL-6 
cells treated with 500 nM IKE, 500nM IKE with 10 μM Fer-1 cotreatment, 500nM IKE with 10 μM β-
Me cotreatment, and 10 nM staurosporine for 24 hours.  (B) Analysis of caspase and cleaved-caspase 
abundance by western blot. 
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NOD/SCID mice. Determination of IKE concentration over a period of eight hours revealed IP to be the 
most effective and practical means of IKE administration (Table 3).  
Next, IKE concentration in plasma and tumor samples was determined after single dose of IKE 
(50 mg/kg, 5% DMSO in HBSS, IP) to SUDHL-6-xenograft-bearing NCG mice over a period of 24 
hours. IKE reached the highest plasma concentration of 5.2 g/mL at 2 h, and the highest tumor 
accumulation of 2.5 g/mL at 4 h (Table 4 and Figure 3.11A).  
 













IP 0.31 19515 1.82 8 1527 53898 
IV 0 11384 1.31 8 16 16983 
PO 0.72 5203 0.96 8 48 5723 
 













Plasma  1.35 5185 1.83 24 30 10926 
Tumor 3.30 2516 3.50 24 283 9857 
 
We collected tumor samples from each time point after a single dose of IKE (50 mg/kg, 5% 
DMSO in HBSS) and evaluated the abundance of ferroptosis biomarkers. There was significant GSH 
depletion upon IKE dosing starting from 4 h (Figure 3.11B). The GSH depletion in tumors induced by 
IKE was persistent at 24 h, as there was little IKE left in the bulk tumor sample, but up to 70% GSH 
depletion. Consistent with IKE accumulation kinetics in the tumor samples, CHAC1, SLC7A11, and 
PTGS2 mRNAs were upregulated starting at 3 h. (3-5 fold for PTGS2 and SLC7A11, and 2-fold for 
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Figure 3. 11 PK/PD study of IKE in NCG mice bearing SUDHL-6 xenograft 
(A) A pharmacokinetic study performed in SUDHL6 subcutaneously xenografted NCG mice 
measured IKE accumulation over time in plasma and tumor using LC-MS. (B) Analysis of GSH 
extracted from tumor tissue by fluorometric-green showed over 50% GSH depletion with IKE 
treatment starting at 4 hours. *** P<0.001, **** P<0.0001 by one-way ANOVA.   
 
 
Figure 3. 12 Analysis of ferroptosis gene biomarkers in tumor tissues of IKE treated SUDHL-6 
xenografts  
RT-qPCR performed using RNA extracted from tumor tissue showed PTGS2, SLC7A11, and CHAC1 
mRNA increase starting from 3 hours, colored as blue in the heatmap. 
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Immunofluorescence analysis of samples at 4 h post-treatment showed that there was increased 
abundance of MDA adduct and 8-hydroxy-2’-deoxyguanosine (8-OHdG), a biomarker for free radical-
induced oxidative lesions, indicating that IKE induced lipid peroxidation and DNA damage in these 
tumor samples (Figure 3.13 and 3.14). 
 
3.3 Conclusion and Discussion  
DLBCL cell lines have differential sensitivity to IKE-induced ferroptosis. The intrinsic factors 
determining DLBCL ferroptosis sensitivity remain to be explored to increase the understanding to 
ferroptosis and to enable patient selection. In summary, IKE has nanomolar cellular activity in vitro. The 
treatment of IKE induced GSH depletion, lipid peroxidation and ferroptosis. A series of biomarkers 
including lipid peroxidation level, oxidative stress, gene expression level of PTGS2, CHAC1, and SL7A11 
could be used to evaluate IKE-induced ferroptosis in vitro and in vivo.  
  
 
Figure 3. 13 Measurement of MDA level in tumor tissues of IKE treated SUDHL-6 xenografts using 
immunofluorescence 
Immunofluorescence of MDA in paraffin-embedded tumor samples from mice treated with one 
dosage vehicle or IKE for 4 hours showed increased MDA-lysine adducts upon IKE treatment. 
Quantification of fluorescence intensity showed 1.6-fold increase of MDA-lysine adducts in IKE 
treated mice tumor tissue relative to the vehicle treated mice tumor tissue. (sections were cut from 3 
mice in each group, five images from each section were captured on Zeiss LSM 800 63x/1.40 Oil DIC 






Cell lines and media.  
The SUDHL-5, SUDHL-6, SUDHL-16, and HT-1080 cell lines were obtained from ATCC. The DOHH-2 
cell line was obtained from DSMZ. The HBL-1, U2932, SUDHL-7, SUDHL-9, A4/FUK, WSU-DHL, 
Ly18, Karpas422, SUDHL-1, SUDHL-2, SUDHL-8, SUDHL-10, A3/KAW, RIVA, Ly9, U937, and Ly7 
cell lines were provided by Dr. Owen A. O’Connor (Columbia University) and the Columbia Genome 
Center. HT-1080 cells were grown in DMEM with glutamine and sodium pyruvate (Corning 10-013) 
supplemented with 10% heat-inactivated fetal bovine serum (FBS) (Life Technologies, 10437036) 1% 
non-essential amino acids (Thermo Fisher Scientific, 11140076) and 1% penicillin-streptomycin mix 
(pen-strep) (Thermo Fisher Scientific, 15140148). SUDHL-1, SUDHL-2, SUDHL-6, SUDHL-8, 
SUDHL-10, SUDHL-16, A3/KAW, RIVA, Ly8 and U937 cells were cultured in RPMI-1640 (ATCC 30-
2001) with 10% FBS and 1% pen-strep. DOHH-2, HBL-1, U2932, SUDHL-7, SUDHL-9, A4/FUK, 
 
Figure 3. 14 Measurement of 8-OHdG level in tumor tissues of IKE treated SUDHL-6 xenografts 
using immunofluorescence 
Immunofluorescence of 8-OHdG in paraffin-embedded tumor samples from mice treated with one 
dosage vehicle or IKE for 4 hours showed increased 8-OHdG upon IKE treatment. Quantification of 
fluorescence intensity showed 1.6-fold increase of 8-OHdG in IKE treated mice tumor tissue relative 
to the vehicle treated mice tumor tissue. (sections were cut from 3 mice in each group, five images 
from each section were captured on Zeiss LSM 800 63x/1.40 Oil DIC objective). *** P<0.001, **** 




WSU-NHL, and Ly8 were cultured in RPMI-1640 with 10% heat-inactivated FBS and 1% pen-strep. 
SUDHL-5 and Karpas422 were cultured in RPMI-1640 with 20% FBS and 1% pen-strep. Ly7 was 
cultured in IMDM (Thermo Fisher Scientific, 12440053) with 15% heat-inactivated FBS and 1% pen-
strep. All cells were maintained in a humidified environment at 37 °C and 5% CO2 in an incubator.  
 
Animal studies 
The animal studies reported in this manuscript adhere to the ARRIVE guidelines. All animal study 
protocols were approved by the Columbia University Institutional Animal Care and Use Committee 
(IACUC). Male NOD-Prkdcem26Cd52Il2rgem26Cd22/NjuCrl (NCG) mice (Charles River, strain code 572) mice 
and NOD.CB17-Prkdcscid/J (NOD SCID) mice (The Jackson Laboratory, stock number 001303) were 
acclimated after shipping for >3 days before beginning experiments. Mice were fed a standard diet 
(PicoLab 5053) and maintained with no more than 5 mice per cage.  
 
Pharmacokinetic analysis in mice 
NOD/SCID mice 12-weeks of age and ~28 g weight were weighed before injection and divided into 
groups of 3 mice per cage. IKE was dissolved in 5% DMSO/95% Hank’s Balanced Salt Solution (HBSS) 
(Thermo Fisher Scientific, 14025076), pH 4, to create a 5 mg/mL solution. 5% DMSO/95% HBSS at pH 
4 solution (Vehicle 1) without IKE was used as vehicle. The solution was sterilized using a 0.22 μm 
Steriflip filter unit (Thomas Scientific 1189Q46). Mice were dosed using three different routes, IP and PO 
with 50 mg/kg IKE, and IV with 17 mg/kg IKE. Samples were collected at 0, 1, 3, 4, and 8 h from three 
mice per time point. Additionally, three mice per group were used as control by administration with 
equivalent amount of vehicle 1 by IP, PO, and IV, and samples were collected at 8 h. At the appropriate 
time, mice were sacrificed by CO2 asphyxiation for 3 min and ~0.5 mL of blood was collected via cardiac 
puncture. Blood was immediately put into K3 EDTA micro tube (SARSTEDT 41.1504.105) and placed 
on ice. Samples were centrifuged for 10 min at 2,100 x g at 4°C, then plasma was transferred to a clean 
tube. Plasma samples were flash frozen in liquid nitrogen and stored at -80°C. IKE was extracted from 
93 
 
plasma by adding 900 μL acetonitrile to 100 μL plasma. Samples were mixed for at least 5 min by 
rotating at room temperature and were sonicated prior to concentration for 10 min at 4,000 x g and 4°C. 
The supernatant was removed and dried on a GeneVac evaporator overnight on an HPLC setting. After 
drying, the samples were resuspended in 100 μL of methanol and analyzed on the liquid chromatography 
mass spectrometry (LC-MS), with each sample analyzed twice. Quality control standard samples were 
prepared by dissolving IKE in 100 μL water and extraction with the same procedures to ensure that the 
extraction was efficient.  LC-MS analysis was performed on a platform comprising a Thermo Scientific 
Dionex Ultimate 3000RS controlled by Chromeleon (Dionex) and a Bruker amazon SL ESI ion-trap mass 
spectrometer.  
 
Chromatographic separation was performed at 20°C on Agient Eclipse Plus C18 column (2.1 x 50 mm, 
3.5 μm) at 20°C over a 12 minute gradient elution. Mobile phase A consisted of water with 0.1% acetic 
acid v/v and mobile phase B was methanol with 0.1% acetic acid v/v. After injection, the gradient was 
held at 80% mobile phase A for 1 min. The gradient was then ramped in a linear fashion to 80% mobile 
phase over 0.5 min. Over the next 3.5 min, the gradient was ramped in linear fashion to 100% mobile 
phase B and held at 100% mobile phase B for 3.25 min.  The gradient was then ramped in a linear fashion 
to 80% mobile phase over 0.5 min and held there for the duration of the run. The flow rate was set to 400 
µL/min and injection volumes were 5 µL. The retention time for IKE in this gradient was 2.8 min.  
 
Mass spectrometry analysis was performed on a Bruker Amazon SL (Billerca, MA) in positive ESI mode. 
Trap Control was used to control the ESI settings with the inlet capillary held at -4500 V and the end plate 
offset at -500 V. Nitrogen was used as the desolvation gas. Hystar  v 3.2 was used to integrate the 
UHPLC and MS applications, and data analysis was performed with the Compass DataAnalysis software. 
The base peak chromatogram at m/z 655.2 with a width of ± 0.1 was integrated and peak area quantified 




Pharmacokinetics (PK) of IKE were assessed using Prism fitted with lognormal of one phase exponential 
decay.  
 
pharmacodynamic analysis in mice 
 
IKE was dissolved in 5% DMSO/95% HBSS at pH 4 to create a 5 mg/mL solution or 3 mg/mL solution. 
5% DMSO/95% HBSS at pH 4 was used as vehicle 1. IKE PEG-PLGA nanoparticles and 
unfunctionalized PEG-PLGA nanoparticles (without IKE) (vehicle 2) prepared with a NanoAssemblr 
were dialyzed with deionized water overnight, and the water was changed at least twice. Dialyzed IKE-
PEG-PLGA nanoparticles and unfunctionalized PEG-PLGA nanoparticles were concentrated by Amicon 
Ultra-15 Centrifugal Filter Units to create a solution with 80 mg/mL PEG-PLGA nanoparticles. All above 
solutions were sterilized by filtering through a 0.2 μm syringe filter.  
 
NCG mice 6-weeks of age were injected with 10 million SUDHL-6 cells subcutaneously. Visible tumors 
appeared after 2 weeks. Tumor size was measured by electronic caliper every 2 days and calculated using 
the formula: 0.5 x length x width2. After another 2 weeks, mice were randomly separated into group of 3 
mice per cage with roughly tumor size (1200 mm3). Mice were dosed at 50 mg/kg IKE, 22 mg/kg IKE, 22 
mg/kg IKE PEG-PLGA nanoparticles (equal to 600 mg/kg PEG-PLGA) using IP at one time and samples 
were collected at 0, 1, 2, 3, 4, 6, and 24 h with three mice per time point. Mice were dosed with Vehicle 1 
and Vehicle 2 (600 mg/kg PEG-PLGA) by IP and samples were collected at 24 h. Mice were euthanized 
using a CO2 gas chamber before xenograft dissection and cardio puncture. Plasma samples were collected 
and analyzed as described above. Tumors were dissected and divided into 6 segments, frozen on dry ice, 
and stored at -80°C. Before IKE extraction, tumor tissue samples were thawed at room temperature and 
weighed. A 2.5-fold ratio of volume of phosphate-buffered saline (PBS) (mL/g) was added to the sample 
and homogenized using Bead Ruptor 4 at speed 4 for 30 sec. The homogenization step was repeated until 
the samples were homogenized well (final weight/volume was 0.4 g/mL). 100 μL of homogenized tissue 
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(equal to 40 mg) was added to a new microfuge tube, 900 μL of acetonitrile was added. The samples were 
mixed for at least 5 minutes by rotating on a shaker and were sonicated for at least 30 sec prior to 
centrifugation for 10 min at 4,000 x g and 4°C. The supernatant was removed and dried on the GeneVac 
overnight on the HPLC setting. After drying, the samples were resuspended in 100 μL of methanol and 
analyzed on the LC-MS with each sample analyzed twice. Technical replicates were averaged. The 
concentration of IKE in the sample was determined by comparison against a standard curve of IKE in the 
range of 25 to 2,500 ng/mL. Pharmacodynamic analysis of ferroptosis biomarkers is described in the RT-
qPCR, glutathione, immunofluorescence, and lipidomics sections below. Pharmacokinetics parameters of 
IKE was assessed using Prism fitted with Lognormal of one phase exponential decay. 
 
Measurement of DLBCL lines sensitivity to IKE 
DLBCL cells were plated at 10,000 cells per well in white 384-well plates (32 μL per well) in technical 
duplicates and incubated overnight. The cells were then treated with 8 μL medium containing a two-fold 
dilution series of vehicle (DMSO), IKE (starting from 100 μM) with or without Fer-1 (starting from 200 
μM). After 24 h incubation, 40 μL of 50% CellTiter-Glo (Promega) 50% cell culture medium was added 
to each well and incubated at room temperature with shaking for 15 min. Luminescence was measured 
using a Victor X5 plate reader (PerkinElmer). All cell viability data were normalized to the DMSO 
vehicle condition. Experiments were performed three independent times with different passages for each 
cell line. From these data, dose-response curves and IC50 values were computed using Prism 7.0 
(GraphPad).  
 
C-11 BODIPY lipid peroxidation measurement 
0.20 million SUDHL-6 cells were seeded in six-well plates and treated with DMSO, IKE, or Fer-1 at 
specific concentration. The final cell density of 0.05 million cells/mL. After 24 h, cells were harvested by 
centrifuging at 300 x g for 5 min. Cells were resuspended in 500 μL HBSS containing 2 μM C11-
BODIPY (BODIPY 581/591 C11) (Thermo Fisher Scientific, D3861) and incubated at 37 °C for 15 min. 
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Cells were pelleted and resuspended in HBSS. Fluorescence intensity was measured on the FL1 channel 
with gating to record live cells only (gate constructed from DMSO treatment group). A minimum of 
10,000 cells were analyzed per condition.  
 
Reduced glutathione measurement in cell culture 
2.4 million cells incubated with DMSO, IKE, or β-mercaptoethanol (β-Me) at a density of 0.2 million 
cells/mL for 24 h. Cells were collected and washed with cold PBS once. Cell number was counted by Vi-
Cell. Cells were resuspended in ice cold RIPA buffer (Thermo Fisher Scientific, 89900) with 100 μL/one 
million cells. Samples were centrifuged for 15 min at 4°C at 17,000 x g. The resulting supernatant was 
deproteinized using a trichloroacetic acid and sodium bicarbonate solution and kept on ice. The sample 
was diluted with assay buffer provided in GSH/GSSG Ratio Detection Assay Kit (Abcam, ab13881) ten-
fold. Reduced glutathione (GSH) levels were determined using Fluorometric-Green provided in the kit 
following the manufacture’s protocol. 384-well (Corning) low volume black flat bottom polystyrene non-
treated microplates 1230F99 were used in this experiment.  
 
Reduced glutathione measurement in mouse tumor tissue   
10 mg of tumor tissue was mixed with 400 μL RIPA buffer, homogenized at speed 5 for 30 sec using a 
Bead Ruptor 4 (OMNI International). The sample was centrifuged at 17,000 x g for 5 min, then the above 
deprotenization and measurement steps performed.  
 
qPCR analysis of gene expression 
DLBCL cells were treated with 0-10 μM IKE, Fer-1, or β-Me for the indicated times. RNA was extracted 
using the Qiashredder and Qiagen RNeasy Mini kits (Qiagen) according to the manufacture’s protocol. 2 
μg RNA from each sample was reversed transcribed to cDNA using a High Capacity cDNA Reverse 
Transcription Kit ( (Thermo Fisher Scientific, 4368814). Quantitative PCR reactions were performed 
using Power SYBR Green PCR Master Mix (Applied Biosystems) with triplicate measurement on ViiA 7 
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Real-Time PCR instrument (Thermo Fischer). HPRT1 was used as an internal reference. Differences in 
mRNA levels compared with HPRT1 were computed between vehicle and experimental groups using the 
ΔΔCt method. The primers used in the study was listed below. 
Genes Foward Reverse 
HPRT1 5’-GCCCTGGCGTCGTGATTAGTG-3’ 5’-GCCTCCCATCTCCTTCATCAC-3’ 
CHAC1 5'- GAACCCTGGTTACCTGGGC-3' 
5'- CGCAGCAAGTATTCAAGGTTGT-
3’ 





qPCR in mouse tumor tissue 
~20 mg of tumor tissue was prepared and kept on dry ice. The frozen tissue was homogenized with Bead 
Ruptor 4 at speed 4 for 30 sec. The homogenization was repeated once if there remained unhomogenized 
tissue. Total mRNA was prepared from the cleared homogenate using Ribopure Kit (Thermo Fisher 
Scientific, am1924). RNA was reverse transcribed to cDNA then used in quantitative PCR experiment 
following the same steps used in cell qPCR experiment.  
 
Immunofluorescence on cell and quantification 
SUDHL-6 cells were treated with IKE. The cells were harvested by centrifugation and washed with PBS 
once. The cells were resuspended in PBS, fixed by adding equal volume of 4% paraformaldehyde (PFA), 
and incubated at room temperature for 15 min. The cells were washed with PBS/0.1% Tween 20 (PBST) 
twice, resuspended in 10% goat serum (ThermoFisher 50197Z) for 1 h. The cells were incubated with 
mouse mAb 1F83, which specifically recognizes malondialdehyde (MDA)-lysine adduct 4-methyl-1,4-
dihydropyridine-3,5-dicarbaldehyde (MDHDC)135-136 (1:100 dilution) overnight at 4°C. The cells were 
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washed with PBS three times by centrifugation. The cells were incubated with goat anti-mouse IgG H&L 
(Alexa Fluor 647) (Abcam ab150115) (1:1000) at room temperature for 1 h. The cells were washed with 
PBST twice by centrifugation, then resuspended in PBS in 24-well plate with poly-lysine-(Sigma Aldrich 
P4832)-coated cover slips and centrifuged at 1,000 x g for 10 min. ProLong Diamond antifade mountant 
with DAPI (ThermoFisher P36962) was added to stain the nucleus. All images were captured on a Zeiss 
LSM 800 confocal microscope at Plan-Apochromat 63x/1.40 Oil DIC objective with constant laser 
intensity for all samples. When applicable, line-scan analysis was performed on representative confocal 
microscopy images using Zeiss LSM software to qualitatively visualize fluorescence overlap. The 
intensity above threshold of the fluorescent signal of the bound antibodies was analyzed using NIH 
ImageJ software. Data were expressed as fold change compared with the vehicle.  
 
Immunofluorescence on paraffin-embedded tissue sections and quantification 
Tumor tissue was fixed in 4% paraformaldehyde (PFA) for 24 h at 4°C followed by washing three times 
with PBS. The samples were fixed in paraffin. Six series of 5 μM sections were obtained with a sliding 
microtome. The serial sections were then mounted on gelatin-coated slide. The paraffin-embedded tissue 
sections were deparaffinized with xylene three times, 5 min each, followed by rehydrating in 100%, 90%, 
70%, and 50% ethanol, two washes 5 min each, then rinsed with distilled water. Antigen retrieval was 
performed in Tris-EDTA buffer, pH 9.0, 95-100°C for 10 min. Then sections were rinsed in PBST, 2 min 
each. A hydrophobic barrier pen was used to draw a circle on each slide. The slides were permeabilized 
with PBS/0.4% Triton X-100 twice before non-specific-binding blocking by incubating the sections with 
10% goat serum (ThermoFisher 50197Z) for 30 minutes at room temperature. The sections were 
separately incubated with mouse anti-MDA mAb 1F83 (1:1000 dilution), anti-cyclooxygenase 2 (COX 2, 
AKA PTGS2) antibody (Abcam, ab15191, 1:200 dilution), or anti-8-OH-dG (DNA/RNA damage) 
antibody (Abcam, ab62623, 1:200 dilution) overnight at 4°C in humidified chambers. Sections were 
washed with PBST for twice before incubating with goat anti-mouse IgG H&L (Alexa Fluor 647) 
(Abcam, ab150115, 1:1000 dilution) or goat anti-rabbit IgG H&L highly cross-absorbed secondary 
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antibody (Alexa Fluor488, Thermo Fisher Scientific, A-11034, 1:1000) at room temperature for 1 h. 
Slides were then washed twice with PBST. ProLong Diamond antifade mountant with DAPI 
(ThermoFisher P36962) was added onto slides, which were then covered with the coverslips, sealed by 
clear fingernail polish and observed under confocal microscopy. All images were captured on a Zeiss 
LSM 800 confocal microscope at Plan-Apochromat 63x/1.40 Oil DIC objective with constant laser 
intensity for all analyzed samples. The intensity above threshold of the fluorescent signal of the bound 
antibodies was analyzed using NIH ImageJ software. Data were expressed as fold change comparing with 
the vehicle 
 
Caspase-3 activity measurement 
Caspase-3/7 activity of SUDHL-6 cells treated with indicated compounds for 24 hours were measured by 
Apo-ONE homogeneous caspase-3/7 assay (Promega) followed by the reagent manual). 
 
Western blot 
SUDHL-6 cells treated with indicated compounds for 24 hours were lysed in ice cold RIPA buffer with 
cocktail protease inhibitor (Roche) followed by centrifugation. The supernatant was used in western blot 
analysis. Caspase-3 antibody (Cell Signaling Technology 12691) which could recognize both full-length 





Chapter 4: in vivo Study of IKE Nanoparticle Formulation in Xenograft Model3 
4.1 Introduction 
While small molecule system xc– inhibitors are promising agents for inducing ferroptosis in 
cancers that are addicted to cystine import, there are a number of potential concerns in translating such 
agents for therapeutic benefit. First, many compounds, including some system xc– inhibitors, do not 
accumulate sufficiently in target tumor tissues, resulting in a minimal pharmacodynamic effects; thus, 
improving delivery and accumulation of such compounds to tumors would be beneficial. Second, while 
system xc– inhibitors are expected to be largely tolerable based on the observation that SLC7A11 
knockout mice have few phenotypes, it is possible that acute inhibition of system xc– would cause toxicity 
in normal tissues, or that off-target effects of system xc– inhibitors might cause undesirable toxicities. For 
these reasons, we hypothesized that improving the formulation and delivery of IKE to tumors might 
enhance its therapeutic index and translational potential.   
Nanotechnology represents a potentially promising platform to address the above issues as well 
as others associated with conventional therapeutic agents, including poor water solubility, nonspecific 
distribution, inadequate accumulation, limited efficacious responses, and systemic toxicity98-99. We 
suspected that the enhanced permeability and retention (EPR) effect might increase DLBCL tumor 
targeting of IKE100. We thus developed an IKE-loaded nanoparticle (NP) formulation using PEG-PLGA, 
a well-tolerated di-block copolymer, to achieve enhanced tumor tissue accumulation and improved in vivo 
delivery of IKE in a DLBCL xenograft model. The IKE PEG-PLGA NPs were formulated using a high 
flow microfluidic NanoAssemblr, with mean size of ~80 nm, polydispersity index of 0.2, and loading 
efficiency of 24% by weight. The IKE PEG-PLGA NPs have increased IC50 in SUDHL-6 cells, which 
might result from the increased internalization rate of NPs with cells. This IKE NP formulation achieved  
  
3 This chapter is adapted from the manuscript submited:  Zhang, Y.; Tan, H.; Daniels J. D.; 
Zandkarimi, F.; Liu, H.; Brown, L. M.; Uchida, K.; O’Connor, O. A.; Stockwell, B. R., Imidazole 
ketone erastin nanoparticles induce ferroptosis and slow tumor growth in a mouse lymphoma model 
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enhanced accumulation in xenograft tumor tissue, and inhibited tumor growth with less toxicity in mice 
compared to free IKE. In summary, we found that the small molecule ferroptosis inducer IKE is able to 
reduce tumor growth in a DLBCL xenograft model and that IKE PEG-PLGA NPs are suitable for 
inducing ferroptosis in mouse models. 
 In this chapter, the optimization of nanoparticle formulation, efficacy study of IKE and IKE PEG-
PLGA NP efficiency, and characterization of IKE efficacy study biomarkers will be described.  
 
4.2 Results 
4.2.1 PLGA and PEG-PLGA nanoparticle system optimization 
IKE is soluble to acidic aqueous conditions, but not to the same degree in neutral aqueous 
conditions (solubility in neutral water is 0.25 mM). To improve delivery of this compound and at the 
same time improve its tumor accumulation, we sought to use a nanoparticle formulation. We selected 
biocompatible and biodegradable PEG-PLGA di-block copolymer-based nanoparticle as an IKE carrier 
(Figure 4.1). The PEG block was used to create a deformable hydrating layer by tight associations with 
water molecules, which prevents clearance by the mononuclear phagocyte system (MPS), prolonging 
circulation lifetime. The PLGA block was used to form a hydrophobic core to incorporate IKE, which 
provides sustained release by diffusion and surface/bulk erosion.  
To formulate <100 nm nanoparticles with a reproducible method, we the employed 
NanoAssemblr platform, which is equipped with a high flow microfluidic chip139-140. Self-assembly of 
nanoparticles by nanoprecipitation occurs when the organic phase containing IKE and the PEG-PLGA 




 NanoAssemblr platform is a scalable system with multiple parameters to tune the formation of 
desired nanoparticles, which includes: (1) process parameters: total flow rate and flow rate ratio; (2) 
formulation parameters: polymer concentration, surfactants concentration, and drug concentration; (3) 
post-processing: purification and concentration. Upon optimizing these parameters, drug loaded 
nanoparticles with optimal particle size, polydispersity (PDI), and encapsulation efficiency could be 
achieved. As PLGA polymer is also widely used in drug delivery, a PLGA system is also described here 
as compassion with PEG-PLGA system.  
 At total flow rate of 8 mL/min, both PLGA and PEG-PLGA NPs have around 100 nm size, so we 
didn’t optimize the total flow rate further. We tested flow rate ratios and found with increasing 
Aqueous:Organic ratio, the size of nanoparticles increased (Figure 4.2A).  While increasing acetone 
percentage in organic phase decreased nanoparticle size a little, and with 25% of acetone in DMSO, the 
IKE PEG-PLGA NP has the highest encapsulation efficiency as indicated by IC50 measurement in 
SUDHL-6 cells (Figure 4.2B). While, during IKE PLGA NP formulation, increasing acetonitrile 
percentage in DMSO resulted in increased size and PDI, thus 100% DMSO as the organic phase was used 
in IKE PLGA NP formulation. Besides, since PLGA is hydrophobic, polyvinyl alcohol (PVA) a 
hydrophilic surfactant, was used to form the hydrophilic surface of PLGA NP. 
 
 




One of the problems with the use of nanoparticles as drug carriers in vivo is the low content of 
drug and low concentration of nanoparticles in suspension. We were able to achieve concentration factors 
up to 20 using centrifugal filter units without causing nanoparticle aggregation or dramatically decreasing 
IKE loading efficiency in IKE PEG-PLGA NP (Figure 4.3A). However, it was hard to concentrate PLGA 
NP, the main reason is that the PVA surfactants tend to clog the membrane of the filter units, as with 
increasing of PVA molecular weight, it was harder to concentrate the PLGA NP (Figure 4.3B). 
 To improve the final IKE loading in PEG-PLGA NPs, different IKE concentration used in the 
formulation was tried (Figure 4.4) With 15 wt% IKE in PEG-PLGA polymer, the final IKE loading is the 
highest as suggested in cellular activity test. Increasing IKE percentage further during the formulation 
didn’t contribute to increasing final IKE loading. So 15wt% IKE was used in the in vivo study.  
 
 
A                                                                                     B 
 
 
Figure 4. 2 Optimization of organic phase in PEG-PLGA nanoparticle formulation 
(A) At a total flow rate of 8 mL/min and PEG-PLGA polymer concentration of 10 mg/mL in DMSO, 
with aqueous: organic (water: DMSO) ratio increases, the average diameter of PEG-PLGA 
nanoparticles formulated by NanoAssemblr increased. (B) At a total flow rate of 8 mL/min, PEG-
PLGA polymer concentration of 10 mg/mL, and aqueous: organic ratio of 1: 1, IKE PEG-PLGA NP 
prepared from 25% acetone/DMSO has relatively smaller IC50 comparing with 0% acetone/DMSO 
and 50% acetone/DMSO, indicating higher IKE encapsulation rate in 25% acetone/DMSO. All three 








A                                                                                 B 
         
 
Figure 4. 3 Optimization of concentration step in PEG-PLGA and PLGA nanoparticle formulation 
(A) After concentration using filter units with concentration factors up to 20, PEG-PLGA NP’s 
average diameter, PDI, and IC50 were not significantly increased. (B) PLGA NP formulated with 
different size of PVA as surfactants were concentrated using filter units. The concentration factors up 
to 5, 10, and 20 was achieved in 89 kD PVA, 31 kD PVA, and 13-23 kD PVA individually due to the 
clog of filter membranes by PVA.  
 
 
Figure 4. 4 Optimization of IKE loading in nanoparticles 
IKE PEG-PLGA nanoparticle cellular activity with different percentage of IKE loaded in 
nanoparticles during formulation. 
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As a summary, the highest IKE loading efficiency with < 100 nm nanoparticle size was achieved 
by using 1:1 ratio of organic to aqueous phases, with 25% acetone / 75% dimethyl sulfoxide (DMSO) as 
the organic phase, and 15% (by weight) IKE to PEG-PLGA polymer in the organic phase.  IKE PEG-
PLGA nanoparticles (NPs) with a diameter as small as 80 nm and polydispersity index (PDI) of 0.17 were 
formulated using this approach. (Figure 4.5) The surface possessed a slightly negative charge with zeta 
potential of -17.0 mV to prevent nanoparticle aggregation. While, the PLGA NPs with diameter as small 
as 80 nm, PDI of 0.21, and zeta potential of -11 mV were formulated, it was not used in the in vivo study, 
partially due to the difficulty in concentration and less favored properties comparing with PEG PLGA NP, 
for example, deformability141.  
 
Comparing with free IKE, IKE PEG-PLGA NPs have enhanced cellular activity in SUDHL-6 
cells, a sensitive DLBCL cell line to IKE, which might result from increased internalization of IKE NPs 
 
 
Figure 4. 5 Nanoparticles’ size and surface potential parameters 
Nanoparticle size distribution of IKE PEG-PLGA nanoparticles and IKE PLGA nanoparticles. IKE 
PEG-PLGA nanoparticles formulated at a total flow rate of 8 mL/min, PEG-PLGA polymer 
concentration of 10 mg/mL in 25% acetone/DMSO (organic phase), and aqueous: organic ratio 1:1 has 
size of 82 nm, PDI 0.17, and zeta potential -17.0 ± 7.6 mV. IKE PLGA nanoparticles formulated at a 
total flow rate of 8 mL/min, PLGA polymer concentration of 10 mg/mL in DMSO (organic phase), 89 
kD PVA as surfactant, and aqueous: organic ratio 1:1 has size of 82 nm, PDI 0.21, and zeta potential -
11.3 ± 8.6 mV. 
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to cell (Figure 4.6). However, IKE PLGA NPs didn’t have the enhanced cellular activity effect, which is 
one of the factors making us eventually choose to use PEG-PLGA NP as the IKE carrier .  
IKE content as high as 3 mg/mL (drug loading 3.65% by weight, encapsulation efficiency 24%) 
with PEG-PLGA NP was used for the in vivo study. Administration of 750 mg/kg PEG-PLGA NP daily 
for two weeks didn’t result in any detectable weight loss or other observable signs of toxicity, suggesting 




4.2.2 IKE PEG-PLGA NPs have suitable properties to be applied in vivo 
We investigated the efficacy of IKE in vivo in NCG mice bearing SUDHL-6 subcutaneous 
xenografts. Once tumor volumes reached 100 mm3, mice were randomized into five groups and treated 
with vehicle (5% DMSO in HBSS at pH 4), unfunctionalized PEG-PLGA NPs in water, 40 mg/kg free 
IKE (5% DMSO in HBSS at pH 4), 23 mg/kg free IKE (5% DMSO in HBSS at pH 4), or 23 mg/kg IKE 
NP (IKE PEG-PLGA NPs in water) via intraperitoneal (IP) injection once daily. During the experimental 
period, mouse weight and tumor volume were measured daily to determine IKE’s antitumor effect and 
possible toxicity. Tumor growth was calculated as the fold change to original tumor volume on day 0 
before the first dose (Figure 4.7A). Administration of 40 mg/kg IKE, 23 mg/kg IKE, and 23 mg/kg IKE 
NPs caused a significant decrease in tumor growth starting from day 9 of treatment (Table 5). The tumor 
 
 
Figure 4. 6 IKE PEG-PLGA nanoparticles have enhanced cellular activity comparing with free IKE. 
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growth inhibition effect was not significantly different between 23 mg/kg free IKE and 23 mg/kg IKE 
NP; however, IKE NPs showed less toxicity as evidenced by weight loss (Figure 4.7B). Compared to 
saline vehicle, free-IKE (5% DMSO in HBSS at pH 4) treated mice started losing weight from day 9, 
which might be caused by the accumulated low pH precipitation of IKE after administrated into the 
peritoneum, an environment with pH ranges of 7.5-8.0, causing damage to abdominal organs, or possible 
toxicity of systemic system xc– inhibition, or off-target toxicity of IKE. However, IKE NP-treated mice 
had a similar weight as the saline vehicle and the NP vehicle groups; the lower toxicity of the IKE NP 
formulation might derive from the NP EPR effect, which decreases the non-specific distribution and 
systemic toxicity associated with conventional hydrophobic drugs.  
 
 
A                                                                                      B 
 
       
 
Figure 4. 7 IKE and IKE NPs inhibited tumor growth in NCG mice bearing SUDHL6 xenografts 
(A) Tumor volume fold change compared with day 0, measured by electronic caliper daily and 
calculated using the formula volume = 0.5 x length x width2, revealed a reduction of tumor growth by 
IKE 40 mg/kg (n=9), IKE 23 mg/kg (n=11), and IKE NP 23 mg/kg (n=13) treatment for 14 days 
comparing with vehicle (n=13) and NP vehicle (n=13) controls (data analyzed by two-way ANOVA). 
(B) Mouse weight was measured daily and indicated no weight loss upon NP and IKE NP treatments, 
but weight loss upon IKE 40 mg/kg and IKE 23 mg/kg treatment starting from day 9. 
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Table 4. 1 Percentage of tumor growth inhibition by IKE and IKE NP 
Days 8 9 10 11 12 13 
NP vehicle vs. Saline vehicle ns ns ns ns ns ns 
 * **** **** **** **** **** 
IKE 40 mg/kg vs. Saline vehicle 0.47 0.68 0.67 0.72 0.82 0.73 
 ** **** **** **** **** **** 
IKE 23.3 mg/kg vs. Saline vehicle 0.53 0.61 0.54 0.61 0.64 0.59 
 ns *** **** **** **** **** 
IKE NP 23.3 mg/kg vs. NP vehicle 0.42 0.56 0.62 0.60 0.56 0.53 
ns P > 0.05; * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001 
 
By analyzing IKE tumor accumulation using LC-MS, we found that IKE NP at 23 mg/kg had 
slightly enhanced tumor accumulation compared with free IKE at 23 mg/kg and was comparable with the 
free IKE 40 mg/kg treatment (Figure 4.8). This suggests that IKE NPs likely accumulate in tumor tissue. 




Figure 4. 8 Measurement of IKE accumulation in tumor tissues 
LC-MS analysis of tumor IKE concentration showed IKE NP 23 mg/kg treated mice have higher 
tumor IKE accumulation comparing with IKE 23 mg/kg group. Tumor samples were from mice 
treated with saline vehicle, NP vehicle, IKE NP 23 mg/kg, IKE 23 mg/kg, and IKE 40 mg/kg daily for 
14 days and sacrificed after 3 hours of the final dosage. 
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4.2.3 Investigation of ferroptosis biomarker expression in IKE and IKE PEG-PLGA efficacy study 
Given the fact that PTGS2 gene expression was upregulated during ferroptosis, we hypothesized 
that after IKE treatment, there might be increased level of PTGS2 protein in the tumor. Indeed, using 
immunofluorescence, we found PTGS2 protein expression was increased in IKE-treated tumor tissue 
(Figure 4.9). There was no significant PTGS2 protein increase in IKE NP treated tumor, which might be 
due to the slower release of IKE from PEG-PLGA NP, making the free IKE concentration less than with 
free-IKE-treated tumors.  
 
                 
 
Figure 4. 9 Measurement of PTGS2 level in tumor tissues from efficacy study by immunofluorescence 
Immunofluorescence of PTGS2 on frozen tumor sections showed 2.0 and 2.8-fold increase on PTGS2 
intensity upon IKE 23 mg/kg and IKE 40 mg/kg treatment daily for 14 days. (sections were cut from 5 
randomly chosen mice in each group, three images from each section were captured on Zeiss LSM 




We further characterized the lipid peroxidation level in tumor tissues in this efficacy study. 
Immunofluorescence analysis of tumor tissue from the five groups showed significantly increased MDA 
adduct levels in IKE-treated and IKE-PEG-PLGA-NP-treated groups, compared with the saline vehicle 
and NP vehicle groups (Figure 4.10).  Compared to saline vehicle, the NP vehicle group had increased 
levels of MDA adduct, which might be caused by low level ferroptosis induction of ultrasmall (<10 nM in 
diameter) nanoparticles distributed in the sample, as observed in PEG-coated silica nanoparticles 
previously142. In addition, the Thiobarbituric Acid Reactive Substances (TBARS) assay, which measures 
fluorescence of MDA-TBA adducts formed also showed increased MDA levels in tumors from the free 
IKE and IKE PEG-PLGA NP groups (Figure 4.11). This assay is not as sensitive as immunofluorescence 
to detect small increases of MDA adducts, suggesting a possible explanation for our inability to detect 
this increase in the NP vehicle group. Immunofluorescence analysis of 8-OHdG showed increased 
oxidative DNA damage in IKE-treated and IKE-PEG-PLGA-NP-treated groups, confirming that IKE 





              
 
Figure 4. 10 Measurement of MDA level in tumor tissues from efficacy study by immunofluorescence 
Immunofluorescence of MDA on frozen tumor sections measured by confocal microscopy showed 
1.4, 1.8, 1.8, and 2.0-fold increase in MDA intensity upon NP vehicle, IKE NP 23 mg/kg, IKE 23 
mg/kg, and IKE 40 mg/kg treatment daily for 14 days.  
 
Figure 4. 11 Measurement of MDA level in tumor tissues from efficacy study by TBARS assay 
TBARS assay measuring MDA-TBA adducts’ fluorescence showed 1.6, 1.4, and 1.8-fold MDA 
increase upon IKE NP 23 mg/kg, IKE 23 mg/kg and IKE 40 mg/kg treatment. ns P>0.5, * P<0.05, ** 





Besides, there was no caspase-3 activity increase upon IKE treatment in tumor tissue, suggesting 
that the inhibition of tumor growth was not resulted by apoptosis (Figure 4.13).   
 
             
 
Figure 4. 12 Measurement of 8-OHdG in tumor tissues from efficacy study by immunofluorescence 
Immunofluorescence of 8-OHdG on frozen tumor sections measured by confocal microscopy showed 
2.3, 1.8, and 2.2-fold increase in 8-OHdG intensity upon IKE NP 23 mg/kg, IKE 23 mg/kg, and IKE 




Figure 4. 13 Measurement of cleaved-caspase 3 abundance in tumor tissues from efficacy study 
Western blot analysis of tumor tissue from the efficacy study showed there was no cleaved-caspase 3 
increase upon IKE and IKE NP treatment for 14 days. Tumor samples of 9 individual mouse from 





Recent discoveries have suggested that ferroptosis inducers can have anti-tumor efficacy and may 
synergize with chemotherapy in some cell contexts. However, there is a lack of potent, selective, and 
metabolic stable tools to study ferroptosis in vivo. This study of the ferroptosis inducer IKE in an 
SUDHL-6 xenograft model demonstrated IKE and IKE NP’s abilities to reduce tumor growth while 
causing ferroptosis. In addition, IKE PEG-PLGA NP formulation was suitable for in vivo use to increase 
IKE’s therapeutic window by decreasing toxicity. The increased PTGS2 protein expression and oxidative 
biomarkers have been identified in IKE and IKE PEG-PLGA NP treated tumor tissues (Figure 4.14).   
We partially addressed the observed toxicity associated with free IKE administration by 
formulating IKE in PEG-PLGA nanoparticles. The toxicity of high dose free IKE treatment might stem 
from systemic system xc– inhibition in normal tissues, or the possible precipitation of IKE after injecting 
into the peritoneal cavity. Targeted nanoparticles might further increase IKE tumor accumulation and 
without systemic toxicity.  
There are various xenograft models used in preclinical assessment of anticancer drug 
development such as ectopic tumor xenograft model, orthotopic xenograft model, metastasis model, 
syngeneic models, humanized mouse, and patient derived xenografts. Here, we used the ectopic tumor 
xenograft model. Ectopic tumor xenograft model is the standard model of cancer used for validation and 
assessment in oncology studies. There are both pros and cons using this model. Firstly, the ectopic tumor 
xenograft model is reproducible, homogeneous, and amendable. Secondly, it is easy to monitor 
tumorigenicity and tumor growth rate. In addition, there are many parameters to assess drug efficiency 
including T/C ratio, tumor growth delay and tumor regression, and drug toxicity including drug-related 
death and body weight change.  On the other hand, the ectopic tumor xenograft model is not applicable 
for tumors that show necrosis during tumorigenicity and non-solid tumors. Besides, the 
immunosuppressed mice represent a different microenvironment than that of human cancer, thus might 
not be able to mimic the human context. Another limitation is that it is hard to assess tumor invasion and 
metastasis. The efficacy of IKE in additional animal cancer models would be valuable to explore.  
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In summary, we have developed a suitable small molecule and formulation for inhibiting system 
xc– and inducing ferroptosis in mouse tumor models, which will we used in determining whether there are 
specific cancer contexts in which ferroptosis induction would be therapeutically beneficial.  
 
4.4 Methods 
IKE PEG-PLGA nanoparticle formulation 
(Poly(ethylene glycol) methyl ether-block-poly(lactide-co-glycolide) (PEG-PLGA) with PEG average 
Mn 5,000, PLGA Mn 15,000, and lactide:glycolide 50:50 was purchased from Sigma-Aldrich (900948). 
PEG-PLGA nanoparticles were prepared using a microfluidic mixer with the NanoAssemblr Benchtop 
instrument (Precision NanoSystems Inc., Vancouver, BC) by mixing oil and aqueous phases. PEG-PLGA 
was dissolved in 25% acetone/75% DMSO at concentration of 10 mg/mL.  Milli-Q water was used as 
aqueous phase.  For synthesis of PEG-PLGA nanoparticles, two phases were injected through two inlets 
of the microfluidic mixer with a speed of 8 mL/min and a volume ratio of 1:1. Nanoparticles were 
 
 
Figure 4. 14 Schematic overview of IKE-induced ferroptosis 
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collected in the sample collection tube by discarding an initial and final waste volume of 0.25 and 0.05 
mL. Samples were dialyzed in at least 500 x deionized water overnight using 10 kD cut-off dialysis bag 
(ThermoFisher, SnakeSkin Dialysis Tubulin, 68100) and the water was changed twice in between to 
remove organic solvent. Then the purified nanoparticles were concentrated by centrifuging using Amicon 
Ultra-15 Centrifugal Filter Units (Millipore, UF9050) at 2,168 x g to the desired concentration. For 
encapsulation of IKE, IKE was dissolved in a solution of PEG-PLGA in 25% acetone and 75% DMSO. 
The final concentration of PEG-PLGA was 10 mg/mL and IKE is 1.5 mg/mL. The process was the same 
with PEG-PLGA nanoparticles preparation. Nanoparticle  size and potential were measured using a 
Malvern Zetasizer Nano ZS. 
 
IKE quantification in PEG-PLGA nanoparticles 
IKE concentration was determined in PEG-PLGA nanoparticles using Liquid Chromatography- Mass 
Spectrometry (LC -MS). IKE was extracted from nanoparticles by mixing 100 μL of samples with 900 μL 
of acetonitrile. After mixing for 1 h, the mixture was sonicated for 5 min and then centrifuged at 4000 
rpm for 10 min. The supernatant was transferred to a new vial.  The organic solvent was removed by 
Genevac evaporation.  The residues were re-dissolved in 100 μL MeOH in a LC-MS vial. Calibration 
standards and quality control samples were prepared spanning a range of 25 ng/ml to 1250 ng/ml IKE in 
MeOH. Peak integration and data analysis were performed. Using the standard curve, IKE concentration 
in the sample was determined. 
 
Measurement of IKE PEG-PLGA cellular activity 
DLBCL cells or HT-1080 cells were plated at 2,000 cells per well in white 384-well plates (32 μL per 
well) in technical duplicates and incubated overnight. The cells were then treated with 8 μL medium 
containing a two-fold dilution series of vehicle 1 (DMSO), IKE, Fer-1, vehicle 2 (unfunctional PEG-
PLGA nanoparticles), or IKE PEG-PLGA nanoparticles. The final concentration of IKE in PEG-PLGA 
nanoparticles were measured by LC-MS as described in the sections below. After 24 h incubation with 
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compounds, 40 μL of 50% CellTiter-Glo (Promega) 50% cell culture medium was added to each well and 
incubated at room temperature with shaking for 15 min. Luminescence was measured using a Victor X5 
plate reader (PerkinElmer). All cell viability data were normalized to the DMSO vehicle condition. 
Experiments were performed in three independent times with different passages for each cell line. From 
these data, dose-response curves and IC50 values were computed using Prism 7.0 (GraphPad).  
 
IKE Efficacy study 
IKE was dissolved in 5% DMSO/95% HBSS at pH 4 to create a 4 mg/mL solution. 5% DMSO/95% 
HBSS at pH 4 was used as vehicle 1. IKE PEG-PLGA nanoparticles and unfunctionalized PEG-PLGA 
nanoparticles (without IKE loading) (vehicle 2) prepared with a NanoAssemblr were dialyzed with 
deionized water overnight; the water was changed at least twice. Dialyzed IKE-PEG-PLGA nanoparticles 
and unfunctional PEG-PLGA nanoparticles were concentrated by Amicon Ultra-15 Centrifugal Filter 
Units to create a solution with 80 mg/mL PEG-PLGA nanoparticles. All above solutions were sterilized 
by filter through a 0.2 μm syringe filter.  
 
NCG mice, 6-weeks old, were injected with 10 million SUDHL0-6 cells subcutaneously. The mice were 
treated after the tumor size reached 100 mm3.  Mice were separated randomly into treatment groups and 
dosed with 23 mg/kg IKE, 40 mg/kg IKE, 23 mg/kg IKE PEG-PLGA nanoparticles (equal to 700 mg/kg 
PEG-PLGA), vehicle 1 (based on volume), and vehicle 2 (700 mg/kg PEG-PLGA) once daily by IP for 
14 days. Tumor volume was measured daily with electronic caliper and calculated using the formula: 0.5 
x length x width2. 3 h after the final dosage, mice were euthanized with CO2 and tumor tissue was 
dissected, weighed, divided into 4-6 segments, frozen, and stored at -80°C. Tumor volume change was 
analyzed in Prism using one-way ANOVA. Tumor tissues were analyzed as described in the RT-qPCR, 
immunofluorescence, TBARS, and lipidomics sections below.  
 
Immunofluorescence on frozen tissue sections and quantification 
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Tumor tissues were fixed in 4% paraformaldehyde (PFA) for 24 h at 4°C followed by washing with PBS 
three times. The tissues were perfused in 30% sucrose for 24 h at 4°C for cryo-protection.  The samples 
were embedded in OCT cryostat sectioning medium, and then moved directly into a cryostat. After 
equilibration of temperature, frozen tumor tissues were cut into 5 µm thick sections. Tissue sections were 
mounted on to poly-L-lysine coated slides by placing the cold sections onto warm slides. Slides were 
stored at -80°C until staining. For staining, slides were warmed to room temperature followed by washing 
with PBS twice. A hydrophobic barrier pen was used to draw a circle on each slide. The slides were 
permeabilized with PBS/0.4% Triton X-100 twice before non-specific-binding blocking by incubating the 
sections with 10% goat serum (ThermoFisher 50197Z) for 30 minutes at room temperature. The sections 
were separately incubated with mouse anti-MDA mAb 1F83 (1:1000 dilution), anti-cyclooxygenase 2 
(COX 2, AKA PTGS2) antibody (Abcam, ab15191, 1:200 dilution), or anti-8-OH-dG (DNA/RNA 
damage) antibody (Abcam, ab62623, 1:200 dilution) overnight at 4°C in humidified chambers. Sections 
were washed with PBST for twice before incubating with goat anti-mouse IgG H&L (Alexa Fluor 647) 
(Abcam, ab150115, 1:1000 dilution) or goat anti-rabbit IgG H&L highly cross-absorbed secondary 
antibody (Alexa Fluor488, Thermo Fisher Scientific, A-11034, 1:1000) at room temperature for 1 h. 
Slides were then washed twice with PBST. ProLong Diamond antifade mountant with DAPI 
(ThermoFisher P36962) was added onto slides, which were then covered with the coverslips, sealed by 
clear fingernail polish and observed under confocal microscopy. All images were captured on a Zeiss 
LSM 800 confocal microscope at Plan-Apochromat 63x/1.40 Oil DIC objective with constant laser 
intensity for all analyzed samples. The intensity above threshold of the fluorescent signal of the bound 
antibodies was analyzed using NIH ImageJ software. Data were expressed as fold change comparing with 
the vehicle.   
 
Western blot 
10-25 mg tumor tissue was placed into a 1.5 mL Eppendorf microfuge tube, and the sample was placed on 
dry ice until use. 20 μL/mg ice cold RIPA buffer with cocktail protease inhibitor (Roche) was added. The 
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tumor tissue was homogenized at speed 5 for 30 sec using Bead Ruptor 4. The sample was centrifuged at 
4°C at 1,600 x g for 10 min. The sample was kept on ice and the supernatant used for analysis. Caspase-3 
antibody which could recognize both full-length caspase-3 and cleaved caspae-3 was used. -Tubulin 
antibody was used as the reference.  
 
Quantification and statistical analysis 
T-test, one-way ANOVA, and two-way ANOVA were performed in R (version 3.5.1) environment and 





Chapter 5 Untargeted Lipidomics Study of IKE Induced Ferroptosis4 
5.1 Introduction 
Increased evidences have shown the involvement of lipid metabolism and the associated enzymes 
in ferroptosis. Acyl-CoA synthetase long-chain family member 4 (ACSL4) and lysophosphatidylcholine 
acyltransferase 3 (LPCAT3) were enriched in ferroptosis resistant cell lines86. An independent genome-
wide CRISPR-based genetic screen and microarray analysis also identified key function of ACSL4 in 
ferroptosis69.  A quantitative redox global phospholipidomics revealed that doubly and triply oxygenated 
species of PE are significantly increased in ferroptosis89. PEs containing arachidonoyl (AA) and adrenoyl 
moieties (AdA) were identified as the preferred substrates for oxidation in ferroptosis89. In addition, 
inhibition of lipoxygenases (ALOXs) but not cyclooxygenases (COXs) and cytochrome P450 prevented 
RSL-3 induced ferroptosis82, 89. However, the genes regulating change of different lipid species during 
ferroptosis, and lipidomics of in vivo ferroptosis have not been investigated. Here, we described the 
lipidomics in IKE-, and IKE in combination with Fer-1-, DFO-, or β-Me-treated SUDHL-6 cells to 
identify the lipids change during IKE-induced ferroptosis. Besides, a series of genes associated with lipid 
metabolism were identified to be upregulated with IKE treatment in SUDHL-6 cells. To our surprise, the 
lipids change in tumor samples of IKE treated NCG mice bearing subcutaneously SUDHL-6 xenograft is 







4 This chapter is adapted from the manuscript submited:  Zhang, Y.; Tan, H.; Daniels J. D.; 
Zandkarimi, F.; Liu, H.; Brown, L. M.; Uchida, K.; O’Connor, O. A.; Stockwell, B. R., Imidazole 




5.2.1 Untargeted lipidomics study of IKE induced ferroptosis in cell culture 
To investigate the effects of IKE on lipid composition and metabolites, we performed untargeted 
mass-spectrometry-based lipidomics and gene expression analysis of related enzymes during lipid 
biosynthesis and oxidation. SUDHL-6 cells treated with 1 µM IKE, and 500 nM IKE with or without 10 
M fer-1, 10 M β-Me, and 10 M deferoxamine (DFO) co-treatment, were subjected to UPLC-MS 
analysis. We observed significant (one-way ANOVA, p < 0.05) depletion in the relative abundance of 74 
lipid ions including lysophosphatidylcholines (LPC), phosphatidylcholines (PC), 
phosphatidylethanolamines (PE), and triacylglycerols (TAG) mainly containing poly-unsaturated fatty 
acids (PUFAs) in IKE-treated groups, while co-treatment with β-Me or fer-1 reversed this effect and 
maintained the levels of these specific lipids near to baseline (Figure 5.1). The annotations of the lipid 
species were confirmed with LipoStar software (Version 1.0.4, Molecular Discovery, UK)143. These 
results are consistent with the effects of piperazine erastin and erastin +/- fer-1 treated HT-1080 cells on 
lipid composition67, 82. While the levels of monoacylglycerols (MAG), the hydrolysis product of TAG 
lipids were increased significantly in IKE-treated samples, fer-1 co-treatment decreased significantly the 
levels of these MAG lipids. The iron chelator DFO was not able to reverse IKE-induced lipidomic 
changes, although this may be due to the toxicity of DFO at concentrations that are needed to suppress 
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Figure 5. 1 Untargeted 
lipidomics study in 
SUDHL-6 cells 
Heatmap of significantly 
changed (one-way 
ANOVA, p < 0.05) lipid 
species in SUDHL-6 cells 
treated with DMSO, 500 
nM IKE, 1 μM IKE, 500 
nM IKE with 10 μM fer-1 
cotreatment, 500 nM IKE 
with10 μM β-Me 
cotreatment, 500 nM IKE 
with10 μM DFO 
cotreatment, measured by 
LC-MS.  Each row 
represents z- score 
normalized intensities of 
the detected lipid species 
(A) in negative 
electrospray ionization 
mode and (B) in positive 
electrospray ionization 
mode. Each column 
represents an independent 
biological replicate. The 
lipid abundance is color 
coded with red indicating 
high signal intensity and 
dark blue indicating low 
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5.2.2 Investigation of enzymes relating to IKE induced lipids change 
By measuring the mRNA levels of lipid biosynthesis enzymes upon IKE treatment, we found 
significant upregulation of acetyl-CoA carboxylase 1 (ACC1), which catalyzes the rate-limiting step of 
fatty acids biosynthesis from acetyl-CoA to malonyl-CoA, and elongation of very long chain fatty acids 
protein 7 (ELOVL7), which catalyzes the rate-limiting reactions of long-chain fatty acids elongation cycle 
especially the elongation of C18:3 (n-3) and C18:3 (n-6)-CoAs (Figure 5.2). The upregulation of these 
two mRNAs was partially reversed by co-treatment of 10 M fer-1 or 10 M β-Me, indicating that fatty 
acid biosynthesis was activated by cysteine depletion and lipid peroxidation during IKE-induced 
ferroptosis. Moreover, there was significant upregulation of adipose triglyceride lipase (ATGL), secretory 
phospholipase A2f (sPLA2F), lysophosphatidylcholine acyltransferase 4 (LPCAT4), and 
lysophosphatidylethanolamine acyltransferase 1 (LPEAT1), suggesting that phospholipid biosynthesis 
remodeling was activated with IKE treatment. Lipids peroxidation during ferroptosis is a deleterious 
process, and the best way to repair such damage is to selectively cleave the oxidized PUFA, replace with 
the native fatty acids, and subsequently reduce the lipid hydroperoxides by glutathione peroxidase144. The 
activation of sPLA2, which selectively release arachidonic acid at the sn-2 position of phospholipids, 
ATGL, which hydrolyzes triacylglycerides, LPCAT4 and LPEAT1, which catalyze the conversion of 
LPC to PC and LPE to PE respectively, is thus important for this repair process. In addition to Fenton-
chemistry-mediated lipid peroxidation, enzyme-mediated lipid peroxidation was also activated in IKE-
induced ferroptosis as there were increased lipoxygenase 12 (ALOX12) and lipoxygenase 15 (ALOX15) 
expression.  
Genes upregulated with IKE treatment were highlighted as red color in the schematic lipids 
biosynthesis overview (Figure 5.3). In summary, these lipidomic studies provides us with a detailed 







Figure 5. 2 Expression level of genes involving lipid metabolism  
Fold change in expression of lipids biosynthesis and metabolism associated genes with 500 nM IKE 
treatment, 500 nM IKE with 10 μM fer-1 cotreatment, and 500 nM with 10 μM β-Me cotreatment 
comparing with DMSO control in SUDHL-6 cells. ACC1, ELOVL7, ATGL, sPLA2F, LPCAT4, 
LPEAT1, ALOX12, and ALOX15 were upregulated in SUDHL-6 cells with IKE treatment. 
Cotreatment with fer-1 and β-Me partially reversed the effects (left). FASN, ELOVL1, ACSL4, 
PLA2G6C, LPCAT1, and LPCAT3 were not upregulated in IKE treated SUDHL-6 cells (right).  
 
 
Figure 5. 3 Schematic view of fatty acid biosynthesis, lipids remodeling, and arachidonic acid 
oxidation  
The genes upregulated in IKE treatment were labeled with red color.   
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5.2.3 Untargeted lipidomics study of IKE induced ferroptosis in vivo 
While lipidomic study in SUDHL-6 cell culture helps us understand the mechanisms leading to 
the lipids change, we want to further investigate lipids change with IKE treatment in vivo, as the solid 
tumor has complex microenvironment which is hard to mimic by cell culture. We performed untargeted 
lipidomics on tumor tissue with a single dose of IKE across different time points. Different from the in 
vitro lipidomic results, we identified significant (one-way ANOVA p < 0.05) accumulation in the relative 
abundance of free fatty acids, phospholipids, and diacylglycerol (DAG) upon IKE treatment (Figure 5.4). 
This might stem from the different tumor microenvironment in vivo. The lipids identified were enriched 
in linoleic acid and arachidonic acid metabolism (Figure 5.5).  
The significant increase in the levels of DAG and free fatty acids might result from the ATGL-
mediated-TAG hydrolysis (Figure 5.6). We also observed accumulation of MAG lipids in IKE-treated 
cell (Figure 5.1). The increased fatty acids in turn promote phospholipid remodeling to synthesize 
specific types of phospholipids, including PC and PE.  
To explore the free fatty acids effects on cells and ferroptosis, we performed a cell survival test of 
free fatty acids in the presence or absence of IKE. We found that high concentrations of PUFAs, 
including  γ-linolenic acid, eicosapentaenoic acid, and arachidonic acid, were toxic to cells (Figure 5.7A), 
low concentration of free fatty acids sensitized to ferroptosis, while oleic acid and palmitoleic acid had 








Figure 5. 4 Untargeted lipidomics study in vivo 
Heatmaps of dysregulated lipids in SUDHL6 subcutaneously xenografted NCG mice treated with one 
dosage IKE for at 0, 4, and 24 hours or with vehicle, detected by untargeted UPLC-MS analysis. Data 
shown in heatmaps are lipid species that were identified as being statistically significant (p < 0.05) 
among the groups in negative electrospray ionization mode (Top) and positive electrospray ionization 
mode (Bottom). Each column represents an independent biological replicate. Each row represents z- 
score normalized intensity of a lipid feature. The relative abundance of each identified lipid is color 
coded with blue indicating low signal intensity and red indicating high signal intensity. Abbreviations: 
PC, phosphatidylcholine; PE, phosphatidylethanolamine; PI, Phosphatidylethanolamine; PS, 
phosphatidylserine, LPC, lysoPC; LPE, lysoPE; FA, free fatty acid; TAG, triacylglycerol; DAG, 







Figure 5. 5 Metscape network analysis of lipids identified in IKE treatment in vivo 
Significant accumulated lipids in vivo and significant genes in ferroptosis are highlighted as green 








Figure 5. 6 Gene expression analysis in vivo 
RT-qPCR analysis of gene expression related to lipids biosynthesis and peroxidation in tumor tissue 




Figure 5. 7 Lethality and sensitivity effects evaluation of lipids  
(A) Dose-response curves of SUDHL-6 cells was determined by adding free fatty acids in a 10-point, 
two-fold dilution series for 24 hours, followed by a  Cell Titor-Glo luminescent cell viability test. γ-l-
linolenic acid, eicosapentaenoic acid, and arachidonic acid are toxic to cells at high concentration. (B) 
Dose-response curves of SUDHL-6 cells was determined by treating with IKE in a 10-point, twofold 
dilution series in the presence of DMSO or free fatty acids. Relative Area Under Curve (AUC) to 
DMSO cotreatment was used to indicate the sensitization or protection effect of free fatty acids to 




Lipidomics is an emerging area in biomedical research. By performing untargeted lipidomics 
study in IKE treated SUDHL-6 cells in combination with different ferroptosis inhibitors, we identified 
decreased PE, PC, and TAG upon IKE treatment. This might result from the cleavage of oxidized PUFA 
in PE, PC, and TAG to prevent the oxidative damage to cells induced by IKE treatment. The cotreatment 
of β-Me, which transport cysteine through L systems, completely reversed the lipids change resulted by 
IKE treatment. Besides, the antioxidant reagent Fer-1 partially prevented the phospholipids decrease in 
cells, but dramatically increased TAG. The increased TAG pool might serve as a buffer against lipo-
toxicity induced by IKE145. In addition, the iron chelator DFO didn’t prevent IKE induced phospholipids 
and TAG decrease, indicating that Fenton chemistry-mediated lipid peroxidation is not the driver of lipids 
change during ferroptosis.  
A series of genes regulating lipid metabolism have been proved to participate in ferroptosis 
(Table 6). mRNA level of genes encoding lipid biosynthesis enzyme ACC1 and ELOVL7 were increased 
with IKE treatment, which might function to increase PUFA production to compensate the oxidized 
PUFA. LPCAT4 and LPEAT1, which encode enzymes to promote PC and PE synthesis, were dramatically 
upregulated upon IKE treatment. Given the evidence that PE peroxides were significantly increased in 
ferroptosis89, and PE has important structural function in cell membrane84, the upregulation of LPEAT1 is 
thus important for maintaining cellular PE concentration and integrity of cell membrane. Lipid 
peroxidation is lethal to cells, the most efficient way to remove this kind of oxidative damage is to cleave 
the oxidized PUFA and exchange with the natural ones. The upregulation of ATGL and sPLA2F strongly 
supports this hypothesis.  
Lipidomics study in vivo proved a different landscape of lipids change. DAG were significantly 
increased in tumor tissue after IKE treatment, which might result from hydrolysis of TAG. The increased 
PUFA might come from the response of tumor microenvironment to protect tumor cells from the 
oxidative stress with IKE treatment.  
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In summary, we proved the involvement of different species of lipids and lipid metabolism genes 
in IKE-induced ferroptosis and the protective effect of different ferroptosis inhibitors to IKE-induced 
lipids change. More investigation could be done to study the execution roles of genes identified here. 
 
Table 5. 1 Genes involved in reduced glutathione (GSH)-depletion induced ferroptosis 
Gene Name  Function 
SLC7A11 Solute carrier family 7 member 11 
(cystine/glutamate antiporter 
system xc– light chain, xCT) 
Upregulated by system xc– inhibitors; 
Inhibition of system xc– leads to glutathione 
depletion and ferroptosis 
CHAC1 ChaC glutathione-specific gamma-
glutamylcyclotransferase 1 
Upregulated by system xc– inhibitors  
GPX4 Glutathione peroxidase-4 Function as phospholipid hydroperoxidase which 
reduces hydrogen peroxide and lipid peroxides by 
using reduced glutathione (GSH) to protect cells 
from lipid peroxidation; 





Upregulated in ferroptosis 
ALOXs lipoxygenases Involved in peroxidation of PUFA in GSH-depletion 
induced ferroptosis 
ACSL4 Acyl-CoA synthetase long-chain 
family member 4 
Converts free fatty acids into fatty CoA ester, 
involved in GPX4-depletion induced ferroptosis 
PLA2 Phospholipase 2 Hydrolyzes polyunsaturated fatty acids and oxidized 




sPLA2F Secretory phospholipase A2f One isomer of PLA2 
ATGL 
(PNPLA2) 




Converts lysophosphatidylcholine (LPC) to 
phosphatidylcholine (PC), localize to the 
endoplasmic reticulum and lipid droplets 
LPCAT2 Lysophosphatidylcholine 
acyltransferase 2 
Converts lysophosphatidylcholine (LPC) to 
phosphatidylcholine (PC), localize to the 
endoplasmic reticulum and lipid droplets 
LPCAT3 Lysophosphatidylcholine 
acyltransferase 3 
Key enzyme to incorporate arachidonic acid into 




acyltransferase, prefers long chain acyl-CoAs (C16, 
C18) as acyl donors. 
LPEAT1 Lysophosphatidylethanolamine 
acyltransferase 1 
Preferentially acylates LPE with acyl-CoA 
ACC Acetyl-CoA carboxylase Catalyzes the conversion of acetyl-CoA to malonyl-
CoA  
ELOVL7 Elongation of very long chain fatty 
acids protein 7 
Catalyzes the fist and rate-limiting reaction of long-
chain fatty acids elongation cycle, with higher 
activity toward C18 acyl-CoAs especially C18:3(n-




5. 4 Methods 
qPCR in cells and mouse tumor tissue 
The experiments followed the same steps used in Chapter 3 and 4. qPCR primers used in this chapter are 
listed below: 
Genes Foward Reverse 
ACSL4 5’-CCCCGCTATCT CTCAGACAC-3’ 5’-GGTGCTCCAACTCTGCCAG-3’ 






















ALOX15 5'-GGAGCCTTCCTAACCTACAGC-3' 5'-CTCACGATTCCTTCCACATACC-3' 
LPCAT1 5'-CACAACCAAGTGGAAATCGAG-3' 5'-GCACGTTGCTGGCATACA-3' 
LPCAT3 5'-ATCACTGCCGTCCTCACTAC-3' 5'-AGTCAACAGCCAAACCAATC-3' 




















Mass spectrometry-based untargeted lipidomics analysis 
Sample preparation in vitro study 
The lipids were extracted from each cell sample using a modified Matyash method146 as described 
previously147. 5 million cells treated with DMSO, 1 μM IKE, 500 nM IKE with or without 10 μM fer-1 
and 10 μM β-Me for 24 hours were homogenized in 250 μL cold methanol containing 0.1% butylated 
hydroxyl toluene (BHT) with micro tip sonicator. Homogenized samples were transferred to fresh glass 
tubes containing 850 μL of cold methyl-tert-butyl ether (MTBE) and vortex-mixed for 30 sec. To enhance 
extraction efficiency of lipids, the samples were incubated overnight at 4 °C on the shaker. On the next 
day, 200 μL of cold water was added to each sample, and incubated for 20 min on ice before 
centrifugation at 3,000 rpm for 20 min at 4 °C. The organic layer was collected followed by drying under 
a gentle stream of nitrogen gas on ice and stored at -80 °C until LC-MS analysis. The protein pellet was 
used to measure protein concentration using Bio-Rad protein assay.  The samples were re-constituted in a 
solution containing IPA/ ACN /water (4:3:1, v/v/v) containing mixture of internal standard for further MS 
analysis. 
A quality control (QC) sample was prepared by combining 40 µL of each sample to assess the 
reproducibility of the features through the runs.  
 
Ultra-performance liquid chromatography analysis 
Chromatographic separation of extracted lipids was carried out at 55 °C on Acquity UPLC HSS T3 
column (2.1× 150 mm, 1.8 μm) over a 17-min gradient elution. Mobile phase A consisted of ACN/water 
(60:40, v/v) and mobile phase B was IPA/ACN/water (85:10:5, v/v/v) both containing 10 mM ammonium 
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acetate and 0.1% acetic acid. After injection, the gradient was held at 60% mobile phase A for 1.5 min. 
For the next 12 min, the gradient was ramped in a linear fashion to 100% B and held at this composition 
for 3 min. The eluent composition returned to the initial condition in 1 min, and the column was re-
equilibrated for an additional 1 min before the next injection was conducted. The flow rate was set to 400 
µL/min and Injection volumes were 5 µL using the flow-through needle mode in both positive and 
negative ionization modes.  
The QC sample was injected between the samples and at the end of the run to monitor the performance 
and the stability of the MS platform. This QC sample was also injected at least 5 times at the beginning of 
the UPLC/MS run, in order to condition the column. 
 
Mass spectrometry analysis 
The Synapt G2 mass spectrometer (Waters, Manchester, U.K.) was operated in both positive and negative 
electrospray ionization (ESI) modes. For positive mode, a capillary voltage and sampling cone voltage of 
3 kV and 32 V were used. The source and desolvation temperature were kept at 120 °C and 500 °C, 
respectively. Nitrogen was used as desolvation gas with a flow rate of 900 L/hr. For negative mode, a 
capillary voltage of -2 kV and a cone voltage of 30 V were used. The source temperature was 120 °C, and 
desolvation gas flow was set to 900 L/hr. Dependent on the ionization mode the protonated molecular ion 
of leucine encephalin ([M+H]+, m/z 556.2771) or the deprotonated molecular ion ( [M-H]-, m/z 554.2615) 
was used as a lock mass for mass accuracy and reproducibility. Leucine enkephalin was introduced to the 
lock mass at a concentration of 2 ng/µL (50% ACN containing 0.1% formic acid), and a flow rate of 10 
µL/min. The data was collected in duplicates in the centroid data independent (MSE) mode over the mass 
range m/z 50 to 1600 Da with an acquisition time of 0.1 seconds per scan. 
The QC samples were also acquired in enhanced data independent ion mobility (IMS-MSE) in both 
positive and negative modes for enhancing the structural assignment of lipid species. The ESI source 
settings were the same as described above. The traveling wave velocity was set to 650 m/s and wave 
height was 40 V. The helium gas flow in the helium cell region of the ion-mobility spectrometry (IMS) 
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cell was set to 180 mL/min to reduce the internal energy of the ions and minimize fragmentation. 
Nitrogen as the drift gas was held at a flow rate of 90 mL/min in the IMS cell. The low collision energy 
was set to 4 eV, and high collision energy was ramping from 25 to 65 eV in the transfer region of the T-
Wave device to induce fragmentation of mobility-separated precursor ions. 
 
Data pre-processing and statistical analysis 
All raw data files were converted to netCDF format using DataBridge tool implemented in MassLynx 
software (Waters, version 4.1). Then, they were subjected to peak-picking, retention time alignment, and 
grouping using XCMS package148 (version 3.2.0) in R (version 3.5.1) environment.  For the peak picking, 
the CentWave algorithm149 was used with the peak width window of 2-25 s. For peak grouping, 
bandwidth and m/z-width of 2 s and 0.01 Da were used, respectively. After retention time alignment and 
filling missing peaks, an output data frame was generated containing the list of time-aligned detected 
features (m/z and retention time) and the relative signal intensity (area of the chromatographic peak) in 
each sample.  
Technical variations such as noise were assessed and removed from extracted features' list based on the 
ratios of average relative signal intensities of the blanks to QC samples (blank/QC >1.5). Also, peaks with 
variations larger than 30% in QCs were eliminated.  
Multivariate and univariate analyses were performed using MetaboAnalyst 150(version 4.0) and in R 
(version 3.5.1) environment. Group differences were calculated using VIP scores of PLS-DA model and 
one-way ANOVA (p < 0.05) and false discovery rate of 5% to control for multiple comparisons.  
 
Structural assignment of identified lipids 
Identification and structural characterization of significant lipid features were confirmed with LipoStar143 
(Version 1.0.4, Molecular Discovery, UK). Lipidomix standard (Avanti Polar Lipids, INC., Alabaster, 
AL, USA) and quality control samples were analyzed in LipoStar with the recommended data processing 
parameters143 except MS/MS signal filtering threshold was set to 20 for both positive and negative 
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ionization mode. The precursor ion (MS) and fragment ion information obtained by data independent MS 
(MSE) were automatically annotated using LipoStar database library with mass tolerances of 5 ppm and 
10 ppm, respectively. Annotated lipid species with the highest score and high-confidence identification 
(matches between experimental and theoretical MS/MS spectra) were approved, and the identified lipids 
with low-confidence matches were further evaluated manually using MSE data viewer (Version 1.3, 
Waters Corp., MA, USA). 
 
Untargeted lipidomics study in vivo 
25 mg frozen tissue was homogenized in 15 μL/mg pre-chilled methanol containing 0.1% butylated 
hydroxyl-toluene (BHT) at speed 5 for 30 secs using a Bead Ruptor 4 (OMNI International). Then, 300 
μL of tissue lysate were transferred to a glass vials containing 1,000 μL ice-cold methyl-tert-butyl ether 
(MTBE) and vortex-mixed for 30 sec. The sample are stored in the -20 °C freezer overnight to enhance 
lipids extraction. In the following day, 250 μL of ice-cold methanol was added to each sample and vortex-
mixed for 30 sec vigorously. Then, samples were incubated on dry ice for 20 min on the shaker followed 
by centrifuge at 3,000 rpm for 20 min at 4°C. Finally, 1,000 μL of upper phase containing lipids were 
transferred to fresh glass vials and evaporated to dryness under the stream of N2 gas. The samples were 
re-constituted in a solution containing IPA/ ACN /water (4:3:1, v/v/v) containing mixture of internal 
standard for further MS analysis. The other steps including LC-MS analysis and data processing are the 




Chapter 6 Conclusions and Future Directions 
 
 This thesis examined the power of small molecule design to validate cancer targets and 
therapeutic mechanisms. In the second chapter, a fragment-based small molecule design strategy 
combined with protein engineering approach was applied to explore the potential of targeting the 
nucleotide-binding site of oncogenic KRAS. In the following three chapters, the nanocarrier strategy was 
exploited to deliver ferroptosis inducer IKE in diffuse large B-cell lymphoma (DLBCL) xenograft model 
and provided increased therapeutic index comparing with free IKE. The small molecule tools, reverse-
transcription quantitative PCR (RT-qPCR) techniques, and untargeted lipidomic approaches employed 
herein greatly facilitated the characterization of ferroptosis therapeutic mechanism in DLBCL xenograft 
model.  
 
6.1 Target validation using protein engineering strategy 
6.1.1 Summary 
  KRAS mutations are prevalent in three of the most deadly cancers in the United States: pancreatic 
(71%), colon (35%), and lung (19%)12. A variety of strategies including disruption of KRAS-GEF 
interaction, effector binding, blocking KRAS membrane-anchoring, targeting the nucleotide-binding site 
and adjacent allosteric pocket have been attempted to discover small molecules that target KRAS13.  
Despite the prevalence of KRAS mutations and enormous efforts attempted to target KRAS, no clinically 
useful KRAS therapy has been developed.  In Chapter 2, our work provided a small molecule tool to 
investigate KRAS on-target inhibition mechanism in an engineered KRAS system.  We engineered the 
oncogenic KRASG12V protein to a functionally indistinguishable but structurally more inhibitable allele, 
KRASG12VL19AN116AV114C (termed KRAS*). KRAS*-GTP form retains effective binding affinity with 
BRAF, and is fully function in cells. At the same time, these large-to-small mutations and cysteine 
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mutation of the gatekeeper residues in the nucleotide-binding site resulted in an enlarged hydrophobic 
pocket vulnerable for covalent inhibitor attacking.  
 Based on the engineered structure generated above, we used fragment-based small molecule 
design to develop a cell-membrane permeable and selective covalent inhibitor targeting KRAS*. This 
small molecule (YZ0711) could irreversibly modify KRAS* nucleotide binding site both in vitro and in 
cells. It selectively disrupts KRAS*-effector interactions, inhibits KRAS* downstream signaling, and 
prevents KRAS* mutant cell line proliferation. The system we developed here suggests the possibility of 
targeting the nucleotide-binding site of oncogenic RAS proteins by generating engineered RAS alleles, 




Developing a new drug from the original idea through clinical trials to FDA approval is a 
complex, expensive, and long process; to bring a drug to market it typically costs between $500 million to 
more than $2 billion per drug151 and takes more than 10 years of development. Therefore, it is critical to 
first identify and validate the therapeutic effectiveness of the target in specific diseases, which requires 
the use of both genetic and small molecule tools. The development of genetic techniques including RNA 
interference, conditional gene targeting (conditional gene knockout and knock-in), and gene editing tools 
has greatly improved the precision and efficiency of studying specific gene function in cells and 
organisms. However, RNA interference often results in a loss-of-function outcome that has the potential 
to impair the important localization or protein-protein interactions, limiting agreement with small 
molecule approaches. Conditional gene targeting is often difficult to apply to cell culture and requires 
intensive efforts to optimize in vivo. Gene editing tools, including CRISPR/Cas9, TALEN and zinc finger 
nucleases, provide an easy and concise method to generate gene mutations. Small molecule tools can both 
complement and supplement genetic approaches in target identification and validation. In addition, small 
138 
 
molecule tools have the advantage of allowing cells to have little time to compensate for the modulation 
of target activity and can have their actions optimized by adjusting the concentration and treatment 
duration.  
 Kras is an essential gene in mouse embryo development and has un-replaceable roles in 
cardiovascular system in mouse adulthood, making it impossible to generate a homozygous Kras 
knockout14-15. The alternative strategy is to create a conditional gene knockout, for example, using a Cre 
recombinase system that can remove floxed alleles of Kras in specific tissues or at a specific time152. The 
effects of Kras gene knockout, however, can be quite different from the results of small molecule 
inhibition due to disruption of important cellular localization and protein-protein interactions, leading to 
the demand of designing small molecule tools to elucidate KRAS function125. Developing a small 
molecule directly targeting KRAS is challenging because of its high affinity for GTP (picomolar binding 
affinity) and lacking other druggable pockets on KRAS surface. We attempted to solve this challenge by 
developing a covalent small molecule based on shape and covalent complementarity to the engineered 
KRAS.   
The strategy of creating an engineered allele amenable to small molecule inhibition has been 
widely used in kinases but not in small GTPases to study the phenotype of inhibitor occupancy105, 153-154. 
Vincent et al. reported an engineered HRAS that cycles between the inactive state and active state upon 
binding with unnatural nucleotides (GDP and GTP analogs harboring a benzyl group), suggesting the 
capability of using small molecule modulator to control HRAS activity112. However, the unnatural 
nucleotides with diphosphate or triphosphate groups are not cell-membrane permeable. Since the 
phosphate groups are critical for maintaining the high affinity of nucleotides to RAS by hydrogen 
bonding, reversible small molecules without phosphate or other polyatomic anions to form the hydrogen 
bonds might not be potent enough to replace GTP. We exploited a covalent targeting strategy to 
irreversibly modify the nucleotide-binding pocket. Computer-aided small molecule design was used to 
design small molecules that can form key hydrogen bond interactions with the nucleotide-binding pocket. 
The covalent inhibitor we designed is cell membrane-permeable; it can displace GTP; and can irreversibly 
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modify KRAS* in cells, leading to the accumulation of inactive KRAS* thereby preventing KRAS* 
signaling. This methodology could be applied to design useful cellular probes to understand functions of 
other small GTPases. In addition, the integration of glide docking, covalent docking, cell membrane 
permeability prediction, combinatorial library design, and biophysical assays employed in the design of 
the KRAS* inhibitor, represents an innovative fragment-based small molecule design pipeline for 
discovery of targeted-covalent inhibitors.  
  
6.1.3 Future directions 
The strategy of generating an engineered allele has greatly facilitated the understanding of the 
phenotype of target inhibition and the associated mechanisms, especially in undruggable targets or highly 
conserved protein families154. The covalent inhibitor developed here showed selective target inhibition of 
KRAS in cells. A pharmacological tool with high target occupancy and metabolic stability to provide 
KRAS therapeutic index in vivo would be even more valuable. Possible strategies towards improving the 
system developed in this work are discussed below.  
 The design of the orthogonal engineering protein-small molecule system is often based on shape 
complementary (bump-and-hole) or covalent complementary (clamping). The nature of both endogenous 
proteins and endogenous ligands is critical for the selection of these two mechanisms to develop a high 
potency small molecule. KRAS shares a conserved nucleotide-binding site with the other two RAS 
isoforms (HRAS and NRAS) and has a picomolar binding affinity with GTP (0.5 mM cellular 
concentration). The potency and selectivity of small molecule could be dramatically decreased with such 
high binding affinity and high concentration of endogenous ligands126. Hence, the combination of bump-
and-hole and clamping mechanisms is required to assure selectivity and potency of small molecules. 
Protein engineering based on shape complementary often mutates conserved hydrophobic residues to 
alanine. In addition, proteins with a slow turnover rate are more suitable for covalent targeting. However, 
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the protein engineered in this work has an asparagine (N) to alanine (A) mutation, which disrupts the 
important hydrogen bonding interaction between asparagine and nucleotides and residues in KRAS, 
making the engineered KRAS less stable with an increased turnover rate compared to KRASG12V.  This 
high turnover rate results in the quick removal of both covalent small molecule-modified KRAS* and 
unmodified KRAS*. Therefore, a high dosage of covalent inhibitor is required to modify the new 
generated KRAS*. Based on the above analysis, generating a structurally more stable KRAS allele by 
mutating hydrophobic residues but not polar or charged residues to alanine would be helpful to prevent 
turnover rate increase thus improve covalent inhibitor’s cellular activity.  
Structural biology information is crucial for computer-aided drug design. In this study, the crystal 
structure of KRASG12V was mutated in silico and minimized using Schrödinger Prime155 to offer the 
engineered KRAS* structure. Although Schrödinger Prime is a powerful tool for accurate protein 
structure predictions, it might not fully represent the structure changes with triple residue mutations. Both 
the engineered KRAS* structure and KRAS*-covalent small molecule cocrystal structure would be 
valuable to facilitate the design of a more potent covalent inhibitor. Besides, developing a small molecule 
that can mimic nucleotides but has druglike properties could significantly improve target occupancy by 
capturing GEFs to catalyze the exchange of nucleotide to small molecule inhibitor.  
 
 
6.2 Application of IKE in vivo 
6.2.1 Summary 
 To use a small molecule tool in vivo, it needs to possess optimized absorption, distribution, 
metabolism, and excretion (ADME) and toxicity properties. Current small molecule tools to elucidate 
system xc- function and activity in vivo are limited. While, erastin has been extensively used in vitro to 
study system xc– and ferroptosis, it lacks the metabolic stability required for in vivo applications. 
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Sorafenib, a multi-kinase inhibitor approved by the FDA in the treatment of advanced renal carcinoma, 
hepatocellular carcinoma, and thyroid cancer, is metabolically stable but lacks sufficient specificity for 
system xc–, limiting its applicability for such approaches. The low potency of glutamate and sulfasalazine 
prevent their use in studies geared towards elucidating system xc– activity and function.  In Chapters 3 and 
4, we investigated the anti-tumor effect and the associated mechanisms of the first selective, potent, and 
metabolically stable erastin analog, IKE.  
Diffuse large B-cell lymphoma (DLBCL) cell lines have defective transsulfuration pathway 
making them dependent on cystine import through system xc– and sensitive to IKE treatment49. The in 
vitro study indicated that IKE is a highly potent system xc– inhibitor with an IC50 less than 20 nM in 
sensitive DLBCL cell lines, and EC50 of 34 nM on GSH depletion in SUDHL-6 cells (a sensitive DLBCL 
line). In addition, it induced lipid peroxidation and ferroptosis biomarker expression at low concentrations 
(125-500 nM). The pharmacokinetics study revealed that IKE has half-life of 1.83 hour in plasma and 
3.50 hour in tumor tissue of DLBCL xenograft model through intraperitoneal (IP) administration. The 
pharmacodynamics study showed that IKE induced GSH depletion and ferroptosis gene biomarker 
upregulation, indicating that IKE inhibited system xc– function and induced ferroptosis in tumor tissue 
from DLBCL xenograft mice. In Chapter 4, we demonstrated that IKE inhibited tumor growth in a 
DLBCL xenograft model and showed that there was increased oxidative stress in tumor tissue upon IKE 
treatment.  Collectively, our preliminary results support the utility of the small-molecule inhibitor IKE as 
an effective novel therapeutic option for DLBCL that requires further clinical evaluation.  
6.2.2 Significance    
DLBCL is an aggressive malignancy of mature B lymphocytes, accounting for 30-40% of non-
Hodgkin’s lymphoma132. It is a clinically and genetically heterogenous malignancy, which is classified 
into two main subgroups based on gene expression profiling, specifically, germinal centre B cell-like 
(GCB) and activated B cell like (ABC). Although most patients with DLBCL respond to chemotherapy 
and chemoimmunotherapy such as R-CHOP (Rituximab-Cyclophosphamide-Hydroxydaunorubicin-
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Oncovin-Prednisone) regime, more than 30% of patients fail to respond or have disease relapse. 
Therefore, there is demonstrated need to develop novel drugs or therapies that can improve response rate 
and survival of DLBCL patients. We have shown that IKE inhibited tumor growth in a DLBCL xenograft 
model through inhibition of system xc– and induction of ferroptosis, indicating the potential application of 
IKE and ferroptosis inducers in anti-cancer therapy of DLBCL.  
In addition to DLBCL, system xc– inhibitors have potential to inhibit tumor growth in other 
cancer models. For example, sulfasalazine, a low potency system xc– inhibitor, has shown tumor 
inhibition effect in xenograft models of prostate cancer (DU-145 and PC-3)156, triple-negative breast 
tumor (M231), small-cell lung cancer (SCLC) (NCI-H69 and LU6-SCLC)157, and pancreatic cancer (MIA 
PaCa-2, PANC-1, and Capan-1)158-159 without major side effects. LU6-SCLC was generated from a 
chemotherapy-resistant SCLC. The antitumor effect of sulfasalazine shown in this xenograft model 
indicates system xc– inhibition could be an option for cancers that are not responsive to other 
chemotherapeutic regiment157. In addition, the efficacy of gemcitabine and etoposide chemotherapies 
could be markedly enhanced by combination with sulfasalazine in xenograft models of pancreatic cancer, 
suggesting the potential of applying system xc– inhibitor in combination chemotherapy158-159. Compared 
with sulfasalazine which inhibits glutamate release and depletes GSH at micromolar to millimolar range 
concentration134, 160, IKE is a more potent system xc– inhibitor with IC50 of 30 nM on inhibition of 
glutamate release and 34 nM on GSH depletion. Therefore, IKE might have improved efficacy in DLBCL 
xenograft model and tumor models mentioned above. In addition, the pharmacokinetic and 
pharmacodynamic properties of IKE we presented here would be useful for future IKE in vivo studies.  
6.2.3 Future directions 
IKE is the first highly potent, selective, and metabolically stable erastin analog. However, there 
are opportunities to optimize its potency, selectivity, and ADME/toxicity properties by addressing the 
following challenges.  
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First, structure-based small molecule design would be useful if the system xc– structure 
information is available. System xc–, which belongs to the heterodimeric amino acid transporters family,  
is composed of a light chain, xCT, and a heavy chain, 4F2, with the transport activity located on xCT. 
xCT has 12 transmembrane domains consisting of 501 amino acids, however, no crystal structure of xCT 
is reported in the literature. Homology modeling might provide structural information for xCT; however, 
only two antiporters in the family have reported crystal structures: (i) amino acid-poly amine-and 
organocation transporter (ApcT) (PDB: 3GLA), a broad-specificity amino acid transporter, which has a 
sequence identity of 25% with xCT; and (ii) arginine agmatine antiporter (AdiC) (PDB: 3NCY), which 
has a sequence identity of 24% with xCT. Since a homology model based on protein with less than 30% 
sequence identity is not accurate, designing system xc– inhibitors through homology modeling would have 
limited success. A pharmacophore model based on all current system xc– inhibitors might provide some 
information on common features of system xc– inhibitors161, but such information is not precise enough to 
guide IKE analog design. Collectively, a crystal structure of xCT domain is required for a structure-based 
approach to design system xc– inhibitors. The development of new membrane crystallization strategies and 
the advancement of cryo-EM techniques has improved structural elucidation for proteins and could allow 
for the determination of the crystal structure of the xCT domain. A cocrystal structure of xCT with IKE as 
well as molecular dynamics (MD) simulation would be helpful for understanding the binding modes of 
IKE and allow for the development of more potent analogs.  
Second, there are questions regarding the toxicity, off-targets, and tissue distribution of IKE to be 
addressed. The in vivo study of IKE described in Chapter 4 identified toxic effects of IKE to mice, with 
the mice losing weight starting at day 9 of treatment. However, the cause of toxicity is currently unknown 
and could result from systemic inhibition of system xc–, formulation issues resulting in drug precipitation 
in vivo causing damage to organs, or another unknown cause. Thus, further studies aimed towards 
determining the cause of toxicity, accounting for drug precipitation, systemic inhibition of system xc–, as 
well as metabolite toxicity is necessary to elucidate any deleterious side effect of IKE. In addition, little is 
known about off-target effects and tissue distribution of erastin and IKE. Identifying off-targets of IKE 
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and defining its exposure at site of action will help us understand the potential risks associated with IKE 
and its potential as a new class of chemotherapeutic agent162.  
 
 
6.3 Nanoparticles as drug carriers 
6.3.1 Summary 
As system xc– is widely distributed in liver, kidney, brain, and macrophages, and acts as key 
regulator for cystine import and glutamate signaling163, systematic inhibition could cause severe toxicity 
in vivo. In Chapter 4, a PEG-PLGA nanoparticle carrier, which takes advantage of the EPR effect, 
allowing for selective accumulation in tumor tissue over normal tissue, is designed and formulated. The 
IKE PEG-PLGA nanoparticle formulated in this work has suitable properties for in vivo application, 
specifically, the average size of 80 nm allows for extravasation, the surface charge of -17 mV prevents 
nanoparticle aggregation, and the PEG coating enables prolonged circulation time. Both free IKE and IKE 
PEG-PLGA nanoparticles showed efficacy in decreasing tumor growth rate in NCG mice subcutaneously 
xenografted with SUDHL-6 cells, however, the PEG-PLGA nanoparticle formulation of IKE had less 
toxic effects, highlighting the potential of this system in cancer therapy. 
6.3.2 Significance 
 Nanoparticle carriers provide an effective way to improve drug efficacy and reduce systemic 
toxicity because of targeted localization in tumors. Despite the various nanocarrier systems available and 
numerous advantages of nanoparticle therapeutics, there are challenges to apply nanocarriers in vivo.  One 
of the challenges is to manufacture uniform nanoparticles with high loading capacity at large scale. We 
utilized a scalable microfluidic platform, which allows for the precise engineering of specific sized PEG-
PLGA nanoparticles with minimal batch to batch variability139. This high-quality nanoparticle is critical 
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for the successful delivery of IKE in xenograft models. Given the rapid optimization process of the 
system and the commercially availability of PEG-PLGA and polymers, the nanoparticle system we 
investigated here could be employed by other researchers or applied to other drug delivery projects. 
6.3.3 Future directions 
The dual role of anti-oxidation and detoxification of xenobiotics to impede chemotherapy makes 
GSH an attractive target.  However, glutathione synthesis inhibitors failed in clinical trials due to 
systemic toxicity resulting from GSH depletion164. Targeting system xc–, which has more tumor 
specificity due to the differential expression and distribution in specific type of cells165, is an alternative 
strategy to deplete GSH. Here, we chose the xenograft model of DLBCL, which is intrinsically sensitive 
to system xc– inhibitor due to a defective transsulfuration pathway, to explore IKE’s potential as a 
chemotherapeutic. At the same time, we employed a PEG-PLGA nanoparticle carrier to allow for the 
accumulation of IKE in tumors. This passive targeting showed reduced systemic toxicity of IKE, which 
leads us to believe that the active targeting of nanocarries by conjugation with molecules that recognize 
tumor cells, like antibodies, would further enhance targeting efficiency.  
DLBCL has a range of surface markers which are overexpressed on DLBCL compared to normal 
cells that could be selectively targeted with commercially available antibodies166. Specifically, the well 
characterized CD19 and CD20 antigens could be used depending on the tumor type and the drug 
mechanism of action. Binding of anti-CD19 antibody to CD19 antigens leads to receptor-mediated 
internalization167, which will significantly increase the therapeutic outcome for nanoparticles that are 
designed to release drug inside the cell. While, anti-CD20 antibody is non-internalizing, targeting 
nanoparticles to CD20 antigen results in the release of drug at the cell surface100. The non-internalizing 
receptors could be beneficial in solid tumors, as internalization can decrease the penetration of 
nanoparticles. At the same time, the non-internalizing nanoparticles allow for the release of drug on cell 
surface followed by diffusion into neighboring cells. However, for IKE delivery, it is hard to predict 
which antigen would be more advantageous. On one hand, IKE targets system xc–, which is a 
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cysteine/glutamate transporter on cell membrane, targeting the nanoparticle to CD20 would allow the 
release of IKE on cell surface. One the other hand, we have identified enhanced cellular activity effect of 
IKE PEG-PLGA nanoparticles comparing with free IKE (Figure 4.6), which might result from the 
increased internalization of IKE PEG-PLGA nanoparticles to cells compared free IKE to cells168. This 
evidence indicates the potential benefit of targeting CD19 instead of CD20.   
 Besides, there are other nanoscale therapeutics that might be beneficial for IKE therapy. For 
example, PEG-conjugated chemotherapeutics are an attractive approach to increase drug circulation time 
by increasing hydrophilicity, evading immune system recognition, and reducing serum protein binding169. 
Reversible PEGylation (PEG-prodrug), which attaches a drug to PEG through a cleavable linker, is used 
to minimize loss of activity. As the plasma half-life of IKE is only 1.8 hours, increasing the circulation 
life of IKE through PEGylation might help improve IKE’s activity in vivo. In addition, designing a 
stimuli-response nanoparticle would enable controlled drug release in specific tissue. For example, tumors 
have a hypoxic and acidic microenvironment; an oxygen- or pH-sensitive nanoparticle would enable 
controlled drug release in tumor tissues.  
 
6.4 Identification of ferroptosis biomarkers 
6.4.1 Summary 
A biomarker is a defined characteristic to indicate normal or pathogenic processes or responses to 
therapeutic interventions, which can be categorized into risk, predictive, diagnostic, monitoring, 
prognostic, response (pharmacodynamic), and safety biomarkers. Pharmacodynamic biomarkers are 
crucial to prove drugs’ clinical benefits and guide dose-response studies. We employed untargeted 
lipidomics, immunofluorescence, and quantitative reverse transcription PCR (RT-qPCR) approaches to 
elucidate biomarkers of ferroptosis and characterize pharmacodynamics of IKE treatment in xenograft 
model. In Chapter 3 and 5, an untargeted lipidomics study, immunofluorescence experiments, and RT-
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qPCR experiments are carried out on cell culture samples and tumor samples from treated mice to study 
IKE-induced changes in lipid composition and gene expression.  
Previously unreported changes in lipid species were identified, including changes in triglycerides 
(TAG), diglycerides (DAG), monoglycerides (MAG) and free fatty acids (FA) following IKE treatment. 
In IKE-treated SUDHL-6 cells, TAG and phospholipids decreased, possibly resulting from the cleavage 
of oxidized polyunsaturated fatty acids (PUFA). TAG is largely increased with Fer-1 co-treatment in IKE 
treated SUDHL-6 cells, which indicates a possible protective role of TAG as a buffer against oxidative 
damage. However, the data from the tumor samples revealed that DAG, MAG and phospholipids are all 
significantly increased upon IKE treatment, possibly resulting from both the activation of TAG hydrolysis 
enzyme, ATGL, and the response of cancer cells to oxidative stress.  
In addition, the RT-qPCR experiments identified a time-dependent upregulation of genes 
including PTGS2, SLC7A11, and CHAC1 in IKE treated SUDHL-6 cells and tumor tissues xenografted 
with the same cell line. Besides, a series of genes encoding lipid metabolism enzymes are upregulated 
upon IKE treatment, specifically, the lipid biosynthesis enzymes ACC1 and ELOVL7, lipid metabolism 
remodeling enzymes ATGL, sPLA2F, LPEAT1 and LPCAT4, and lipid peroxidation enzymes ALOX12 
and ALOX15. Co-treatment of Fer-1 or β-Me in IKE-treated cells prevent the upregulation of these genes, 
indicating the upregulation comes from system xc– inhibition and oxidative stress.  
Moreover, we identified some histologic biomarkers of IKE-induced ferroptosis including PTGS2 
protein and the oxidative stress biomarkers 8OHdG and MDA. The immunofluorescence experiments 
showed increased PTGS2, 8OHdG, and MDA in IKE and IKE PEG-PLGA nanoparticle treated tumor 
compared to vehicle, with no increased caspase-3 cleavage, biomarkers of apoptosis, in IKE and IKE 
PEG-PLGA nanoparticle treated tumor tissues. These data collectively suggest that the antitumor effects 
of IKE results from system xc- inhibition induced ferroptosis and not apoptosis.  
The gene expression, lipids, and histologic biomarkers identified here would be useful to 





 Emerging evidence has shown the potential antitumor effects of using ferroptosis inducers as 
single reagent or in combination with chemotherapies in cell culture and some types of xenografts34, 78. It 
is thus important to identify biomarkers and understand the molecular mechanisms of ferroptosis inducers   
in both tumor cells and cancer models. Here we identify and establish pharmacodynamics of ferroptosis 
inducer IKE in a xenograft model for the first time. The pharmacokinetics and pharmacodynamics 
relationship established here would be beneficial for future study of ferroptosis therapeutic role in cancer 
and other pathological conditions.   
 In addition, previous lipidomics study have revealed depletion of PUFAs and phospholipids, and 
increase of lysophospholipids in erastin or erastin analog-treated HT1080 cells67, 82. However, no one has 
characterized the genes that regulate these lipids change. The work presented here identified a range of 
genes that are upregulated by IKE treatment in SUDHL-6 cells and demonstrated that the upregulation of 
these genes is caused by inhibition of cysteine import and the increase in oxidative stress as illuminated 
following co-treatment with ferroptosis inhibitors. The upregulation of sPLA2F expression indicated that 
the increased lysophospholipids result from the cleavage of oxidized fatty acyl group from PC and PE to 
remove the detrimental oxidized PC and PE67, 82, 170. Similarly, upregulation of ATGL indicates the 
increase of monoglycerides (MAG) might due to hydrolysis of oxidized fatty acyl group in triglycerides 
to minimize the pathology mediated by lipid peroxidation. The integration of small molecule tools, 
untargeted lipidomics, and RT-qPCR provides an efficient way to explore lipids change and lipid 
metabolism mechanisms during regulated cell death.  
 
6.4.3 Future directions 
Ferroptosis acts as an important regulator in specific physiological and pathological conditions34.  
However, identifying biomarkers that determine ferroptosis sensitivity, therapeutic responses, and 
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progress remains an ongoing challenge. For example, DLBCL lines have differential sensitivity to IKE 
(Figure 3.3), making the identification of biomarkers predicting DLBCL sensitivity to system xc- a 
valuable pursuit for future pre-clinical studies as well as precision medicine approaches in the clinic. 
While, ACSL4 and LPCAT3 have previously been reported to be overexpressed in ferroptosis resistant 
cell lines69, 86, these two genes could not predict DLBCL’s differential sensitivity to IKE. Cystathionine-
beta-synthase (CBS), ferritin light chain (FTL), and SLC7A11 genes were found to have higher average 
expression levels in resistant DLBCL lines, however, the increased average expression level could not 
predict the sensitivity or resistance of a specific cell line due to extensive variability within each group. 
The ‘omics’ techniques (genomics, transcriptomics, proteomics, and metabolomics) in combination with 
bioinformatics, which allow for the collection of multidimensional information and identification of 
unknown targets, would help to identify targets regulating ferroptosis sensitivity. In addition, multiple cell 
lines including parental drug sensitive/resistant and derived drug resistant cell lines, are necessary to use 
for identifying intrinsic factors determining ferroptosis sensivity69, 86, 171. 
One such biomarker, NADPH, was found to be a biomarker for ferroptosis sensitivity following 
transcriptome analysis in NCI-60 cell lines171. Identification of metabolite biomarkers like NADPH, 
however, presents unique challenges. First, the detection of significantly changed specific metabolites in a 
complex metabolite pool, where some metabolites are unstable or in low abundance, requires careful 
sample preparation and sample analysis. Second, metabolite biomarkers identified in vitro might not be 
translatable to in vivo as cell culture is a highly simplified and artificial system compared to humans and 
animals. For example, in Chapter 5, the results from the untargeted lipidomics experiments on the cell 
culture samples were conflicting with the results from the tumor samples, suggesting that different lipid 
metabolism pathways are active following IKE treatment in vitro and in vivo, limiting the overall 
applicability of the in vitro data. A similar finding is observed with GSH depletion following IKE 
treatment in vitro and in vivo. Tumors harvested from mice 24 hours after IKE administration had 
dramatically decreased GSH levels despite there being little IKE present. However, we didn’t observe the 
persistent effect of GSH depletion upon IKE treatment in cell culture of SUDHL-6. This difference might 
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result from the faster uptake of cystine from the cell culture media than from the nutrient-poor tumor 
microenvironment. Thus, metabolomics analysis in vitro at conditions more representative of the in vivo 
environment, or directly from in vivo samples would be more beneficial for understanding ferroptosis role 
in physiology, pathology, and cancer therapy.  
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